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Investigation into the molecular mechanisms underlying invasion in 
the lung carcinoma cell line DLKP and its chemotherapeutic drug 
resistant variants 
Abstract
This research described in thesis was undertaken in an attempt to increase our 
knowledge of mechanisms by which lung cancer cells acquire the capacity to invade 
This is a critical step m cancer metastasis To study the molecular nature of invasion, 
the gene-expression profiles of five lung cancer cell lines (DLKP) with differing levels 
of mvasiveness (as determined by an in vitro invasion assay) were analysed using 
expression microarray methodology Two invasive, non-drug exposed, variants of the 
DLKP cell line were used in the study along with a non-invasive Vincnstine-selected 
(VCR) cell line, an invasive Taxotere (TXT) resistant variant and a non-mvasive TXT- 
selected cell line that had lost its resistance to TXT This provided us with a panel of 
lung cancer cell lines with various levels of mvasiveness Lists were generated from 
the array data contaimng genes that may potentially serve as transcriptional signatures 
for mvasiveness and/or drug resistance in these cell lines From the genelists compiled, 
and taking into account results from PCR-based validation and evidence from existing 
literature, five genes were picked as high priority targets for further investigation in 
the context of our invasion model These were IGF-1R, KCNJ8, S100A13, SFN, and 
TFPI2
Functional studies to investigate the role of these targets in invasion included gene 
over-expression and knockdown using cDNA and siRNA transfection respectively, 
with confirmation by semi-quantitative RT-PCR, qRT-PCR and Western blotting 
where possible Most importantly any functional effect in our cell model was 
examined by in vitro invasion assay The functional analyses identified a role for IGF- 
1R and TFPI2 in the invasive phenotype and also identified novel roles for the proteins 
KCNJ8 and S100A13 in invasion
xxi
Section 1.0: Introduction
1.1 General Introduction
Invasion and metastasis is a major cause of death for cancer patients The complexity 
of the metastatic process has forced investigators to focus on one contributing factor at 
a time in order to reduce the number of variables Invasion is one of the most cntical 
steps in metastasis Dynamic interactions among cell adhesion molecules, extracellular 
matrix, proteases, cytoskeletal proteins and signalling molecules contribute to the 
invasive behaviour of tumour cells
Chemotherapy is the pnncipal therapeutic tool used to treat metastatic cancers that 
cannot be eradicated by surgery Although there has been significant impact on 
survival of certain malignancies, the majority of human cancers are resistant to 
chemotherapy at presentation or become resistant after an initial response This 
suggests that resistance is inherent in a tumour cell or evolves under the selection 
pressure of drug administration
Drug resistance and invasion/metastasis are correlated phenomena Highly multidrug 
resistant tumour cells can survive chemotherapy and escape to distant sites of the body 
or highly metastatic cells can escape the effect of chemotherapy A relationship 
between these two phenotypes has been demonstrated by two types of experiments, 
firstly, in some cases, invasive/metastatic cells develop drug resistance more readily 
than non-invasive metastatic cells (Cillo et a l , 1987), secondly, some tumour cells 
selected for resistance to chemotherapeutic drugs are more invasive/metastatic relative 
to non-resistant cells (Lucke-Huhle et a l , 1994) Mechanisms underlying this 
relationship have not yet been elucidated It is supposed that malignant tumours anse 
as a result of an accumulation of genetic mutations involving a number of oncogenes 
and tumour suppressor genes Many of these genes could affect the expression of cell 
growth, differentiation, drug resistance, invasion and metastasis Hence, an important 
goal of fixture research would be to determine whether a common factor exists that 
activates two sets of genes, those responsible for drug resistance, and those responsible 
for increased tumour cell invasion and metastasis
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The advent of DNA microarray technology allows the investigation of these processes 
either alone or in tandem depending on how the array data is mined By using 
microarray technology, it is hoped in this project to identify a group of genes involved 
in the invasive phenotype and to understand which signals and signal transduction 
pathways are activated or restrained in malignant invasion
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1.2 Lung Cancer
Cancer is one of the most feared diseases of the last century in the western world. In 
fact, the term “cancer” includes over a hundred different forms of the disease. Cancer 
can develop from nearly every tissue in the body and subtypes of tumours can also be 
found within specific organs. Cancer cells have defects in the regulatory circuits that 
control cell proliferation and homeostasis (Hanahan and Weinberg, 2000). Among all 
types of cancer, lung cancer is the most common form. The national cancer registry 
(All-Ireland cancer statistics 1994-1996) reported that there are approximately 2000 
lung cancer related deaths per year in Ireland. It is suggested that 87% of lung cancer 
cases are as a result of cigarette smoking (Hecht, 2002), but this figure may be as high 
as 95%. Other causes of lung cancer include exposure to chemicals such as asbestos, as 
well as the naturally occurring radioactive gas radon. Passive smoking of 
environmental tobacco smoke (ETS) has also been linked with the development of 
lung cancer in non-smokers.
Symptoms associated with lung cancer are cough, dyspnoea, haemoptysis and post 
obstructive pneumonia, (Hoffman et al., 2000), although lung cancer can present with 
no initial symptoms. Diagnosis is achieved by invasive and non-invasive methods. 
Non-invasive methods for diagnosing lung cancer include sputum cytology and chest 
radiography. After this point, invasive techniques such as bronchoscopy and lung 
biopsy are performed. While the location and size of the lung tumour can be estimated 
from a chest x-ray or CT scan, accurate diagnosis and staging requires a biopsy, to 
histologically type the cells and determine if local nodes are involved.
Lung cancer is divided into 2 main groups, small cell lung cancer (SCLC) and non­
small cell lung cancer (NSCLC). The World Health Organisation (WHO) compiled 
this histologic classification. SCLC and the subtypes of NSCLC -  adenocarcinoma, 
squamous cell carcinoma and large cell carcinoma, account for 95% of lung cancers. 
SCLC presents less frequently than NSCLC and generally originates from a central 
location in the lung. These tumours are very aggressive, have a rapid growth rate and 
generally present with distant metastases at diagnosis. These tumours have the poorest 
prognosis of all lung cancer subtypes.
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NSCLC is divided into three categones, squamous cell carcinoma (30% of all lung 
cancers), adenocarcinoma (40%) and large cell carcinoma (10%) Squamous cell 
carcinoma develops from within a central bronchus in the lung and frequently displays 
central cavitation from necrosis They are characterised by keratm formation 
Squamous cell carcinomas have slow growth rates and develop metastases at a late 
stage Adenocarcinomas generally develop centrally from surface epithelial cells in 
larger bronchi They are characterised by gland formation and mucus production 
These tumours tend to metastasise early and have a rapid growth rate Large cell 
carcinoma is characterised by large cells with large nuclei and prominent nucleoli 
These tumours are usually poorly differentiated and tend towards large peripheral 
masses
Staging of lung cancer is very important, since it will determine the type of treatment 
received The international staging system classifies the cancer based on the Tumour, 
Node, Metastasis (TNM) designation The designation Tl-4 refers to the size and 
location of the primary tumour N0-N3 describes the extent of lymph node 
involvement In cases where distant metastases are present (Ml), the tumour is 
diagnosed as stage IV lung cancer Early stage lung cancers are the most treatable, 
with later stage cancers such as stage IIIB and IV being virtually unbeatable
Lung cancer, particularly SCLC, is characterised by rapid growth and metastatic 
spread (Yano et a l , 2005) By the time of diagnosis clinically undetectable 
micrometastasis may already have developed within the lung Yano et a l , (2005) 
injected immunodeficient mice with SCLC cell lines, SBC-3 and SBC-5 resulting in 
metastasis formation in liver, bone and kidney Lung cancer itself often arises as a 
metastasis from another site, for example, cancer of the breast (Minn et a l , 2005)
The choice of treatment for patients with lung cancer depends strongly on the clinical 
stage Other details taken into account include pulmonary function and cell type 
Surgery is the major therapeutic option for lung cancer patients, however, 
approximately 75% of lung cancers are inoperable at time of diagnosis therefore 
surgery is only curative m patients with early stage lung cancer Radiation therapy can 
also be curative for a small percentage of patients To date, chemotherapy can offer 
improvement in short-term survival, but overall survival from lung cancer is poor The
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main aim of chemotherapy is to kill the tumour cells with the least possible effect on 
normal cells and chemotherapy regimens are based on empirical data and clinical 
experience (Debatin, 2000) Chemotherapy is often used in combination with surgery 
or other therapies such as radiotherapy, known as adjuvant chemotherapy It is 
especially important for increased survival in cancer patients where these other 
treatments have failed Chemotherapy can increase median survival time in patients 
with advanced lung cancer, and prevent recurrence in resected early stage lung cancer 
However, the design of improved treatments for lung cancer lies in a better 
understanding of the disease at a molecular level
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13 Pharmacology of Chemotherapy drugs
Two chemotherapeutic drugs were used to generate the drug-resistant cell lines used in 
this study These are Taxotere (Docetaxol (TXT)) and Vincristine (VCR), their 
mechanisms of action will be discussed in the following section
1.3.1 The Vmca Alkaloids
Vincristine (Figure 1 1) and Vinblastine are complex plant alkaloids isolated from the 
periwinkle plant Catharanthus roseus They are members of a general class of drug 
that function as mitotic inhibitors which act by interfering with the function of 
microtubules a class of long, tube-like cellular organelles approximately 250nm 
diameter (Pratt et a l , 1994) Microtubules and microfilaments play an important role 
in the movement of cells relative to each other and in the movement of organelles 
within the cytoplasm of a single cell The cytotoxicity of vincristine is attributed to its 
ability to interrupt cell division in metaphase (Bruchovsky et a l , 1965), but other 
effects could also contribute to cell death Their action is specific to the M phase of the 
cell cycle (Wilson et a l , 1975)
The vmca alkaloids specifically exert their effect by binding to tubulin and preventing 
its polymerisation As polymensed microtubules form the spindles that retract 
chromosomes into daughter cells at mitosis, their disruption results in blocked mitosis 
Exposure of mitotic cells to the drug is followed by the rapid disappearance of the 
spindle apparatus and the maintenance of the chromosomes in the condensed state 
Although the effects are seen at the time, the actual vincnstine-tubuhn interaction 
occurs during interphase
Vincristine and vinblastine have very similar chemical structures and behave 
essentially the same way at the level of drug-tubulm interaction, however there are 
differences m the spectrum of antitumour activity of the two drugs in both 
experimental animal tumours and clinical cancer The reason for these differences 
remains unknown These compounds are active against a broad spectrum of cancers
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including lung, ovarian and testicular cancer (Culine et a l , 1994, Einhom, 1997, 
Schiller, 2001 and Schuette, 2001) They induce bone marrow and neural toxicities, 
and development of drug resistance to both agents via overproduction of P- 
glycoprotein (Bradley et a l , 1989)
R -is CHO
Figure 1.1: Chemical structure of Vincristine
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1.3.2 The Taxanes
The taxanes are a group of drugs including paclitaxel (taxol) and docetaxol (taxotere) 
Taxol was originally isolated from the yew tree Taxus brecifoha Despite the 
elucidation of its broad activity and its unique structure (Warn et a l, 1971), it is still in 
the early stage of clinical development in so far as its role/potential role m the 
treatment of many cancer types has yet to be conclusively defined Taxotere 
(docetaxol) is a semi-synthetic taxane extracted from the needles of Taxus baccata, 
and is slightly more soluble than taxol The chemical structure of taxotere is shown in 
Figure 1 2 In a similar manner to the vinca alkaloids, the taxanes exert their anti­
tumour effect through the disruption of mitosis They interfere with chromosome 
changes during the cell cycle and are toxic to proliferating cells They induce a shift in 
the physiological equilibrium between microtubules and tubulin toward polymerisation 
and formation of dysfunctional microtubules
Taxol and taxotere have been shown to be active in the treatment of refractory ovarian 
cancer (Rowinsky et a l , 1990) Encouraging results have been obtained in patients 
with metastatic breast cancer (Holmes et a l , 1991 and Marty et a l , 1999) Like the 
majority of chemotherapy drugs, the taxanes have a number of side effects Bone 
marrow suppression (principally neutropenia), complete alopecia (hair loss) and 
hypersensitivity reactions are the most common dose limiting toxicities for the taxanes 
(Markman et a l , 2003) Other side effects include, hypersensitivity reaction 
characterised by dyspnea, urticaria and hypotension A variety of cardiac abnormalities 
have also been associated with taxol treatment (Pratt et a l , 1994)
Resistance to taxotere arises through the mechanisms of multidrug resistance (MDR) 
Mechanisms of MDR include exclusion of the drug from the cell, increased 
detoxification of the drug, alteration in drug targets, failure to activate the drug to its 
active form, enhanced repair capability of the cell after injury or failure to engage an 
appropriate response leading to apoptosis in the damaged cells An additional 
mechanism of drug resistance is the mutation of the gene coding for one of the tubulin 
subunits (Schibler et a l , 1986) It is thought that, in the absence of drug, the 
equilibrium between free tubulin and microtubules is shifted towards disaggregation 
(Cabral et a l , 1986), therefore the mutant cells have slightly greater tolerance for
9
taxol-induced stabilisation than that of the parent cells. Some mutants were not only 
resistant to taxol, but required it for growth as a result of extreme shift towards 
disaggregation (Pratt et al., 1994).
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Figure 1.2 Chemical structure of Taxotere
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13 3 Chemotherapy resistance
A major obstacle in the use of chemotherapy for cancer treatment is the development 
of resistance Consequently, a better understanding of the mechanisms of drug 
resistance would help to overcome this obstacle Intrinsic and acquired drug resistance 
are believed to cause treatment failure in over 90% of patients with metastatic cancer 
(Longley & Johnston, 2005) Some tumours are initially sensitive to an anticancer 
agent and, over time, develop a resistance to it and this is referred to as acquired 
resistance Whereas, other tumours are resistant before treatment and this is known as 
intrinsic resistance One of the major factors leading to drug resistance is decreased 
drug accumulation This is caused by decreased drug influx or enhanced drug efflux, 
both of which result in the chemotherapeutic agent not exerting its effect on the 
tumour Drug resistance can also be caused by modified drug activation, drug 
inactivation, alterations in DNA repair mechanisms and altered response to apoptosis 
Treatment with one agent can often lead to associate resistance to a number of 
unrelated agents The development of resistance to a variety of unrelated 
chemotherapeutic drugs is called multiple drug resistance (MDR) MDR is caused by a 
variety of changes in the cancer cells and is almost always multifactonal
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1.4 Metastasis
By the time of diagnosis, a high proportion of patients have clinically detectable 
metastasis It is assumed that dissemination is impossible until invasion has occurred 
For breast cancer, the period of transition from hyperprohferative but non-invasive 
disease to invasive cancer is estimated to average 6 years (Sprat et a l , 1986) The time 
period after the invasive carcinoma grows to reach the minimum threshold size of 
detection (0 25cm in diameter), to establishment of the first metastasis, can be less than 
one year (Sprat et al, 1986) Thus transition of preinvasive carcinoma to invasion 
provides a much larger window for intervention compared to the conventional goal, 
which focuses on established invasive carcinoma
Metastasis is the spread of cancer from a primary tumour to distant sites in the body A 
distinguishing feature of malignant cells is their capacity to invade surrounding normal 
tissues and metastasise through the blood and lymphatic systems to distant organs 
This process of metastasis is the most devastating aspect of cancer It is estimated that 
in almost 50% of cancer patients, surgical excision of a primary tumour is not curative, 
as metastasis has occurred to a further site in the body (Fidler et a l , 1994) In many 
patients, metastases develop some years after the resection of the primary neoplasm
Most deaths from cancer are due to metastasis that are resistant to conventional 
therapies Current therapies fail to eradicate metastasis for three major reasons Firstly, 
when initially diagnosed, most tumours are well advanced and metastasis has already 
occurred Secondly, specific organ environment can modify the response of a 
metastatic tumour cell to systemic therapy and alter the efficiency of anticancer agents 
The third reason and the greatest obstacle to the success of therapy, is the 
heterogeneous composition of tumours, where highly metastatic cells can escape from 
the effect of therapeutic agents
Cancer metastasis has been described as a complex senes of sequential processes that 
involve (1) the initial transforming event, (2) proliferation of transformed cells, (3) the 
ability of cancer cells to avoid destruction by immune mechanisms, (4) nutritional 
supply to the tumour mass requinng the release of tumour angiogenesis factors, (5)
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local invasion and destruction of extracellular matrix components and parenchymal 
cells, (6) migration of tumour cells away from the primary tumour mass, (7) 
penetration of cancer cells through the blood vessel wall, (8) embolisation of cancer 
cells m “clumps” to distant organs, (9) arrest of cancer cells m the lumen of small 
blood vessels or lymphatics, (10) reverse penetration of blood vessels, (11) repetition 
of the process beginning at step 2, resulting in the formation of a secondary tumour 
(metastases) (Fidler et a l , 1994)
Metastasis is thought to be an inefficient process Large numbers of cells can be shed 
into the circulation from a primary tumour but only a small fraction of the cells will 
succeed in forming metastases Results from a series of experiments using mtravital 
videomicroscopy (IW M ), a technique which permits direct observation of the 
microcirculation in vivo, suggest that early steps in metastasis, including destruction of 
cells m circulation and extravasion, contribute less to metastatic inefficiency than 
previously assumed Rather, regulation of growth of individual extravasated cells in 
target tissue appears to be the rate-limiting step (Chambers et a l , 1995)
Some metastases will arise on the basis of circulatory anatomy The lungs are a 
common site of metastasis Similarly, metastases from the colon often arise in the liver 
as the liver receives direct drainage from the large intestine Metastases also arise in 
other organs due to “Seed and soil” theory In 1889, Paget concluded that metastasis 
occurred only when certain favoured tumour cells (the “seed”) had a special affinity 
for certain specific organs (the “soil”) The formation of metastases required the 
interaction of the right cells with the compatible organ environment Metastasis 
favours the survival and growth of a few subpopulations of cells that pre-exist within 
the parent neoplasm (Fidler and Knpke, 1977) Thus, metastases can have a clonal 
ongin, and different metastases can originate from the proliferation of different single 
cells (Talmadge et a l , 1982)
In the past our inability to accurately diagnose patients at high risk for the development 
of metastasis has precluded the possibility of tailored treatment, increased momtonng, 
or preventive action However, advances in gene expression profiling have allowed 
many researchers including van’t Veer et a l , (2002) to distinguish metastatic primary 
tumours from non-metastatic primary tumours These results have led to much debate
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as to the mechanisms of metastatic development The ability to identify metastatic 
tumours using transcriptional signatures from bulk tumour tissues suggests that 
primary oncogemc mutations determine the metastatic potential of a tumour This idea 
may be viewed as incompatible with the conventional theory of tumour progression 
which predicts that only a small number of cells from the primary tumour achieve 
metastatic potential Both seemingly contradictory models have a variety of supporting 
data suggesting that both are correct to some extent (Hunter, 2006)
Organ microenvironment can influence the biology of cancer growth and metastasis in 
several different ways During the interaction of metastatic cells with host tissues, 
signals from autocrine, paracrine or endocrine pathway can influence tumour cell 
growth and proliferation, due to the different concentrations of hormones in particular 
organs, local factors that are differentially expressed or paracrine growth factors 
concentrated in different tissues In this way metastatic tumour cells can respond to 
physiological signals produced when homeostasis is disturbed Tumour cells can also 
originate from or have an affinity for growth in a particular organ by responding to 
these physiological signals (Fidler, 2002) For example, human colon carcinoma 
(HCC) cells implanted subcutaneously (ectopic site) into nude mice produce low levels 
of secreted type IV collagenase, whereas the same cells growing in the wall of the 
colon (orthotopic site) produce high levels of type IV collagenase (Nakajima et a l , 
1990) In another study highly metastatic clones of human prostate cancer were 
implanted into the prostate (orthotopic site) and subcutis (ectopic site) Tumours 
growing in the prostate exhibited higher levels of epidermal growth factor receptor 
(EGF-R), basic fibroblast growth factor (bFGF), interleukin 8 (IL-8), type IV 
collagenase and the multidrug resistance (mdr-1) gene than those growing in the 
subcutis This data indicates that the expression level of metastasis-regulating genes by 
metastatic cells can be induced by factors in the organ microenvironment (Fidler, 
2002)
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Metastasis is the final stage in tumour progression from a normal cell to a fully 
malignant cell in some cases The best-developed example is the characterisation of the 
molecular progression in colon cancer, in which specific changes (e g loss of tumour- 
suppressor genes and mutation of oncogenes) are preferentially associated with 
specific changes of progression (Fearon and Vogelstein, 1990, Kinzler and Vogelstein,
1996) However, the final stage in tumour progression to a metastatic phenotype 
remains to be elucidated at a molecular genetic level in colon and other cancers 
Transfection with a variety of oncogenes (e g ras and src) has been shown to produce 
metastatic cells (Chambers and Tuck, 1993) For example, metastatic H-ras transfected 
NIH-3T3 cells had increased levels of a variety of gene products including proteinase 
and adhesive proteins (Tuck et a l , 1991a and 1991b) Loss of tumour-suppressor gene 
function has also been implicated in the conversion to metastatic ability in specific 
tumour types, e g nm23 (MacDonald et a l , 1995), KAI1 (Dong et a l , 1995), KiSS-1 
(Lee et a l , 1996), although none is likely to be universally implicated in all tumour 
types It appears more likely that regulation of expression of genes that contribute 
functionally to metastasis can occur in a tissue-specific manner The development of 
gene expression profiling may help to elucidate the genes that contribute to metastatic 
development in many cancer types
15
1.5 Invasion
Invasion is the active translocation of neoplastic cells across tissue boundaries and 
through host cellular and extracellular matrix barriers Invasion is not only due to 
growth pressure but is attributed to additional genetic deregulation over and above 
those molecular events that cause uncontrolled proliferation At the biochemical level, 
the mechanism of invasion used by tumour cells may be similar to that used by non- 
malignant cells which traverse tissue boundaries under normal physiological 
conditions Examples of physiological invasion are smooth muscle cell migration from 
the tunica media (which contains smooth muscle fibres and elastic and collagenous 
tissues) to the mtima (which is composed of the endothelial cell layer) of blood 
vessels, angiogenesis, embryogenesis, morphogenesis, nerve growth cone extension 
and homing, and trophoblast implantation In contrast to malignant invasion, 
physiological invasion is tightly regulated and ceases when the stimulus is removed 
Invading tumour cells appear to have lost the control mechanisms that which prevents 
normal cells from invading neighbouring tissue at inappropriate times and places 
Thus, the fundamental difference between normal and malignant cells is regulation 
The difference must lie in the proteins that start, stop or maintain the invasion 
programme at times and places that are mappropnate for non-malignant cells A major 
goal is to understand what signals and signal transduction pathways are perpetually 
activated or deregulated in malignant invasion (Kohn and Liotta, 1997)
Liotta et a l , (1977) has proposed a simplified three step theory of invasion (1) tumour 
cell attachment via cell surface receptors which specifically bind to the components of 
the extracellular matrix (ECM), (2) the anchored tumour cell secretes hydrolytic 
enzymes, such as matrix metalloproteinases, to degrade the extracellular matrix, (3) 
tumour cell locomotion into the region of the matrix modified by the proteolysis Thus, 
regulation of the molecular events necessary for invasion requires spatial and temporal 
coordination at an individual cell level
For cells migrating within a three dimensional extracellular matnx, such as penetrating 
a basement membrane, protrusion of a cylindrical pseudopod occurs prior to 
translocation of the whole cell body (Condeelis, 1993) A number of observations
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support the central role of the cytoskeleton-dnven pseudopodia as organs of motility 
and invasion Pseudopodia aggregate or concentrate cell surface degradative enzymes 
and adhesion receptors (Guirguis et a l , 1987) A balance must switch from proteolysis 
to adhesion in order for the advancing pseudopod to grip the matrix and pull the cell 
forward General unregulated proteolysis alone cannot be responsible for the entire 
invasion cascade When the cell moves into the zone of lysis, adhesion is required and 
proteolysis must be shut down At the rear of the cell, dissociation from adjacent cells, 
and detachment from previous attachment sites are necessary to release the cell This 
type of motility is described as mesenchymal motility (Sahi, 2005)
The basement membrane and interstitial stroma also have important regulatory roles in 
invasion They serve as a storage depot for latent proteinases, cytokines and growth 
factors, which can be activated or released by the invading cells The critical 
pathological turning point is in the initiation of local invasion leading to the 
dissemination of tumour cells Tumour-induced neovasculansation occurs in parallel 
with invasion and provides vascular entry necessary for dissemination A positive 
correlation between tumour aggressiveness and protease levels has been documented 
for all four classes of proteases including senne, aspartyl, cysteinyl and matrix 
metalloproteinse (MMP) It has been established that the integrity of the basement 
membrane can be regulated by the balance between MMPs and their inhibitors 
(Talhouk e ta l, 1992)
Altered signalling pathways are also associated with invasion In 1986, Pozzatti et a l , 
transfected activated H-ras into primary rat embryo fibroblast cells This resulted in the 
generation of a malignant and invasive phenotype that was characterised by the 
production of gelatmase B and marked pulmonary colonisation after tail vein 
inoculation of transfected cells Similar effects have been observed with the expression 
of other oncogenes including Her-2/neu (Yu et a l , 1993) These studies demonstrate 
the overlap between oncogene-induced tumour development and dissemination but 
highlight the fact that distinct signals must be in place for the functional separation of 
transforming activity and metastasis to occur Signal transduction pathways that are 
further downstream of activated oncogenes may regulate the invasive phenotype
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The molecular characterisation of invasion has led to the identification of two 
categones of checkpoints that constitute possible intervention targets The first 
category includes cell surface and secreted proteins e g adhesion receptors, 
degradative enzymes and their inhibitors and motility stimulating cytokines The 
second checkpoint category includes regulatory proteins and pathways such as 
calcium-mediated signalling, G-protein activation and tyrosine phosphorylation events 
It is the molecular examination of these checkpoint molecules that may provide the 
basis for the development of therapeutics that can potentially block tumour invasion or 
growth (Kohn and Liotta, 1997)
Mechanisms of invasion are known to involve a complex array of genetic and 
epigenetic changes many of which are specific for different types of tumours and 
different sites of metastasis The roles of adhesion molecules such as integnns and 
cadhenns in invasion have undergone a major transition over the past decade It is now 
apparent that these molecules have a critical role in signalling from the outside to 
inside a cell thus controlling how a cell can interact with and sense its local 
environment It has also become clear that proteolytic enzymes and their inhibitors not 
only degrade the ECM, but are involved m the release of factors that can positively or 
negatively affect the growth of tumour cells In more recent years, the importance of 
the post-extravasional stages of invasion was highlighted, where adhesion and 
proteolysis are now known to play a role along with other processes including 
apoptosis, dormancy, growth factor-receptor interactions and signal transduction It has 
also been found that it is not only the immediate cellular microenvironment, but also 
the extended cellular microenvironment that can modify cellular gene expression and 
enhance metastasis Our improved understanding of the expanded roles of the 
individual molecules involved has resulted m a mechanistic blurring of the previously 
described discrete stages of the metastatic process (Cairns et a l , 2003)
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1.5.1 The extracellular matrix and basement membrane
The extracellular matrix is a complex structure of carbohydrate- and protein-containing 
components that comprise the basement membrane underlying epithelial tissues and 
that surround structural tissues such as bone and muscle (Yurcheno and Schittny, 
1990) Almost all multicellular organisms have basement membranes They are the 
first extracellular matrices that are produced during embryogenesis Epithelial, 
endothelial and many mesenchymal cells are supported by this thin sheet-like ECM 
structure The membrane acts as a solid regulator of cell attachment, differentiation 
and growth, as well as a passive barrier that segregates tissue compartments 
Metastatic cancer cells have to penetrate the tumours own basement membrane, that of 
the vasculature and target tissue in order to establish secondary disease sites (Hood and 
Cheresh, 2002)
The basement membrane has a complex molecular architecture that consists of 
lamimns, type IV collagen, entactin and heparan sulphate proteoglycans Lamimns are 
flexible four-armed, 850kDa glycoproteins Laminin monomers polymerise into 3D 
structures in a time- and concentration- dependent manner As an initial step in 
metastasis, many epithelial tumours exhibit altered localisation or expression of 
lamimn-binding mtegnns (e g a6p4) This promotes invasion through the basement 
membrane and increases motility in the stroma, where tumour cells can remodel the 
matrix by depositing laminin (Hood and Cheresh, 2002) The most prevalent protein in 
the basement membrane is type IV collagen Type IV collagen is a thread-like flexible 
molecule that can itself form a heterotnmer involving hydrophobic and disulphide 
bonds The covalent binding of collagen provides mechanical stability to the basement 
membrane Proteins such as entactin, which forms connections between networks of 
collagen and laminin, further stabilise the membrane Many of the proteases with 
increased expression m metastatic tumours exhibit high enzymatic activity against type 
IV collagen The basement membrane also contains heparan sulphate proteoglycans -  
a class of molecules that contain a protein core covalently linked to heparan sulphate 
chains These molecules are linked to the membrane through interactions with laminin 
and may influence tumour biology by acting as a repository for growth factors 
including fibroblast growth factor
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1.5.2 Integrms and cancer
The integrms are composed of a large family of heterodimenc integral cell surface 
receptors that mediate cell-to-ECM and cell-to-cell interactions (Hynes, 1992) 
Derangement of integnn expression may be responsible for many aberrant cellular 
activities during tumour onset, progression and metastasis The integrms, composed of 
a  and P chain heterocomplexes act as integral cell membrane receptors that form focal 
adhesion contacts with ECM ligands e g fibronectin, lamimn, entactin, intercellular 
adhesion molecule (ICAM) and the collagens to name but a few Integrms also interact 
with cytoplasmic cytoskeletal filament-associated proteins e g actin, paxillin and talin 
The family can form at least 25 distinct pairings of its 18 a  and 8 p subunits, with each 
integnn consisting of a noncovalently linked a- and P-subunit, with each subunit 
having a large extracellular domain, a single membrane-spanning domain and a short, 
non-catalytic cytoplasmic tail (Mizejewski, 1999) In addition to regulating cell 
adhesion to the ECM, mtegnns relay molecular cues regarding the cellular 
environment that influence cell shape, proliferation, survival, migration and gene 
transcnption
1 5 2.1 Integnn expression and function
Invasive cells undergo changes in integnn expression levels and integnn affinity for 
ECM substrates Many studies have reported significant differences m the surface 
expression and distnbution of mtegnns in malignant tumours when compared with 
pre-neoplastic tumours of the same type For example, a5p3 integnn is strongly 
expressed at the invasive front of melanoma cells and angiogenic blood vessels, but 
weakly expressed on pre-neoplastic melanomas and blood vessels (Brooks et a l , 
1994) While the expression of some mtegnns is mcreased dunng tumuongenesis, the 
expression of others decreases Cells can also assume a more migratory and invasive 
phenotype by altenng their adhesive and signalling profile by increasing the affinity of 
mtegnns for their ligand (Hood and Cheresh, 2002)
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1.5.2 2 Integrins and proteolytic enzymes
Epithelial to mesenchymal transformation (EMT) is the process by which epithelial 
cells lose their strong intracellular adhesion and their basolateral polanty to gain front- 
end to back-end polanty, and the ability to migrate through the ECM (Savagner, 2001) 
As cells lose cell-cell contact, new cell-ECM interactions are generated Thus, many 
cell surface-associated adhesion molecules change function and are the source of 
signals that activate growth, ECM degradation and metastasis (DeClerck et a l , 2004) 
Important changes in integnn interaction occur dunng EMT For example, contact of 
mtegnns a6(34 and a3pi with the ECM decreases the expression of cell-cell adhesion 
molecules such as E-cadhenn and promotes the expression of proteases and their 
receptors and growth factors The co-localisation of urokinase plasminogen activator 
receptor (uPAR) and integnn allows a physical interaction between the a3 subunit and 
uPAR which downregulates E-cadhenn and further promotes EMT Together, these 
changes alter the interactions that occur at the cell surface from cell-cell to cell-ECM 
thereby promoting ECM degradation, invasion and motility (DeClerck et a l , 2004)
Integnns are also involved in regulating the activities of proteolytic enzymes that 
degrade the basement membrane The activation of these enzymes and cellular 
invasion are correlated under many pathophysiological settings In human melanomas 
and metastatic breast tumours, for example, stromal cells close to the invasive front 
have increased levels of MMP activity compared with non-malignant control cells 
(Monteagudo, et a l , 1990) Integnns may also be involved in activating specific 
MMPs For instance, MMP2 is activated on the cell surface by a multimenc complex 
that is composed of MMP2, membrane type 1 MMP (MT1-MMP) and tissue inhibitor 
of metallopreteinase 2 (TIMP2) Studies on melanomas, gliomas and angiogenic 
endothelial indicate that this MMP2 activating complex also includes a5P3 integnn 
(Hood and Cheresh, 2002) Thus, dunng invasion, a5P3 integnn functions as an 
adhesion/migration receptor and in activating and localising proteases that are required 
to degrade the ECM Negative-feedback regulation of mtegnn/protease bmding is 
needed to prevent excessive degradation of the ECM Proteolysis is negatively 
regulated by MMP2-dependent generation of hemopexin fragments, called PEX, which 
inhibits pro tease activation by competing with MMP2 for binding to a5p3 integnn 
(Brooks e ta l , 1998)
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1.5.2.3 Integrms and signalling; from the outside m
A further function of integrms is m the regulation of the intracellular signalling 
pathways that control cytoskeletal organisation, force generation and survival 
Depending on ECM composition, integrms can activate one or more intracellular 
signalling pathways These pathways involve phosphorylation of focal adhesion kinase 
(FAK), the recruitment of adaptor proteins, activation of small GTPases and the 
activation of downstream effector molecules These signals, along with growth factor 
signals, regulate cell behaviour in a complex tissue microenvironment
Integnn binding of ECM ligands induce integnn clustenng and FAK activation FAK 
is a cytoplasmic protein kinase that colocahses with integrms at focal adhesion 
structures Activated FAK binds to many signalling molecules which promote cell 
proliferation through activation of the Ras-extracellular-signal-regulated-kinase (REK) 
pathway FAK activation also promotes mtegnn-or growth factor-induced cell survival 
and migration (Hood and Cheresh, 2002)
Activated FAK also associates with the adaptor protein CAS FAK and Src both 
phosphorylate CAS at multiple tyrosine kinase residues which results m the 
association of CAS with another adaptor protein, CRK, and localise to membrane 
ruffles The CAS-CRK complex is part of the molecular migration machinery found at 
the leading edge of motile cells (Klemke et a l , 1998) This complex acts as a 
molecular switch that induces cell motility by activating dedicator of cytokinesis 180 
(DOCK-180), which in turn activates the small GTP-binding protein RAC (Hood and 
Cheresh, 2002)
The SHC family is a group of adaptor proteins that are recruited to activated tyrosine 
kinase in response to ligation of certain integrms and extracellular receptors in 
response to growth factor binding This leads to SHC-dependent cell cycle 
progression, migration, survival and ERK activation (Wary et a l , 1996)
In highly motile cells, initiation of migration is characterised by the reorganisation of 
actin to the cell edge, the protrusion of a leading lamellipodium and membrane ruffling 
at the advancing front of the lamellipodium The RHO family of small GTPases can 
regulate these changes Family members include RHO, CDC42 and RAC RHO 
activation is dependent on integrms, syndecan-6 and other cell surface receptors,
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whereas RAC and CDC42 are activated by ligation of integnns (Ren et al, 1999) 
Activation of RHO leads to the formation of actm stress fibres and the assembly of 
focal adhesions Activation of CDC42 is involved in the formation of filopodia and 
activation of RAC leads to membrane ruffling and cell migration (Hood and Cheresh, 
2002) The expression of active RAC and CDC42 can depolarise differentiated 
mammary epithelial cells and induce mtegnn-mediated invasion through a 3D collagen 
matrix (Kealy et a l , 1997)
During cell migration, the formation of new integnn contacts provides the cell with 
molecular signals that activate ERK signalling Integnns regulate ERK activity 
through several FAK-dependent and independent pathways and also by modulating 
growth factor-stimulated ERK activity ERK activation influences gene transcnption 
cell survival and cell motility (Hood and Cheresh, 2002) Dunng cell migration, the 
ERK signal decreases mtegnn-mediated adhesion and phosphorylates myosin-light- 
chain kinase (MLCK), which regulates the contractile force withm the cell MLCK 
phosphorylates and activates myosin II, an ATPase found in leading lamellae and 
postenor regions of motile cells that generates force by promoting translational 
movement along actin cables Activated myosin then generates contractile forces that 
pull the cell forward towards the new integnn contacts and breaks the contacts at the 
trailing edge of the cell (Klemke et a l , 1997) Phosphatidyhnositol 3-kmase (PI3K) 
regulates integnn dependent cell movement by modulating integnn responses in 
normal and neoplastic tissue PI3K activity is needed for CDC42 and RAC-induced 
cell motility and mvasiveness in mammary epithelial cells (Kealy, et a l , 1997)
The Protein Kinase C (PKC) family of senne/threonme kinases are important in 
regulating integnn function and signalling For instance, ligation of fibronectin by 
integnns and syndecan-4 recruits PKC to membrane adhesions where it is required for 
focal adhesion formation, phosphorylation of FAK, cell spreading, migration and 
SHC-dependent ERK activation (Hood and Cheresh, 2002)
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1.5.2.4 Integrms and signalling; from the inside out
For cells to aquire the traction needed for movement, adhesion to ECM through 
mtegnn heterodimers is critical Maximum cell movement occur at intermediate levels 
of adhesion where the cells can generate enough traction to move efficiently at the cell 
front while releasing contacts at the rear Thus, integrms respond to intracellular clues 
and modify the way in which they act with the extracellular environment by 
modulating their affinity and avidity for their ECM ligands thereby regulating invasion 
and migration (Hood and Cheresh, 2002)
1.5.2.5 Survival durmg invasion
Invading cells must be able to activate survival mechanisms and escape apoptosis 
Indeed, integnn-bmdmg to ECM ligands initiates pro-survival mechanisms Many 
anti-apoptotic pathways are the same as those that are involved in regulating migration 
Many targets of FAK signalling such as RAS, RAC, PI3K and ERK have also been 
implicated in cell survival (Hood and Cheresh, 2002)
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15 3 Proteases and Invasion
Tumour cell invasion involves attachment of tumour cells to the basement membrane, 
local proteolyisis and migration of tumour cells through the proteolytically modified 
region (Liotta et a l , 1983) Localised proteolysis is earned out by proteases outside the 
tumour cell that may be bound to the cell surface or secreted from the tumour cell 
Proteases inside the tumour cell also partake in local proteolyisis by digesting 
phagocytosed ECM Most investigations to date have focused on the role of proteases 
in invasion and metastasis More recent studies have demonstrated that proteases are 
also involved in tumour growth at both pnmary and metastatic sites (Koop et a l , 1994, 
Sympson et a l , 1995 and Wilson et a l , 1997)
Endopeptidases are categonsed into five major classes cysteine (e g cathepsins B, L, 
S, K, Q, caspases, bleomycin hydrolase), aspartic (e g urokinase-type plasminogen 
activator, plasmin, chymase) metallo- (e g gelatinises A and B, mepnn), threonine 
(e g proteasome) and senene proteases This introduction will focus on cathepsin B 
and the MMPs as examples of the involvement of proteases in tumour progression, 
invasion and metastasis
1.5.3.1 Cathepsin B
Increased cathepsin B expression, activity and changes in localisation have been 
observed in many different tumours including breast (Poole et a l , 1978), colorectal 
(Campo et a l , 1994) and lung (Sukoh et a l , 1994) The increased expression of 
cathepsin B at mRNA level is associated with gene amplification, increased 
transcnption, the possible use of multiple promoters and alternatively spliced 
transenpts Changes in the localisation of cathepsin B seem to precede the increase in 
protein levels, which suggests that alterations m trafficking of cathepsin B are 
independent of increased expression (Kobhnski et a l , 2000)
Proteases can interact, leading to the activation of proteolytic cascades that can 
degrade ECM components For example, Procathepsin B can be activated by cathepsin 
D, tPA, uPA, cathepsin G and elastases Active cathepsin B in turn activates pro-uPA, 
which converts plasminogen to plasmin, which can degrade several ECM components 
and activate MMP-1, -3, -9, -12 and -13 The MMPs can then degrade other ECM
25
components e g collagen -I and -IV, gelatins and activate further MMPs (Koblinski et 
a l , 2000) Cathepsin B can activate MMPs indirectly via the plasminogen activator 
cascade and directly activate MMP-1 and -3 Thus, cathepsin B may be an important 
regulator of the activation of pro-uP A/ plasminogen and pro-MMPs
Both direct and indirect interactions between tumour and stromal cells can increase the 
expression of proteases For example the expression of gelatinises A and B are 
increased in fibroblasts upon contact with tumour cells These fibroblasts then partake 
in further degradation of the ECM Expression of cathepsin B and D can also be 
regulated by diffusible factors such as basic fibroblast growth factor (bFGF), insulin 
growth factor-1 (IGF-1) and epidermal growth factor (EGF) Paracrine factors secreted 
from tumour and stromal cells can thus regulate the expression of proteases (Koblinski 
et a l , 2000)
There is an inverse correlation between cathepsin B and basement membrane staining 
m many cancers including lung (Sukoh et a l , 1994) This result is consistent with a 
role for cathepsin B in ECM degradation in vivo Sameni and Slaone developed an 
assay that allows the visualisation of matrix proteolysis by living cells dunng invasion 
through a 3D gelatin matrix The matnx contains a quenched fluorescent substrate that 
fluoresces when cleaved by proteases By using this assay they have observed 
cathepsin B mvolvment in matnx degradation (Koblinski et a l , 2000) Furthermore, 
the proteolytcally active cells facilitate invasion by other cells by attracting them to 
cleared tracks in the matnx (Kramer et a l , 1986)
Cathepsin B may increase cell proliferation by activating growth factors e g bFGF, 
EGF, IGF, vascular endothelial growth factor (VEGF) and transforming growth factor 
p (TGF-p) by freeing them from the ECM where they are sequestered Oursler et a l , 
(1993) found that dexamethasone treatment of normal human osteoblast-like cells 
simultaneously increased cathepsin B and TGF-P expression
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1.5.3.2 Matrix Metalloprotemses (MMPs)
MMPs are a zinc dependent family of endopeptidases that have a pro-domain a 
catalytic domain and a highly conserved active site domain MMPs are synthesised and 
secreted in inactive zymogen form and depends on the presence of zinc and calcium 
ions The production of active enzymes requires that proteolytic removal of the pro- 
domain Over twenty MMP family members are known to exist (Polette et a l , 2004) 
Most MMPs can cleave at least one component of the ECM, as listed m Table 1 1 
MMPs are subdivided into collagenases, stromelysins, gelatinises and MT-MMPs 
based on their substrate preference MMPs are physiologically expressed during 
various stages of development in processes requiring cell migration, tissue 
remodelling, wound healing, placentation or tumour progression Many external 
stimuli can induce the expression of many MMPs
Table 1.1 MMPs and their substrates.
Group MMPs Preferred Substrate
Collagenases MMP1, MMP 18 & 
MMP 13
Collagen I-III 
Collagen IV
Gealtinases MMP 2 & MMP9 
(type IV collagenases)
Type IV collagen 
Laminin
Stromelysins MMP3 (stromelysin 1 ), 
MMP 10 (stromelysin 2), 
MMP 19 (collagenase 4) & 
MMP 11
MMP 7 & MMP26 
(Matnlysins)
MMP 12 (metallo-elastase)
Type IV, V, IX & X 
collagen
Fibronectin, laminin, 
elastin, gelatin & 
proteoglycn core proteins
MT-MMPs MMP 14, MMP 15, 
MMP 16, MMP24 & 
MMP25
Activators of pro-MMP2
Type I-III collagenases
Fibronectin, laminin, 
gelatin, mdogen & 
cartilage proteoglycan core 
protein
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Plasmin has been described to proteolytically activate some latent MMPs (Mignatti et 
a l , 1996) and the cooperation between MMPs and the plasminogen activator/ plasmin 
cascade have an important role in the regulation of tumour invasion in vivo MMPs can 
autoactivate in some cases and can also effect mutual activation For example, MMP1 
can activate latent MMP2 (Nagase, 1996) The proteolytic activity of MMPS is 
controlled by tissue inhibitors of MMPs (TIMPs), which specifically block activity of 
active MMPs by binding to the conserved zinc-bmding site (Polette et a l , 2004) Four 
TIMPs are currently known TIMP-1 and -2 inhibit most MMP activity, while TIMP-2 
and -3 inhibit MT1-MMP TIMP-3 inhibits MMP-1, -2, -3, -7, -9 and -13 TIMP-4 
inhibits MMP-2 and-7 (Knauper et a l , 1996, and Liu et a l , 1997)
It was originally thought that tumour cells were implicated in the invasion process via 
secreted proteolytic enzymes However, in vivo in situ hybridisation studies 
demonstrated that stromal cells were the source of MMPs In 1990, Basset et a l , 
demonstrated that MMP 11 was expressed specifically by fibroblasts in breast 
carcinomas and not by their benign counterparts Thus, host cells have an important 
role m the production of MMPs and tumour invasion due to the cooperation of stromal 
and tumour cells Extracellular matrix metalloproteinase inducer (EMMPRIN) is 
produced by tumour cells and can stimulate MMP-1 -2 and -3 by fibroblasts (Biswas 
et a l , 1995) EMMPRIN mRNA is overexpressed in many carcinomas compared to 
benign and normal tissues, which suggests a role in invasion (Polette et a l , 1996)
A complex interplay exists between cell adhesion molecule organisation and MMP 
expression that can also be involved in the development of an invasive phenotype by 
tumour cells P-catemn is an intracellular attachment protein that can attach 
cytoplasmic actin bundles to cadhenn transmembrane adhesion molecules at the site of 
cell-cell junctions Since tumour cells detach from neighbouring cells in invasion 
abnormalities in the P-catemn/E- cadhenn complex are likely to be involved (Curran 
and Murry, 2000) p-catemn and the DNA binding protein T Cell Factor 
4/Transcnption factor 4 (TCF4) also acts a transcnptional regulator of specific genes 
Normally, the protein product of tumour suppressor gene adenomatous polyposis coli 
(APC) binds to cytoplasmic p-catemn and causes its degradation In most colorectal 
cancers APC is mutated, so p-catemn accumulates and complexes with TCF which 
activates the transcnption of target genes including cyclin D1 and c-myc Brabletz et
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a l , (1999) report that MMP-7 is also a target of P-catemn/ TCF Brooks e/ a / , (1996) 
demonstrated that melanoma cells expressing mtegnn avp3 had the ability to bind 
active MMP-2 facilitating collagen degradation Thus, a cell surface receptor known to 
be involved in directed cellular motility can also bind an enzyme that can degrade a 
major component of the basement membrane Furthermore, the cell surface receptor 
determinant CD44 which is known to promote growth and metastasis of tumour cells, 
has been shown by Yu and Stamenkovic (2000) to associate with active MMP-9 at the 
cell surface of human melanoma cells Disruption of MMP-9/CD44 aggregates 
decreases the invasiveness of tumour cells in vivo
Cytokines have also been shown to regulate MMPs For example, interleukin -1 (IL-1) 
induces the transcription of MMP-1 and -3 (Borghaei et a l , 1998) In a study by Bar- 
Eli (1999) transfection of human melanoma cells with IL-8 increased the activity of 
MMP-2 and the mvasiveness of the cells
MMPs can also regulate cell growth, either directly through the release of growth 
factors or indirectly by changes in cell adhesion as described above MMPs can 
degrade msulin-like growth factor (IGF) binding protein 3, which regulates the 
bioavailability and activity of IFG-II (Fowlkes et a l , 1995) Powell et a l , (1999) 
demonstrated that MMP-7 proteolytically generates active soluble Fas ligand and 
potentiates epithelial cell apoptosis These different effects of MMPs and their 
inhibitors depend on the balance between them in the local microenvironment
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1.5.3.3 Urokinase-type plasminogen activator
Urokinase-type plasminogen activator (uPA) is a serine protease that is involved in the 
progression of cancer particularly in invasion and metastasis. Many studies of breast 
cancer patients whose primary cancers have high uPA levels have significantly poorer 
outcome than those with low uPA levels. Paradoxically, high levels of plasminogen 
activator inhibitor-1 (PAI-1) a uPA inhibitor, is also predictive of poorer patient 
outcome (Duffy, 2002).
The human uPA gene encodes a 53kDa protein that is initially synthesised as a 
catalytically inactive single chain peptide. Conversion to active form is brought about 
by a number of proteases including plasmin, cathepsin-B and -L. uPA is a 
multifunctional protein involved in both proteolysis and signal transduction. As a 
protease, uPA catalyses the conversion of plasminogen to active plasmin. Plasmin can 
then promote the degradation of ECM substrates that include fibrin, fibronectin and 
laminin. It can also activate MMPs and activate or release specific growth factors such 
as FGF-2 and TGF-p. uPA-catalysed proteolysis occurs in vivo while the protease is 
attached to a membrane anchored protein receptor, uPAR (Andreasen et al., 1997). 
Binding of uPA to its receptor enhances proteolysis and also results in signal 
transduction, including activation of mitogen-activated protein kinase (MAPK), 
extracellular signal-regulated kinases 1 and 2 and other signalling pathways that 
activate Fos and Jun (Ossowski and Aguirre-Ghiso, 2000). uPA activity can be 
neutralised in vivo by two inhibitors called as plasminogen activator inhibitors 1 and 2 
(PAI-1 and PAI-2), which belong to the serpin family of protease inhibitors and inhibit 
apoptosis. PAI-1 can also modulate adhesion and migration independently of its role as 
a protease inhibitor (Duffy, 2002).
Positive correlations between uPA levels and metastasis have been found in both cell 
lines and animal tumours. Transfecting cell lines with uPA cDNA enhances the 
metastasis of the transfected cells. Inhibition of uPA activity or expression reduced 
metastasis in model systems. Blocking uPA:uPAR binding also decreases metastasis in 
systems studied. Tumours in uPA null mice exhibit less progression than those in mice 
expressing uPA (Andreasen et a l , 1997). Since metastasis is the main cause of death
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in cancer patients, and since uPA is an important mediator of this process, uPA is an 
ideal candidate for use as a marker to predict the likely formation of metastasis 
Indeed, as a predictor of outcome for breast cancer patients, uPA acts as a potent 
biological marker High levels of uPA are also correlated with poorer patient outcome 
in patients with stomach, colorectal, bladder, ovary, endometrium and brain cancers 
(Duffy, 2002b, Schmidt et a l , 1997) High levels of PAI-1 are also associated with 
aggressive disease and poorer patient outcome Although the reason for this is not 
clear, there are many possible explanations For example, a critical PAI-1 
concentration may be needed to prevent excessive ECM degradation by uPA dunng 
cancer invasion, where excessive ECM degradation could leave insufficient substrate 
on which cancer cells could migrate PAI-1 is also needed for angiogenesis to occur 
and can modulate both cell adhesion and migration and thus metastasis and can inhibit 
apoptosis, hence increased PAI-1 expression is a poor prognostic factor (Duffy, 2002, 
Duffy, 2002b) Both uPA and PAI-1 are possible targets for cancer therapeutics, 
specifically with applications in the prevention of metastases
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1.5.3 4 Proteases and clinical trials
The detection of high expression of MMPs in many cancers and their association with 
poor prognosis make them ideal candidates for therapeutic targets Therapeutic 
approaches using anti-MMP agents in conjunction with conventional chemotherapy 
have been developed over the last decade (Baker et a l , 2002, Coussens et a l , 2002) 
However, these new treatments have not provided any significant results due to the 
side effects caused Also, since the matrix metalloproteinase inhibitors are cytostatic 
rather that cytotoxic, traditional endpoints used in anticancer drug trials, such as a 
decrease in tumour size, may not be appropriate in assessing the inhibitor 
effectiveness Indeed, the conversion of tumours from an aggressive type to a more 
dormant state may be an acceptable therapeutic outcome and one will need to be able 
to document their biological activity on angiogenesis or tumour proliferation using 
non-invasive imaging technologies in vivo If tumour dormancy is the aim, a drug 
would have to be administered long term therefore the issue of toxicity would have to 
be addressed
Pre-clmical models that more closely mimic the interaction between neoplastic and 
stromal cells in cancer progression are needed A consortium of several investigators 
including Carl Blovel (Sloan-Kettenng), Lisa Coussens (UCSF) and Ching Tung 
(Harvard) to name but a few was recently created to determine the exact role that 
proteases play in tumour growth and invasion The consortium determined that an 
optimal assortment of model systems would need to be evaluated based on the 
following criteria (1) examination of multiple stages of tumour progression, (2) an 
orthotopic environment for tumour cells, (3) tumours are grown at organ sites of the 
most prevalent sites of human cancers (4) multiple classes of proteases are expressed 
They hope to identify causal role in malignant progression, validate proteases as 
therapeutic targets, develop functional assays for imaging proteolytic activity to 
analyse interactions among the cell types comprising a solid tumour, and develop 
functional assays for non-invasive imaging of the activity of the proteases that are 
validated as potential targets (Curran and Murry, 2000, Koblinski et a l , 2000, and 
DeClerck et a l , 2004)
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1.5.4 Rho proteins and invasion
1.5.4.1 Rho proteins and growth factors
The Rho (Ras homology) GTPases are a subfamily of small GTP-binding proteins that 
are related to the Ras oncogene. All aspects of motility and invasion are regulated by 
the Rho GTPases and are closely linked to signals from the extracellular environment, 
particularly in response to growth factors. Most Rho GTPases act as molecular 
switches that cycle between an inactive GDP-bound conformation and an active GTP- 
bound conformation. To be effective in achieving the invasive phenotype, the Rho 
proteins need to complete a full GTPase cycle, alternating between an active and 
inactive state (Ren et al., 1999; Lin et al, 1999 and Symons and Settleman, 2000). 
Rho proteins are activated via extracellular signals which result in the binding and 
hydrolyses of GTP and the induction of downstream effector molecules generating a 
cellular response (Kjoller et al., 1999). It is the activation state of Rho proteins and not 
their expression levels that dictate cellular response. Rho activation by growth factors 
occurs through interactions with Rho regulatory proteins. These include; GTPase- 
activating proteins (GAPs); guanine nucleotide dissociation inhibitors (GDIs); GDI- 
dissociation factors (GDFs) and guanine nucleotide exchange factors (GEFs) (Geyer 
and Wittnghofer, 1997). The cycle is balanced by GDIs, which prevent guanosine 
diphosphate (GDP) dissociation and sequester Rho in the cytoplasm.
During the progression of cancer, early disregulation of growth factor signalling such 
as EGFR amplification may have a mitogenic effect needed for tumour cell growth and 
survival. However, later in cancer progression these same growth factor signals may 
activate Rho GTPases and drive metastasis. The ability to migrate is critical for 
tumouregenic cells and requires cellular depolarisation and turnover of focal 
adhesions, which contain integrins, cytoskeletal and signalling proteins such as a- 
actinin and focal adhesion kinase (FAK). FAK expression in FAK null mice leads to a 
transient inhibition of RhoA and RhoC activity, ROCK activation, restoration of focal 
adhesion turnover and cell migration. Loss of FAK expression activates Rho/ROCK 
and decreased migration (Ren et a l , 2000).
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1.5.4.2 Rho and Insulin-like growth factors (IGFs)
Treatment of IGF-1R overexpressmg MCF-7 breast cancer cells with IGF-1 leads to 
actin filament disassembly, cellular depolarisation and the formation of fascin 
microspikes associated with lamellipodia (Guvakova and Surmacz, 1999) These 
changes involve the activation of the phosphotidylinositol 3-kinase (PI3K) pathway 
and transient dephosphorylation of FAK and Crk-associated substrate and paxillin 
(Guvakova et a l , 2002) causing Rho activation, actin depolymensation, focal adhesion 
turnover and loss of cellular polarity Phosphorylation of FAK inhibits Rho activity, 
stabilises focal adhesions and activates Rac and Cdc42 needed for fascin microspike 
formation and lamellipodial formation This demonstrates how Rho GTPases must 
work together to induce cell motility A study by Penmsi et a l , (2002) demonstrated 
that decreased IGF-1R levels increased motility and invasiveness in MCF-7 cells by 
increasing the activity of Rac and Cdc42 and decreasing Rho activity and E-cadhenn 
expression This implies that activation of IGF-1 R stabilised the E-cadhenn/p-catemn 
complex and potentially activates RhoA, promoting cellular aggregation In RIP1- 
Tag2 munne model of pancreatic tumongenesis by Lopez and Hanahan (2002) IGF-1R 
is increased in invasive tumours Here, IGF-II activates IGF-1R in hyperprohferative, 
oncogene-expressing p cells and is uniformly expressed m invasive tumours Thus, 
overexpression of IGF-1 R accelerates tumour progression and enhances invasive and 
metastatic capabilities of the cells, possibly mediated by Rac and Rho
1.5.4.2 Rho and Epidermal growth factor (EGF)
EGF-mduced cellular motility and invasion by Rho proteins is well documented In 
vivo invasive properties of the MTLn3 rat mammary carcinoma cell line are 
significantly decreased when transfected with dominant negative forms of RhoA, 
Racl, and Cdc42 (Bouzahzah et a l , 2001) Kusama et a l , (2001) demonstrated a dose- 
dependent increase of RhoA-mediated in vitro cellular invasion in Panc-1 human 
pancreatic cancer cell line stimulated with EGF Treatment of the cells with statins, 
inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A, abrogates EGF-mduced
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invasion, possibly by preventing Rho-A from localising in the inner plasma membrane, 
where it can be activated by RhoGEFs.
1.5.4.4 Other aspects of Rho and invasion
There is also evidence that Rho proteins can change the expression of genes encoding 
proteins that degrade the ECM. Rac stimulates activation of the kinase JNK and 
subsequent phosphorylation of the transcription factor Jun. Jun is a component of API 
transcription factors, which induce MMP expression (Ozanne et al., 2000). Cell cycle 
progression involves the sequential activation of various cyclin-dependent kinases 
(CDKs). The expression of cyclins and other CDK regulators vary during the 
progression of the cell cycle and are frequently deregulated in cancers. Rho, Rac and 
Cdc42 have been reported to effect the expression of CDK regulators in cultured cells 
(Ridley, 2004). RhoH is the only Rho family member known to be genetically altered 
in human cancers. Its rearrangement leads to the expression of a fusion protein that 
expresses the full RhoH protein. It remains to be seen if RhoH can contribute to the 
development of cancer in animal models (Ridley, 2004). Tiaml is a Rac specific 
guanine nucleotide exchange factor (GEF) originally identified by Price and Collard, 
(2001) for its ability to promote T lymphoma invasion in vitro. Studies of human 
cancer and animal cancer models indicate that Tiaml has an effect on cancer 
development.
Altered Rho family expressions have been revealed in many human cancer studies. 
Indeed, there is often isoform-specific upregulation i.e. RhoA, RhoB, RhoC, Racl, 
Rac2 and Rac3. The expression of RhoC mRNA is selectively increased in metastatic 
melanomas, and is sufficient to stimulate melanoma cell metastasis in a murine model 
(Clark et al., 2000). Regulators of Rho GTPases whose expression is increased in 
human tumours include the GEFs P-PIX in breast cancers (Ahn et al., 2003) and Vavl 
in glioblastomas (Homstein et al., 2003).
A key question arising from gene expression profiling is whether increased expression 
of a particular gene is important for the development of cancer or whether it is an
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indirect result of the change in state of the cancer cell compared to the normal cell A 
study by Wang et a l , (2002) where the gene expression in a metastatic breast cancer 
cell line was compared to its non-metastatic counterpart revealed that many genes 
encoding actin-regulatory proteins were more highly expressed in the metastatic cells 
The fact that Rac and Rho family members and their regulators are also upregulated in 
various cancers may simply reflect a higher migration capacity in these cells While 
this may be diagnostically informative, it remains to be seen if Rho and Rac pathways 
are good targets for cancer therapy To determine this will require testing the effects of 
inhibiting or deletion of these genes on cancer development in animal models
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1.5 5 Chemokines
Chemokines are a family of low molecular weight pro-inflammatory cytokines that 
bind to G-protem coupled receptors More than forty different chemokines have been 
isolated Their mam function is chemoattraction and activation of specific leucocytes 
in immuno-mflammatory responses Chemokines have been shown to be involved in 
all stages of tumour development There are four groups of chemokines, which are 
defined by the arrangement of cysteine residues of mature proteins (Baggiolim et a l ,
1997) The first three classes all have four conserved cysteines whereas the fourth has 
only two The chemokine receptors are part of a larger family of G-protein-coupled 
receptors, including receptors for hormones, neurotransmitters and inflammatory 
mediators Each receptor binds ligands from only one of the four-chemokine structural 
groups giving four receptor groups (Arya et a l , 2003)
Growth factors induce cells to enter and proceed through the cell cycle 
(Gospodarowicz, 1983) Schadendorf et a l , (1993) found IL-8 (CXCL8) to be an 
essential autocnne growth factor for some human melanoma cell lines This 
chemokine binds to CXCR1 or CXCR2 receptors In a further study by Metzner et a l , 
(1999) showed that proliferation of human epidermoid carcinoma cells A431 and KB 
could be induced by IL-8 and inhibited by antibodies against IL-8 or its receptor This 
indicated an autocnne growth mechanism in these cells CXCL1 is also thought to act 
as an autocnne growth factor for human adenocarcinoma cell lines from the lung, 
stomach and pancreas (Arya et a l , 2003)
Angiogenesis occurs dunng embryonic development and wound healing It is also 
required for tumours to develop beyond 2mm in diameter (Folkman, 1995) Studies 
have shown that CXCL4 has angiostatic properties, it prevents endothelial cell 
proliferation and thus angiogenesis and tumour growth m immunodeficient mice 
(Maione et a l , 1990) The ELR+ CXCL8 was the first chemokine shown to stimulate 
angiogenesis and tumour growth (Koch et a l , 1992) By substituting the ELR motif in 
CXCL8 with the ammo acids TVR (Thr-Val-Arg) or DLQ (Asp-Leu-Gln), Stneter et 
a l , (1995) demonstrated that the ELR motif is cntical for determining the effect of the 
CXCL8 chemokine has on angiogenesis CXCL10 was also shown to inhibit 
angiogenesis stimulated by bFGF in vivo (Angiolillo et a l , 1995) It is thought that
37
CXC chemokmes form a balanced network of angiogenic and angiostatic regulators 
that are deregulated in cancer Indeed, the balance of ELR+ and ELR- chemokmes 
produces by a tumour and its stroma may determine the extent of angiogenesis and 
hence the invasiveness of the tumour
Chemokmes are also important m the induction of proteases during invasion CXCL8 
expression in human melanoma cells has been found to transcriptionally activate 
MMP-2, which increases invasiveness through the ECM (Bar-Eli, 1999) Muller et a l , 
(2001) looked into the mechanisms involved in the metastasis of breast cancer to 
specific organs They found the expression of the receptor genes CXCR4 and CXCR7 
was increased in human breast cancer cell lines, malignant breast tumours and 
metastasis relative to the levels in normal mammary epithelial cells A panel of normal 
human organs were screened for the ligands of these receptors, CXCL12 and CXCL21 
Peak levels of expression of these ligands were found in organs preferred for breast 
cancer metastasis These ligands stimulated pseudopodia formation and directional 
migration and local invasion through the ECM and basement membrane in breast 
cancer cell lines These findings support the theory that certain chemokine ligands and 
their receptors are involved in the homing of metastatic tumour cells to specific organs
Since chemokmes function as immunostimulatory molecules, they may have great 
potential in cancer therapy Vican et a l , (2000) demonstrated that mouse CCL21 had a 
strong antitumour effect by inducing angiostatic and T lymphocyte-mediated tumour 
resistance mechanisms Also, injection of recombinant CCL21 directly into the tumour 
site induced potent antitumour responses and led to the complete eradication of 
alveolar carcinoma and Lewis lung carcinoma (Sharma et a l , 2000)
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1.6 Microarrays
Each cell in the body contains a full set of chromosomes containing identical genes but 
only a fraction of these genes are expressed at any given time It is this group of 
expressed genes that makes each cell type unique Aberrant gene expression profiles 
are responsible for many diseases The completion of the Human Genome project 
(HGP) has led to a vast amount of information becoming available about almost all 
genes m the genome, and is necessary to understand the functions of these gene 
products The development of full genome expression microarrays, have allowed 
researchers to study the expression of almost every gene simultaneously It is 
important to note, however, that we may not yet have identified all genes correctly 
from the sequence data and our knowledge of the range of splice variants remains 
incomplete to date
1.6.1 Introduction to microarray technology
Microarrays are artificially constructed grids of DNA where each element of the grid 
contains a specific oligodeoxynucleotide probe This enables researchers to 
simultaneously measure the expression of thousands of genes in a given sample 
Microarray experiments rely on the ability of RNA to bind specifically to a 
corresponding sequence-complementary probe DNA microarrays are classified based 
on the DNA molecule that is immobilised on the slide There are two basic types 
either oligodeoxynucleotide or cDNA arrays Oligodeoxynucleotide arrays are 
typically made up of 25-80 mer oligodeoxynucleotides while cDNA arrays are printed 
with 500-5000 base pair PCR products
Microarray technology can be used to detect specific gene changes in, for example 
diseased tissue compared to normal healthy tissue or the changing gene expression 
profiles of developing tissues over a defined time period These types of experiments 
have the potential to help explain why a disease occurs and also how best to overcome 
it by improving our understanding of the molecular mechanisms attributing to disease 
development and progression
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The steps of a microarray experiment are shown in Figure 1 3 This is an example of
an Affymetnx genechip expenmental workflow
1 Total RNA is isolated from the cells being studied
2 The RNA is enzymatically converted into a double stranded DNA copy known 
as a complementary DNA (cDNA) This is done through reverse transcription 
(RT)
3 The cDNA is allowed to go through in vitro transcription (IVT) to RNA (now 
known as cRNA) This RNA is labelled with Biotin by incorporating a biotin- 
labelled ribonucleotide during the IVT reaction
4 This labelled cRNA is then fragmented in to pieces anywhere from 30 to 200 
base pairs in length by metal-induced hydrolysis
5 The fragmented, Biotin-labelled cRNA is then hybridized to the array for 16 
hours
6 The array is then washed to remove any unhybndized cRNA and then stained 
with a fluorescent molecule streptavidm phycoerythnn (SAPE), which sticks to 
Biotin
7 Lastly, the entire array is scanned with a laser and the information is 
automatically transferred to a computer for analysis of what genes were 
expressed and at what approximate level
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Figure 1.3 Steps in a microarray experiment (www.affymetrix.com)
1.6.2 Microarray analysis
Microarray experiments generate vast amounts of data in a short period of time. For 
the results of a microarray experiment to be acceptable, the raw data from the 
experiment must be validated. Good experimental design is the first step. It is 
important that the proper controls and replicates are included in each experiment. 
Replicates are particularly important since the methods used to identify differentially 
expressed genes are predominantly statistical. Microarray data is normalised to 
measure real biological changes by minimising processing variation. This process 
standardises the data so that the gene expression levels are comparable.
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Quality control checks must also be included at all stages of the experiment These 
checks would usually include quality checks on the initially isolated RNA and 
processed sample at regular intervals, e g Agilent Bioanalyser The Agilent 
Bioanalyser analyses sample RNA in order to determine quality Detailed information 
about the condition of RNA samples is displayed in the form of highly sensitive 
electropherograms Post-expenmental quality control checks include the chip controls 
shown m Table 1 2
Table 1 2 Array quality control measures
QC measure Result
Background Measure of non-specific binding
375’ Ratio Indicates how well IVT reaction has proceeded
Hybridisation controls Checks spike controls added to each sample
Percentage present All samples should have comparable % genes present
Noise The electrical noise from scanner
Scale factor Measures the brightness of array- All chips in an experiment 
should have scale factors within 3-fold of each other
The format for reporting microarray data was described by Brazma et a l, (2001), and 
is called the “minimum information about a microarray experiment” (MIAME) 
MIAME has two general principles The first is that there should be sufficient 
information recorded about each experiment to allow interpretation of the experiment, 
allow for comparison to similar experiments and enable replication of the experiment 
The second principle is that the data be presented in a structured manner to allow 
automated data analysis and mimng
Bioinformatics is the application of software to large biological data sets for 
interpretation and analysis of molecular biological information In this case, the large 
spreadsheets of Gene Expression data from the microarray experiments were 
manipulated using the Affymetnx MAS and GeneSpnng software packages (Section 
2 16) These software packages enable the selection of potentially important genes in
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the biological system under investigation by statistically comparing experimental 
conditions
Although statistics are used to generate lists of potentially interesting genes from the 
microarray data, many of the filtering choices (e g to include genes above a certain 
level in an analysis) are subjective and influence the resulting gene lists For this work, 
several alternative analyses were performed and genes that were highlighted from 
multiple approaches were prioritised for further investigation
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1.6.3 Affymetrix GeneChips
The microarray experiments performed in these studies employed the Affymetrix 
Genechip system, which are oligodeoxynucleotide microarrays. Affymetrix probes are 
designed using publicly available information (NCBI database). The probes are 
manufactured on the chip using photolithography. Each genechip contains 
approximately 1,000,000 features. Each probe is spotted as a pair, one being a perfect 
match (PM), the other with a mismatch at the centre (MM). Each gene transcript is 
represented on the genechip by 11 probe pairs (PM+MM). This can be seen in Figure
1.4. Each transcript has 22 different probes in total to ensure that the microarray is 
detecting the correct piece of RNA while also helping to estimate and eliminate 
background. The amount of light emitted at 570nm from stained chip is proportional to 
the quantity of labelled RNA bound to each probe. Therefore, after scanning, the initial 
computer file generated (.DAT) contains a numerical value for every probe on the 
array.
For a valid gene expression measurement,
the Perfect Match sticks and the Mismatch does not
Figure 1.4 Perfect match and mismatch probe pairs on Affymetrix GeneChips 
(www.affymetrix.com)
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1.6.4 Microarrays and cancer
Microarray technology is and has been used intensively to better understand the 
development of a metastatic phenotype and cancer progression, both in vivo and in 
vitro In 2002, van’t Veer et a l , used DNA microarray technology to compare the gene 
expression profiles of 117 primary breast tumours from young patients They applied 
supervised classification to identify a 70-gene expression signature that would strongly 
predict the development of distant metastasis m lymph node negative patients in a 
short time frame This study also reported a signature identifying BRCA1 tumours In 
all, these signatures were suitable to select patients who would benefit from adjuvant 
therapy
Ramaswamy et a l , (2003) compared the gene expression profiles of twelve metastatic 
adenocarcinoma nodules of diverse origin with 64 primary adenocarcinomas 
representing the same spectrum of tumour types The group identified a 17-gene 
signature associated with the development of metastasis m multiple tumour types 
indicating that a molecular program of metastasis may exist that is shared by many 
solid tumour types suggesting the possible existence of therapeutic targets common to 
many cancer types
More recently, and in a study more similar in nature to the one described in this thesis 
in that the expression profiles of closely related cell lines were compared, Onan- 
Rousseau (2005) used suppression subtractive hybridisation and cDNA array analysis 
to compare to closely related colon cancer lines, the invasive HT29p and the non- 
mvasive HT29-MTX The expression of fifty-eight genes was increased in metastatic 
cells, the majority were previously undescnbed relevant to the development of 
metastasis
cDNA microarray analyses was also used to distinguish squamous non-small lung 
cancers from normal bronchial tissue (Remmelink et a l , 2005) In this way 19 genes 
were differentially expressed between normal and cancer tissue Rickardson et a l , 
(2005) profiled ten human tumour cell lines including parental and drug resistant sub- 
types using array methodology Hierarchial clustering based on drug-gene correlations 
yielded drug clusters with similar modes of action The analysis also generated
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genelists correlating with both drug resistance and drug sensitivity respectively, which 
may be useful in the development of new therapeutic drugs
This study used Affymetnx U133A expression microarrays to compare the expression 
profiles of five closely related variants of a lung cancer cell line (DLKP), some of 
which are resistant to chemotherapeutic drugs and which differ in their capacity to 
invade as measured using an in vitro invasion assay
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1.7 RNA Interference
RNA interference is the biological mechanism by which double-stranded RNA 
(dsRNA) induces gene silencing at the level of translation by targeting complementary 
mRNA for degradation RNAi has the potential to help elucidate the complex issues 
involved in eukaryotic development, to aid in dissecting cellular pathways, and to 
identify targets for therapeutic intervention that otherwise would remain unidentified
1.7.1 Introduction to siRNA technology
The phenomenon of post translational gene silencing (PTGS) was first discovered in 
plant studies A major study into the silencing of specific genes m C elegans by the 
introduction of dsRNA by Fire and Mello in 1998 demonstrated that the presence of a 
small number of molecules of dsRNA was sufficient to almost completely abolish the 
expression of a gene that was homologous to the dsRNA (McManus and Sharp, 2002)
Experiments conducted in Drosophila have indicated a four-step mechanism for the 
RNAi pathway Briefly, long dsRNA is cleaved into 21-25nt double stranded 
fragments, termed small interfering RNAs (siRNAs) This step is ATP-dependent 
These siRNAs are incorporated into a protein complex ATP-dependent unwinding of 
the siRNA duplex leads to activation of the complex to an RNA-induced silencing 
complex (RISC) The RISC can recognise and cleave a target RNA complementary to 
the guide strand of the siRNA (Hutvagner and Zamore, 2002) A schematic diagram of 
the mechanism of RNAi can be seen in Figure 1 5 A member of the RNase III family 
of endonucleases termed Dicer is responsible for the production of siRNAs Certain 
structural features are important for entry of siRNAs into the RNAi pathway, such as a 
5’ phosphate and 3’ hydroxyl termini and two smgle-stranded nucleotides on the 3’ 
ends
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dsRNA
* D icer
siRNA
RISC protein  
com ponents
RISC
&»RNA unwinding
Activated
RISC
A sso c ia t io n  w ith  
ta rg e t mRNA
T a rg e t rriRNA 
cleavage
Sense • Target rriRNA
Anfcsense
Figure 1.5 The mechanism of RNAi rwww.ambion.com)
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The enzymatic machinery for generating siRNA sequences is also used for the 
production of an additional class of endogenously encoded small RNA molecules 
termed microRNAs These miRNAs are a newly identified, large family of RNAs with 
highly conserved expression patterns Hundreds of miRNAs have been found in C 
elegans, plants and mammals A common feature of miRNAs, not seen m siRNAs, is 
that the miRNAs sequences are found in the stem of a stem-loop structure (Kim, 
2003) A large number of the miRNA targets identified to date are proteins involved in 
cell growth and development or transcription factors (Ke et a l , 2003) The binding 
specificity of miRNA sequences and speed at which miRNAs can be generated (when 
compared to the time taken to synthesise regulatory proteins), result in regulatory 
molecules that are ideally suited for the precise temporal control required during 
development miRNAs may also help to explain the diversity of phenotypes among 
higher organisms with a limited number of protein coding genes
The PTGS mechanisms of siRNA and miRNA are largely identical, as indicated by the 
fact that endogenously encoded human miRNAs can cleave exogenously added RNA 
substrates with fully complimentary target sites while siRNAs can repress translation 
without RNA cleavage when there are slight central mismatches (Zeng et a l , 2003)
1.7.2 Applications of RNAi
Gene silencing using siRNA is quickly becoming the most common method to study 
the function of these genes whose functions are unknown The use of antisense and 
nbozymes to decrease gene expression are laborious and time-consuming Libraries of 
siRNAs and automatic screening systems are now available which make it possible to 
screen large sections of the human genome simultaneously
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It is clear that siRNA may have multiple applications in disease therapy. Diseases that 
may potentially benefit therapeutically from RNAi technology include viral infections, 
cancer and genetic disorders (Kim, 2003). The concentraion of siRNA used is of 
paramount importance for therapeutic applications considering that siRNAs applied at 
lOOnM nonspecifically induced the expression of a number of genes involved in 
apoptosis and cellular stress responses. Reduction of the dosage to 20nM eliminated 
this effect however (Semizarov et al, 2003).
Tumour invasion and metastasis rely on the mobility of tumour cells and their 
interaction with the host microenvironment. Thus, RNAi targeting of molecules 
important for tumour invasion or metastasis may have therapeutic potential (Pai et al., 
2006). For example, insulin-like growth factor-binding protein 2 (IGFBP2) is 
frequently overexpressed in ovarian carcinomas, particularly in serous carcinoma (Lee 
et a l , 2005). These IGFBP2-overexpressing cells were more invasive than control 
cells as measured by in vitro matrigel invasion assay. Furthermore, silencing of 
IGFBP2 expression by RNAi technology in an ovarian cancer cell line (PA-1) 
decreases its invasiveness. An additional study by Zheng et al., (2005) saw the 
application of siRNA technology to decrease E-cadherin expression in gastric cancer 
cells. Invasion was increased in siRNA transfected cells. In fact siRNAs could be used 
to target any of the molecules that regulate tumour cell invasion and metastasis in an 
effort to control cancer spread. In order for siRNA to become a potential therapy, 
problems with delivery must be overcome.
1.7.3 Problems associated with RNAi
Long dsRNA has been found to induce an immune response when introduced into 
mammals (Bridge et al., 2003; Sledz et al, 2003), leading to induction of the 
interferon (IFN) response. In mammalian systems this can be overcome by 
introduction of synthetic siRNAs.
In early studies using RNAi, there were questions regarding siRNA specificity. In a 
study by Jackson and colleagues (2003), using gene expression profiling, it was 
revealed that there was direct silencing of non-targeted genes (some containing as little
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as 11 contiguous nucleotides homologous to the siRNA) This is in agreement with the 
finding that siRNAs can suppress expression of off-target proteins even with 3-4 base 
mismatches and additional G-U mismatches (Saxena et a l , 2003) These results are 
disputed however m a study by Chi et al (2003), where DNA microarray analysis 
demonstrated the precise sequence specificity of siRNA constructs In general, it is 
recognised that well designed siRNA sequences will not elicit “off-target” effects, and 
that many failures in RNAi experiments may have been caused by lack of experiment 
optimisation
1 7.4 Delivery of siRNA
The most widely used delivery technique for RNAi is siRNA transfection Design of 
siRNAs is critical for experimental success Choice of target site, transfection method 
and protein turnover rate must be taken into consideration There are certain guidelines 
available for siRNA design Secondary structures and mRNA binding proteins can 
influence the ability of an siRNA to bind its target Companies such as Ambion create 
siRNAs using algorithms that overcome these issues The choice of transfection 
reagent and conditions, such as cell density, also important in the success of an siRNA 
transfection Transfection of synthetic siRNA duplexes at low concentration can help 
to prevent the IFN response of cells (Kim et a l , 2004) This method of siRNA delivery 
is transient and protein inhibition is lost after a number of days, depending on its 
turnover rate To allow the expression of short hairpin RNAs (shRNAs, these undergo 
post-transcnptional processing into 21nt duplex siRNAs by Dicer), plasmids have been 
designed using promoters based on RNA polymerase II or III e g Sui et a l , 2002 The 
plasmids can contain a selectable marker so that sub- populations of cells with 
permanently silenced target genes can be isolated Viruses are excellent vehicles for 
siRNA delivery, especially retroviruses (Devroe & Silver, 2004) Other viral delivery 
vehicles include HIV based, lenti virus based vectors (Stewart et a l , 2003) or 
adenoviruses (Shen et a l , 2003) although these may trigger an immune response over 
time A lentiviral vector capable of expressing a siRNA against GFP was used to 
silence GFP m a transgenic mouse that had stable expression of GFP (Tiscomia et a l , 
2003)
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Successful silencing m the lung has been achieved by intranasal or intratracheal 
administration of siRNAs Remarkably, siRNA specific effects on pulmonary 
epithelial cells have even been elicited in vivo by siRNAs used without transfection 
reagents or other delivery molecules (Bitko et a l , 2005, and Zhang et a l , 2004) This 
indicates that the lung (and possibly other tissues) may have a means for siRNA 
uptake The transformed cell lines commonly used for in vitro RNAi experiments 
require a transfection reagent or other mechanism for siRNA uptake and knockdown to 
occur The first therapeutic benefit in the lung was demonstrated for influenza A 
infection siRNAs against conserved influenza sequences when complexed with the 
polycation polyethyleneimine (PEI) were delivered to the lung by intravenous low 
pressure injection and reduced viral titers by 1-2 logs (Hagstrom et a l , 2004) A 
concurrent study to that of Hagstrom et a l , which combmed injection of the same 
siRNAs and mtranasal instillation of siRNA complexed to ohgofectamme protected 
mice from lethal challenge with several highly pathogenic stains of influenza A 
(Tompkins et a l , 2004) These studies did not observe evidence of interferon induction 
induced by the siRNA treatment in vivo These experiments established the proof of 
principle for treating pulmonary infections with siRNAs, although the injection 
method is may not be suitable for clinical use and the PEI earner may also have 
unacceptable toxicity (Dykxhoom et a l , 2006)
Delivery of siRNAs to effect treatment is a surmountable hurdle Prechmcal studies 
such as those by Hagstrom et a l, (2004) and Tompkins et a l, (2004) have 
demonstrated successful delivery of siRNA by inhalation and intravenous injection 
however delivery can be local, systemic, and cell selective Whether conjugations that 
enhance delivery interfere with siRNA incorporation into RISC will need to be 
explored Despite this, rapid advances in knowledge of siRNA design foretell that this 
theoretical concern will be solved too (Aronin, 2006)
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1.8 Aims of Thesis
Metastasis is a major cause of mortality in cancer (Fidler et al., 1994). This 
phenomenon occurs when cells detach from the primary tumour and invade through 
the surrounding extracellular matrix, eventually finding their way into the blood 
stream. They then travel to a distant site, re-attach to and invade through the capillary 
wall and into surrounding tissues. Some of the mechanisms that these metastatic 
tumour cells utilise in order to undertake this journey are better understood than others. 
However, on the whole, this process remains poorly understood, particularly in terms 
of the underlying molecular mechanisms that drive the switch to a metastatic 
phenotype. Our laboratory has an ongoing interest in this aspect of cancer biology, and 
this particular project was designed to utilise one of the model cell systems developed 
here, in combination with advanced transcriptional profiling methods, to further our 
understanding of the metastatic process.
The specific aims of the project were as follows:
1. To establish the degree of invasiveness of the individual cell lines within a
panel in an in vitro invasion assay. In order for this model to be of use we 
needed to establish that the relative invasiveness of the sub-lines (compared to 
each other) remained constant over a reasonable number of passages and under 
specific culturing conditions. Defining these parameters at the outset would 
give greater confidence in any of the observed changes subsequent to deliberate 
experimental manipulation, once the established assay protocol and boundaries 
were adhered to.
2. To generate genelists from the array data that may potentially serve as a 
molecular signature for invasiveness and/or drug resistance in these cell lines.
3. To validate the results of the array-based differential expression analyses by 
RT-PCR. Microarray data is generally quite accurate in terms of quantifying 
changes in mRNA abundance, however we felt it was important to confirm the
trends observed, in a small panel of target genes, by an alternative
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quantification method This would not only give greater confidence in the 
significance of gene lists generated from array data mimng but also function as 
a validation step before choosing particular target genes for further 
investigation
)
4 To choose a small group of high priority target genes for follow-on study in the 
laboratory These targets were chosen based on a number of criteria including 
being consistently associated with or correlating (either negatively or 
positively) with invasion during bioinformatic analysis PCR validation should 
confirm array data trends and, in addition, review of published data should 
either demonstrate previous recognised association with cancer/metstasis or 
alternatively, complete novelty in this regard
5 To investigate the role of these targets in invasion by knocking down 
endogenous mRNA levels using siRNA technology This technology is still 
relatively new but has quickly become the first choice in molecular and cell 
biology labs when attempting to identify molecular function Confirmation of 
knockdown by RT-PCR, qRT-PCR and/or Western blotting was undertaken 
where possible In most cases an investigation into a functional effect on 
proliferation was also included Most importantly any functional effect was 
examined by invasion assay using our in vitro cell model
6 To complement the knockdown studies by over expression of the same target 
genes by transient cDNA transfection in the cell line panel Where a target gene 
was chosen on the basis that its endogenous expression levels were very low in 
invasive cells only or vive-versa, it was of interest to discover whether this 
phenotype could be reversed by artificially elevating transcript expression 
Again RT-PCR and/or western blotting confirmed overexpression where 
possible Effect on proliferation was also investigated and most importantly 
any functional effect of the cells was examined by invasion assay
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Section 2.0: Materials and Methods
2.1 Water
Ultrapure water was used in the preparation of all media and solutions This water was 
purified by a reverse osmosis system (Millipore Milli-RO 10 Plus, Elgastat UHP) to a 
standard of 12-18MQ/cm resistance
2.2 Glassware
Solutions pertaining to all cell culture and maintenance were prepared and stored in 
sterile glass bottles Bottles and lids and all other glassware used for any cell related 
work were prepared as follows - all glassware lids were soaked in a 2% (v/v) solution 
of RBS-25 (AGB Scientific) for at least 1 hour Following scrubbing and several rinses 
in tap water, the bottles were then washed by machine using Neodisher detergent, an 
organic, phosphate-based acid detergent The bottles were then washed with distilled 
water, followed by a rinse with ultrapure water and were sterilised by autoclaving
2.3 Sterlisation
Water, glassware and all thermostable solutions were sterilised by autoclaving at 
121°C for 20 minutes (mm) under a pressure of lbar Thermolabile solutions were 
filtered through a 0 22|im sterile filter (Millipore, millex-gv, SLGV-025BS) Low 
protein-binding filters were used for all protein contaimng solutions
2.4 Media Preparation
Medium was routinely prepared and sterility checked by our technician (Joe Carey) 
The basal media used during routine cell culture were prepared according to 
formulations shown in Table 2 4 1 lOx media were added to sterile ultrapure water, 
buffered with HEPES and NaHCC>3 and adjusted to a pH of 7 45-7 55 using sterile 
1 5M NaOH and 1 5M HC1 The media were then filtered through sterile 0 22^im bell 
filters (Gelman, 121-58) and stored in 500ml sterile bottles at 4°C Sterility checks 
were earned out on each 500ml bottle of medium as desenbed in section 2 5 6
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The basal media were stored at 4°C up to their expiry dates as specified on each 
individual 1 Ox medium container Prior to use, 100ml aliquots were supplemented with 
5% foetal calf serum and this was used as routine culture medium This was stored for 
up to 2 weeks at 4°C, after which time, fresh culture media was prepared For all 
DLKP cell lines ATCC (Hams F12/DMEM (11) supplemented with 5% FCS was 
routinely used For the RPMI cell lines Minimum Essential Medium (MEM) 
supplemented with 5% FCS, 1% Sodium pyruvate, 1% Non essential ammo acids 
(NEAA) and 1 % L-glutamine was used
2.5 Cell Lines
All cell work was earned out in a class II down-flow re-circulating laminar flow 
cabinet (Nuaire Biological Cabinet) and any work that involved toxic compounds was 
earned out in a cytogard (Gelman) Stnct aseptic technique was adhered to at all times 
The laminar flow cabinet was swabbed with 70% mdustnal methylated spmts (IMS) 
before and after use, as were all items used in the cabinet Each cell line was assigned 
specific media and waste bottles Only one cell line was worked with at a time in the 
cabinet, which was allowed to clear for 15min between different cell lmes The cabinet 
itself was cleaned each week with mdustnal detergents (Virkon, Antec International, 
TEGO, TH Goldschmidt L td), as were the incubators The cell lmes used dunng the 
course of this study, their sources and their basal media requirements are listed in 
Table 2 1 1 Lmes were maintained in 25cm flasks (Costar, 3050), 75cm (Costar, 
3075) or 175cm2 flasks (Coming, 431079) at 37°C and fed every two to three days
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Table 2.11 Cell lines used during the course of this study
Cell Line Basal
Medium
Cell Type Invasive
Status
Source
DLKP-1 ATCC 
(5% FCS)
Human poorly- 
differentiated lung 
carcinoma
Invasive Dr Yizheng 
Liang, 
NCTCC
DLKP-2 ATCC 
(5% FCS)
Human poorly- 
differentiated lung 
carcinoma
Invasive Dr Rasha
Linehan,
NCTCC
DLKP- 
Taxotere 1 
(TXT-1)
ATCC 
(5% FCS)
Human poorly- 
differentiated 
Taxotere treated 
lung carcinoma
Mildly
invasive
Dr Yizheng 
Liang, 
NCTCC
DLKP- 
Taxotere 2 
(TXT-2)
ATCC 
(5% FCS)
Human poorly- 
differentiated 
Taxotere treated 
lung carcinoma
Highly
Invasive
Dr Rasha 
Linehan, 
NCTCC
DLKP-
Vincnstine
(VCR)
ATCC 
(5% FCS)
Human poorly- 
differentiated 
Vincnstine treated 
lung carcinoma
Almost
Non-
mvasive
Dr Rasha
Linehan,
NCTCC
RPMI-2650 MEM
(5%FCS,
1 %L-glut, 
1%NEAA, 
1& Sodium 
Punivate)
Human nasal 
squamous 
carcinoma cell line
Non-
mvasive
NCTCC 
culture 
collection 
(onginally 
from ATCC)
RPMI-
Melphalan
(RPMI-Mel)
MEM 
(5%FCS, 
l%L-glut, 
1%NEAA, 
1& Sodium 
Punivate)
Human nasal 
squamous 
carcinoma cell line 
treated with 
Melphalan
Highly
Invasive
Dr Yizheng 
Liang, * 
NCTCC
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2.5.1 Subculture of Adherent Lines
Dunng routine subcultunng or harvesting of adherent lines, cells were removed from 
their flasks by enzymatic detachment
Waste medium was removed from the flasks and the cells were nnsed with a pre­
warmed (to 37°C) trypsm/EDTA (TV) solution (0 25% trypsin (Gibco, 5090-028), 
0 01% EDTA (Sigma, EDS) solution in PBS A (Oxoid BR14a)) The purpose of this 
was to remove any naturally occurring trypsin inhibitor that could be present in the 
residual serum Fresh TV was then placed on the cells (2ml/25cm flask, 5ml/25cm or 
75cm2 flask) and the flask incubated at 37°C until the cells were seen to have detached 
(5-10min) The trypsin was then deactivated by addition of an equal volume of 
complete (i e contaimng 5% FCS) growth medium The entire solution was transferred 
to a 30ml sterile universal tube (Stenlin, 128a) and centrifuged at l,000rpm for 5 mm 
The resulting cell pellet was resuspended in pre-warmed fresh complete growth 
medium, counted (Section 2 5 2) and used to re-seed a flask at the required cell density 
or to set up an assay
2 5 2 Cell Counting
Cell counting and viability determinations were earned out using a trypan blue (Gibco, 
15250-012) dye exclusion technique
An aliquot of trypan blue was added to a sample from a single cell suspension in a 
ration of 1 5 After 3 mm incubation at room temperature, a sample of this mixture was 
applied to the chamber of a haemocytometer over which a glass coverslip had been 
placed Cells in the 16 squares of the four outer comer gnds of the chamber were 
counted microscopically, an average per comer grid was calculated with the dilution 
factor being taken into account, and final cell numbers were multiplied by 104 to 
determine the number of cells per ml The volume occupied by the chamber is 0 1cm x 
0 1 cm x 0 1 cm z e 0 0001cm3 Therefore cell number x 104 is equivalent to cells per 
ml Non-viable cells were those that stained blue while viable cells excluded the trypan 
blue dye and remained unstained
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2,5.3 Cell Freezing
To allow long-term storage of cell stocks, cells were frozen and cryo-preserved in 
liquid nitrogen at temperatures below -180°C Once frozen properly, such stocks 
should survive indefinitely
Cells to be frozen were harvested in the log phase of growth (z e actively growing and 
approximately 60-70% confluent) and counted as described in Section 2 5 2 Pelleted 
cells were resuspended in serum An equal volume of a DMSO/serum (1 9, v/v) was 
slowly added dropwise to the cell suspension to give a final concentration of at least 
5xl06 cells/ml This step was very important, as DMSO is toxic to cells When added 
slowly the cells had a period of time to adapt to the presence of the DMSO, otherwise 
cell lysis can occur The suspension was then aliquoted in cryovials (Greiner, 122278), 
which were then quickly placed in the vapour phase of liquid nitrogen containers 
(approximately -80°C) After 2 5 to 3 5 hours, the cryovials were lowered down into 
the liquid nitrogen where they were stored until required
2 5 4 Cell Thawing
Immediately prior to the removal of a cryovial from the liquid mtrogen stores for 
thawing, a sterile universal tube containing pre-warmed complete growth medium was 
prepared for the rapid transfer and dilution of thawed cells to reduce their exposure 
time to DMSO freezing solution which is toxic at room temperature The suspension 
was centrifuged at l,000rpm for 5 mm, the DMSO-contaimng supernatant removed 
and the pellet resuspended in fresh growth medium A viability count was earned out 
(Section 2 5 2) to determine the efficiency of the freezing/thawing procedures Thawed 
cells were placed into tissue culture flasks with an appropnate volume of medium 
(5ml/25cm2 flask and 10ml/75cm2 flask) and allowed to attach overnight After 24 
hours, the cells were re-fed with fresh medium to remove any residual traces of 
DMSO
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2.5.5 Sterility Checks
Sterility checks were routinely earned out on all media, supplements and trypsin used 
for cell culture Samples of basal media were inoculated into Columbia (Oxoid, 
CM331) blood agar plates, Sabauraud (Oxoid, CM217) dextrose and Thioglcollate 
(Oxoid, CM173) broths, which detect most contaminants including bactena, fungus 
and yeast Complete growth media were stenlity checked at least two days pnor to use 
by incubating samples at 37°C, which were subsequently examined for turbidity and 
other indications of contamination
2.6 Mycoplasma Analysis
Mycoplasma examinations were performed routinely (at least every 3 months) on all 
cell lines used in this study NICB staff members, Aine Adams and Michael Henry 
performed these analyses
2 61 Indirect Staining Procedure
In this procedure, Mycoplasma-negative NRK cells (a normal rat kidney fibroblast 
line) were used as indicator cells These cells were incubated with supernatant from 
test cell lines and then examined for Mycoplasma contamination NRK cells were used 
for this procedure because cell mtegnty is well maintained dunng fixation A 
fluorescent Hoechst stain was utilised which binds specifically to DNA and so will 
stain the nucleus of the cell in addition to any Mycoplasma DNA present A 
Mycoplasma infection would thus be seen as small fluorescent bodies in the cytoplasm 
of the NRK cells and sometimes outside the cells
NRK cells were seeded onto stenle coverslips in stenle Petn dishes at a cell density of 
2xl03 cells/ml and allowed to attach over night at 37°C in a 5% CO2, humidified 
incubator 1ml of cell-free (cleared by centnfugation at 1,000 rpm for 5 mm) 
supernatant from each test cell line was then inoculated onto a NRK Petn dish and 
incubated as before until the cells reached 20-50% confluency (4-5 days) After this 
time, the waste medium was removed from the Petn dishes, the coverslips washed 
twice with stenle PBS A, once with a cold PBS/Camoys (50/50) solution and fixed
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with 2ml of Camoys solution (acetic acid methanol -  1 3) for 10 mm The fixative 
was then removed and after air-drying, the coverslips were washed twice in deionised 
water and stained with 2ml of Hoechst 33258 stain (BDH) (50ng/ml) for 10 mm From 
this point on, work was earned out in the dark to limit quenching of the fluorescent 
stain
The coverslips were nnsed three times in PBS They were then mounted in 50% (v/v) 
glycerol in 0 05M citnc acid and 0 1M disodium phosphate and examined using a 
fluorescent microscope with a UV filter
2.6 2 Direct Staining
The direct stain for Mycoplasma involved a culture method where test samples were 
inoculated onto an ennched Mycoplasma culture broth (Oxoid, CM403) -  
supplemented with 16% serum, 0 002% DNA (BDH, 42026), 2mg/ml fungizone 
(Gibco, 15290-026), 2 x 103 units penicillin (Sigma, Pen-3) and 10ml of a 25% (w/v) 
yeast extract solution -  to optimise growth of any contaminants and incubated at 37°C 
for 48 hours Samples of this broth were then streaked onto plates of Mycoplasma agar 
base (Oxoid, CM401) which had also been supplemented as above and the plates 
incubated for 3 weeks at 37°C in a C02 environment The plates were viewed 
microscopically at least every 7 days, the appearance of small “fried egg”-shaped 
colonies is indicative of a Mycoplasma infection
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2.7 Specialised Techniques in Cell Culture
2.7.1 Assessment of cell number -Acid Phosphatase Assay
A Acid Phosphatase in 96-well plate format
1 Following an incubation period of 72 hours, media was removed from the 
plates
2 Each well on the plate was washed with 100|-il PBS This was removed and 
100|il of freshly prepared phosphatase substrate (lOmM /?-mtrophenol 
phosphate (Sigma 104-0) in 0 1M sodium acetate (Sigma, S8625), 0 1% tnton 
X-100 (BDH, 30632), pH 5 5) was added to each well The plates were 
wrapped in tinfoil and incubated in the dark at 37°C for 2 hours
3 The enzymatic reaction was stopped by the addition of 50^1 of 1M NaOH to 
each well
B Acid Phosphatase in 6-well plate format
1 Following an incubation penod of 72 hours, media was removed from the 
plates
2 Each well on the plate was washed with 1ml PBS This was removed and 2ml 
of freshly prepared phosphatase substrate (lOmM p-mtrophenol phosphate 
(Sigma 104-0) in 0 1M sodium acetate (Sigma, S8625), 0 1% tnton X-100 
(BDH, 30632), pH 5 5) was added to each well The plates were wrapped in 
tinfoil and incubated in the dark at 37°C for 2 hours
3 The enzymatic reaction was stopped by the addition of 1ml of 1M NaOH to 
each well
Plates were read in a dual beam plate reader at 405 nm with a reference wavelength of
620 nm
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2 7 2 Invasion Assay experimental procedure
Invasion assays were performed using the method of Albim (1998) using commercial 
invasion assay kits (Beckton Dickinson, Cat no 354480) that were pre-coated with 
matngel The invasion assay kits were allowed to come to room temperature before 
use, were rehydrated on the top and bottom of the insert with 0 5ml pre-warmed 
serum-free media for 2 hours at 37°C Following this incubation, the media underneath 
the insert was replaced with pre-warmed media containing 5% FCS The cells were 
trypsmised, counted and resuspended in pre-warmed media containing 1% FCS at a 
density of lxlO6 cells/ml 100|il of the cell suspension was added to each insert The 
cells were incubated at 37°C for 24 hours After this time, the inside of the insert was 
wiped with a wet cotton swab and the underside of the insert stained with 0 25% 
crystal violet for 10 minutes, followed by washing with UHP and allowed to air dry 
The inserts were then viewed under the microscope and photographed The percentage 
of invasive cells was determined by microscopically counting 10 representative fields 
at 20X
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2.8 Immunocytochemistry
2.8 1 Fixation of cells
For fixation, medium was removed from 6-well plates, cells were rinsed 3 times with 
prechilled sterile PBS The cells were fixed with the addition of prechilled methanol 
placed m -20°C for 5-7minutes The methanol was removed and the cells allowed to 
air dry for approximately 20min at room temperature (RT) The plates were then 
wrapped in tinfoil and stored at -20°C until required, or used immediately
2.8 2 Immunoflourescence
Fixed cells on 6 well plates were taken from storage at -20°C and allowed to come to 
RT for 30min A DAKO pen was used to generate small wells within the centre of 
each well for staining The cells were rehydrated for 5 mins with 50jal tns buffered 
saline (TBS) per well and then blocked with 5% swine serum for 20 mins at RT 
Following removal of the blocker the cells were incubated with rabbit anti-IGF-lR 
(Santa Cruz, sc-713) diluted 1/500 overnight at 4°C The next day the primary 
antibody was removed and the cells were washed three times with TBS allowing 5 min 
per wash Working in conditions of reduced light, swine anti-rabbit secondary 
antibody (DakoCytomation, P0164) was diluted 1/40 in TBS and added to the wells 
(50jLil/well) for 30 mins This was removed and the cells were washed three times with 
TBS The cells were then mounted with fluorescent mounting medium containing 
DAPI (Vectashield, Vector Labs) and coverslips were placed over the stained area 
taking care to avoid bubbles The fluorescence was visualised using a Leica Confocal 
microscope Negative controls whereby primary antibody was replaced with TBS were 
included in each experiment to validate the specificity of staining
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2.9 Western Blot Analysis
Proteins for western blot analysis were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE).
2.9.1 Sample Preparation
Cells were scraped directly on culture dishes using NP40 lysis buffer (20mM Tris pH
7.4, 50mM NaCl, 50mM NaF, 1% NP40) supplemented with ImM PMSF, ImM 
protease inhibitor cocktail (Roche, 1 873 580) and ImM NasVCU. Lysis was carried 
out over twenty min on ice and following vortexing, the lysate was spun at 4°C for 
15min at maximum speed to remove any insoluble debris. The protein was quantified 
using the method of Bradford (Bio-Rad; 500-0006) and the protein samples were 
supplemented with 2X Lamelli sample buffer (contains loading dye, Sigma-Aldrich 
S3401) and water to a final stock concentration. The samples were then boiled for 
2min and stored at -20°C until required.
2.9.2 Quantification of Protein
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad; 500-0006) 
with a series of bovine serum albumin (BSA) (Sigma, A9543) solutions as standards. A 
stock solution of 25mg/ml BSA was used to make a standard curve. lOjul samples were 
diluted into eppendorfs in a stepwise fashion from 0 -  2mg/ml BSA. The Biorad solution 
was first filtered through 3MM filter paper (Schleicher and Schuell, 311647) and then 
diluted 1/5 with UHP as it was supplied as a 5-fold concentrate. The diluted dye reagent 
(490}il) was added to each standard and sample eppendorf and the mixtures vortexed. 
The 500jil samples were divided out in 1 OOjal aliquots onto a 96-well plate (Costar, 
3599). After a period of 5min to lhr, the OD570 was measured, against a reagent blank. 
From the plot of the OD570 of BSA standards versus their concentrations, the 
concentration of protein in the test samples was determined. From this, a relative volume 
for each protein sample was determined for loading onto the gels. Usually 10-20|ig 
protein per lane was loaded.
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2.9.3 Gel Electrophoresis
Resolving and stacking gels were prepared as outlined in Table 2.9.1 and poured into 
clean 10cm x 8cm gel cassettes that consisted of 2 glass plates separated by a plastic 
spacer. The resolving gel was poured first and allowed to set. The stacking gel was 
then poured and a comb placed in the stacking gel in order to create wells for sample 
loading. Once set, the gels could be used immediately or wrapped in aluminium foil 
and stored at 4°C for 24 hours.
Samples containing an equal amount of protein were loaded onto the stacking gels, 
alongside molecular weight markers (Invitrogen, LC5725). The gels were run at 0.04 
Amps for approximately 2 hours in an Atto gel rig (until the protein was run at least 
half way into the gel as judged by the migration of colour markers during the 
electrophoretic process). All gels were made from a stock of Acrylamide (Sigma, 
148660). Sample calculations for an 8% resolving gel and a 5% stacking gel are shown 
in Table 2.1.3.
Table 2.1.2 Preparation of gels for protein electrophoresis
Components Resolving gel (8%) Stacking Gel (5%)
UHP 3.22ml 1.4ml
30% Acrylamide 1.82ml 330pl
1.5mM Tris (pH 8 .8) 1.82ml 250pl
10% SDS (Sigma, L-4509) 70pl 20pl
10% APS (Sigma, A-1433) 70pl 20pl
TEMED (Sigma, T-8133) 4.2pl 2 pi
67
2.9.4 Protein Transfer and Western Blotting
Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer 
(25mM Tris, 192mM glycine (Sigma, G-7126) pH 8.3-8.5 without adjusting) for 
20min. Proteins in gels were transferred onto Hybond ECL nitrocellulose membrane 
(Amersham, RPN 2020D) using a semi-dry transfer cell (Biorad). Eight sheets of 
Whatman 3mm filter paper (Whatman, 1001824) were soaked in transfer buffer and 
placed on the cathode plate of a semi-dry transfer cell. Excess air was removed from 
between the filters by moving a glass pipette over the filter paper. Nitrocellulose 
membrane, cut to the same size of the gel, was soaked in transfer buffer and placed 
over the filter paper, ensuring that there were no air bubbles. The acrylamide gel was 
placed over the nitrocellulose and four more sheets of presoaked filter paper were 
placed on top of the gel. Excess air was again removed by rolling the pipette over the 
filter paper. The proteins were transferred from the gel to the nitrocellulose membrane 
at 0.34 Amps (15 Volts) for 30min.
From this point on, all further steps were carried out on a revolving apparatus to ensure 
even exposure of the membrane blot to all reagents. Following transfer, the membranes 
were blocked in fresh filtered 5% non-fat dried milk (Cadburys; Marvel skimmed 
milk) in TBS (20mM Tris, 0.15M NaCl)/0.1% Tween 20 (Sigma, PI379), pH 7.4 for 2 
hours. After blocking, the membranes were rinsed with TBS/0.1% Tween and 
incubated with primary antibody overnight at 4°C. Primary antibodies used are listed 
in Table 2.1.4. The following day the primary antibody was removed and the 
membranes rinsed three times with TBS/0.1% Tween. The membranes were then 
incubated in 1/1000 dilution of suitable HRP-labelled secondary antibody rabbit anti- 
Mouse (DakoCytomation, P0260), goat anti-Rabbit (DakoCytomation, P0448) or goat 
anti-chicken (Abeam. Ab68771) in 1% marvel for 1 hour at room temperature (R.T.). 
The secondary antibody was then removed and blots were washed three times for 
15min in TBS/0.1% Tween. Bound antibody was detected using enhanced 
chemiluminescence (ECL) (Section 2.9.4).
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Table 2.1.3 Antibodies used for western blot analysis
Antibody Dilution/Concentration Supplier Catalogue
no.
IGF-1R (C-20) (R) 1/1000 Santa Cruz Sc-713
CAF-1 (anti Kir- 
6.1/KCNJ8)
1/200 Gift Prof. Willian 
Coetzee
N/A
14-3-3-a (SFN) (M) 1/250 US Biological 0014-19
S100A13 (R) 1/500 Gift Prof. Claus 
Heizmann
N/A
TFPI2 (R) 1/500 Gift Prof Walt 
Kiesel
N/A
a-Tubulin (M) 1/2000 Sigma T5168
GAPDH (M) 1/5000 Abeam Ab9484
p-actin (M) 1/10000 Sigma A5441
Nomenclature
(M) = Mouse anti-human IgG. 
(R) = Rabbit anti-human IgG. 
(C) = Chicken anti-human IgG.
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2.9.5 Enhanced Chemiluminescence detection
Protein bands were developed using the enhanced chemiluminescence kit (ECL) 
(Amersham, RPN2109) according to the manufacturer’s instructions.
After blots were washed in TBS/0.1% Tween three times for 5min, a sheet of parafilm 
was flattened over a smooth surface, e.g. a glass plate, ensuring all air bubbles were 
removed. 1.5ml of ECL detection reagent 1 and 1.5ml of reagent 2 were mixed and 
covered over the membrane. Charges on the parafilm ensured the fluid remained on the 
membrane. The reagent was removed after one min and the membrane wrapped in 
cling film. The membrane was exposed to autoradiographic film (Kodak; X-OMAT S, 
500 9907) in an autoradiographic cassette for various lengths of time, depending on the 
strength of signal obtained. The autoradiographic film was then developed for 5min in 
developer (Kodak, LX24), diluted 1:6.5 in water. The film was briefly immersed in 
water and transferred to a Fixer solution (Kodak, FX-40) diluted 1:5 in water, for 
5min. The film was transferred to water for 5min and then air-dried.
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2.10 RNA Extraction
RNA extraction was achieved using the Qiagen RNeasy mini kit (Qiagen, 74104). This 
extraction is based on the guanidine thiocyanate method of extraction and yields high 
quality RNA. The procedure was performed as follows:
1. To harvest RNA, culture media was removed from cells in culture and the cells 
were washed with PBS.
2. Cells were then lysed directly in the culture dish by the addition an appropriate 
volume of buffer RLT containing 10|il P-mercaptoethanol per ml of buffer 
RLT. 350|al RLT was used to lyse less than 5 x 106 cells, while 600|il RLT was
6 7used to lyse between 5x10  and 1 x 10 cells.
3. This suspension was then homogenised by passing it through a 20-guage 
needle fitted to an RNase free syringe at least five times.
4. One volume of 70% ethanol was then added to the homogenised sample and 
mixed well by pipetting. This sample was then applied to an RNeasy mini 
column placed in a 2ml collection tube and centrifuged for 15s at 10,000rpm. 
The flow through was discarded.
5. 700(^ 1 of buffer RW1 was applied to the RNeasy column. The tube was closed 
and centrifuged for 15s at 10,000rpm to wash the column. The flow through 
and the collection tube were discarded at this point and the RNeasy column 
transferred to a new collection tube.
6 . 500|il of buffer RPE was applied to the column, the lid closed and the tube 
centrifuged for 15s at 10,000 rpm to wash the column. The flow through was 
discarded and a further 500^1 of buffer RPE applied to the RNeasy column. 
The tube was then closed and spun for 2 min at 10,000rpm to dry the silica-gel 
membrane.
7. The RNA was then eluted in a new 1.5ml collection tube using 20|il RNase- 
free water. The tube was closed and allowed to stand for lmin and then spun 
for 1 min at 10,000rpm.
8 . The RNA was then quantified and diluted as appropriate.
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RNA concentrations were calculated by measuring OD at 260nm and 280nm and using 
the following formula:
OD260nm x Dilution Factor x 40 = |!g/|al RNA
The purity of the RNA extraction was determined by calculating the A26o‘A28o ratio. 
An A260-A280 ratio of 2 in indicative of pure RNA. Only those samples with ratios 
between 1.7 and 2.1 were used in this study.
2.11 Reverse Transcriptase Reaction
Reverse transcriptase (RT) reactions were set up in laminar flow cabinets using 
micropipettes which were specifically allocated to this work.
To form cDNA, the following reagents were mixed in a 0.5ml eppendorf (Eppendorf, 
0030 121.023) heated to 72°C for 10 min and then cooled to 37°C.
1.2|il 25mM MgCl2 (Sigma, M-8787)
2|il lOx PCR Buffer (Sigma, P-2317)
2(al Oligo dT18 (0.5|ng/|il) (MWG/Sigma)
0.4|al lOmM dNTP’s (lOmM of each dNTP; Sigma, D 5038)
0.5(il RNAsin (40U/|il) (Sigma, R-2520)
2jil total RNA (0.5|ag/|il)
6.9|il DEPC water
Added directly to this mixture was, 4(il DEPC water and ljil Moloney murine 
leukaemia virus reverse transcriptase (MMLV-RT) (40,000U/|il) (Sigma, M-1302). 
The RT reaction was carried out by incubating the eppendorfs at 37°C for 1 hour. The 
MMLV-RT enzyme was inactivated by heating to 95°C for 5 min. The cDNA was 
stored at -20°C until required for PCR reactions as outlined in Section 2.12.
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2.12 Polymerase Chain Reaction
A standardised polymerase chain reaction (PCR) procedure was followed in this study. 
The reactions were carried out in 0.5ml safe-lock eppendorf tubes (Eppendorf, 0030 
121.023). All reagents had been aliquoted and stored at -20°C and all reactions were 
performed in a laminar flow cabinet. Primers and annealing temperatures are detailed 
in the appendices.
A typical PCR tube contained the following:
1.5|il 25mM MgCl2 (Sigma, M-8787)
2.5|il lOx PCR Buffer (Sigma, P-2317)
l|il each of the forward and reverse strand target primers (10|iM)
0 .5^1 each of the forward and reverse strand endogenous control primer (15ng/|il)
5.5|il UHP 
2.5|il cDNA
lOjal Taq!dNTP mixture*
*= 0.5(il lOmM dNTP’s (lOmM of each dNTP; Sigma, D 5038)
0.251^ 1 of 5U/|il Taq DNA Polymerase enzyme (Sigma, D-4545)
9.25|il of UHP
DNA was amplified by PCR as follows:
95°C -  5 min -denature 
35* Cycles: 95°C -  30sec - denature 
X°C -  30sec -  anneal 
72°C -  30sec -  extend 
And finally, 72°C -  5min -  extend
*The cycle number varied with primers used but was generally 35 cycles.
X = the annealing temperature varied with primer set used.
The reaction tubes were then stored at 4°C for analysis by gel electrophoresis.
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2.12.1 Real-Time PCR
RNA was extracted (Section 2.10) and cDNA synthesised as per Section 2.11. The 
Taqman® Real Time PCR analysis was performed using the Applied Biosystems 
Assays on Demand PCR kits, and experiments were performed in triplicate as follows:
• 22.5|al of qPCR master mix was added to was added to the relevant wells of 
a 96-well PCR plate (cat no. 4366932).
• 2.5|il of each cDNA sample was added to give a final reaction volume of 
25|il. Each cDNA sample was analysed in triplicate for the separate 
measurement of target gene expression and endogenous control (p-actin). 
The components of the master mix were as follows:
Table 2.1.4 Components of Real Time PCR master mix
Reaction Component Volume/well per 25|il 
reaction
Final
Concentration
TaqMan universal PCR mastermix, 
(2X) (Cat no. 4318157)
12.5|il IX
20X assays on demand gene 
expression assay mix (primers)
1.25|il IX
RNase-free water 8.75|il -
cDNA 2.5|il -
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Table 2.1.5 TaqMan assays used in this study.
Gene TaqMan assay catalog number
IGF-1R Hs001385_ml
KCNJ8 Hs00270663_ml
S100A13 Hs00195583_ml
SFN Hs00602835_sl
TFPI2 Hs00197918_ml
P-actin 4326315E
• The plate was then covered with an optical adhesive cover and placed in the 
ABI 7500 Real Time PCR instrument.
• The thermal cycling conditions were set using the following default 
settings;
1. 2 min at 50°C (default for optimal AmpErase UNG activity. Not 
required when UNG is not added to reaction).
2. 10minsat95°C
3. 40 cycles of 15s at 95°C denaturation and lmin at 60°C annealing.
4. The sample volume was changed to 25(il and the run started.
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Each real time PCR run was analysed as follows:
1. The file detailing the qPCR run for analysis was opened in the 7500 system 
software under Relative Quantification ddCt study.
2. A calibrator sample was selected and set to a value of one, allowing for the 
comparison of all other samples in relation to the calibrator.
3. For the analysis of target gene or endogenous control amplification, the 
baseline was set to average, normalised fluorescent signal before detectable 
increase (usually 3-15 cycles) and the cycle threshold was set in the 
exponential part of the curve.
4. The well information was then analysed. The Ct standard error was ideally less 
than +/-0.161. Ct errors with values greater than this were removed as outliers.
5. The endogenous control was used automatically to normalise the data.
6 . When this was achieved for both the target and endogenous control, the relative 
quantity values for the run were generated and plotted relative to the calibrator 
sample.
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2.13 Electrophoresis of PCR Products
A 2% agarose gel (Sigma, A-9539) was prepared in IX TBE buffer (10.8g Tris base, 
5.5g Boric acid, 4ml 0.5M EDTA, 996ml UHP) and melted in a microwave oven. 
After allowing to cool, 0.003% (v/v) of a lOmg/ml ethidium bromide solution was 
added to the gel which was then poured into an electrophoresis apparatus (BioRad). 
Combs were placed in the gel to form wells and the gel allowed to set.
5|il loading buffer (50% glycerol, lmg/ml xylene cyanol, lmg/ml bromophenol blue, 
ImM EDTA) was added to 25 [i\ PCR samples and 10|il was run on the gel at 80- 
90mV for approximately 2 hours. When the dye front was seen to have migrated the 
required distance, the gel was removed from the apparatus and examined on a UV- 
transluminator and photographed.
2.14 Densitometric Analysis
Densitometric analysis was carried out using the MS Windows 3.1 compatible 
Molecular Analyst software/PC image analysis software available for use on the 670 
Imaging Densitometer (Bio-Rad, CA) Version 1.3. In each gel photograph, a standard 
area was selected and scanned. The amount of light blocked by the DNA band was in 
direct proportion to the intensity of the DNA present. The software calculated a value 
for the Optical Density (O.D.) of each individual pixel on the screen. The average 
value of this O.D. (within a set area, usually 1cm2) was corrected for background of an 
identical set area. The corrected reading, for a given amplified band of interest was 
then normalised by dividing with a normalised reading obtained from an endogenous 
control band (usually P-actin). No comparator was set; as a result, these O.D. readings 
have arbitrary units.
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2.15 DNA Array Analyses
2.15.1 GeneChips
The microarray gene expression experiments that were carried out in this body of work 
were performed using Affymetrix™ Human Genome U133A GeneChips™. 
Affymetrix GeneChip probe microarrays are manufactured using photolithography and 
combinatorial chemistry. Tens to hundreds of thousands of different oligonucleotide 
probes are synthesised and located in a specific area on the microarray slide, called a 
probe cell. Each probe cell contains millions of copies of a given oligonucleotide and 
each feature size on the Affymetrix U133A GeneChip is 10 microns.
The most important aspect in efficient probe design is the quality of the sequence 
information used. Probe selection and array design are two major factors in reliability, 
sensitivity, specificity and versatility of expression probe arrays. Probes selected for 
arrays by Affymetrix are generated from sequence and annotation data obtained from 
multiple databases including GenBank, RefSeq and dbEST. Sequences from these 
databases are collected and clustered into groups of similar sequences. Using clusters 
provided by the Unigene database as a starting point, sequences are further subdivided 
into subclusters representing distinct transcripts.
This categorisation process involves alignment to the human genome, which reveals 
splicing and polyadenylation variants. The alignment also extends the annotation 
information supplied by the databases pinpointing low quality sequences. These areas 
are usually trimmed for subsequent generation of high quality consensus sequences or 
alternatively Affymetrix employ quality ranking to select representative sequences, 
called exemplars, for probe design.
Generally, Affymetrix use 11 to 16 probes which are 25 bases in length for each 
transcript. The probe selection method used by Affymetrix for their U133A GeneChips 
takes into account probe uniqueness and the hybridisation characteristics of the probes, 
which allow probes to be selected, based on probe behaviour. Affymetrix use a 
multiple linear regression (MLR) model in the probe design that was derived from a
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thermodynamic model of nucleic acid duplex formation. This model predicts probe 
binding affinity and linearity of signal changes in response to varying target 
concentrations. A further probe selection criterion used by Affymetrix for quantitative 
expression analysis is that the hybridisation intensities of the selected probes must be 
linearly related to target concentrations.
A core element of Affymetrix microarray design is the Perfect/Mismatch probe 
strategy. For each probe that is designed to be perfectly complementary to a given 
target sequence, a partner probe is also generated that is identical except for a single 
base mismatch in its centre. These probe pairs, called the Perfect Match Probe (PM) 
and the Mismatch probes (MM), allow the quantitation and subtraction of signals 
caused by non-specific cross-hybridisation. These differences in hybridisation signals 
between the partners, as well as their intensity ratios, serve as indicators of specific 
target abundance.
2.15.2 Sample and Array Processing
After RNA isolation, quantification and purification using the Qiagen RNeasy 
isolation method, cDNA was synthesised using the GeneChip T7-01igo (dT) Promoter 
Primer Kit (Affymetrix; 900375) from 10}ig total RNA. First strand cDNA synthesis 
was performed using the SuperScript Choice Kit (BioSciences; 11917-010). First 
strand cDNA synthesis involved “primer hybridisation” where the T7-01igo (dT) 
primer was incubated with the RNA and DEPC-treated water at 70°C for lOmins, 
followed by a short incubation on ice; “temperature adjustment” where 5X first strand 
buffer, DTT and dNTP mix were added to the RNA mix and incubated at 42°C for 
2mins; and “first strand synthesis” where superscript II RT was added to the mix and 
incubated at 42°C for 1 hour. The second strand mastermix was assembled containing: 
91|il RNase-free water; 30|il 5X 2nd strand reaction mix; 3|il dNTP(lOmM); ljil E.coli 
DNA ligase; 4jil E.coli DNA polymerase I and ljil RNase H. To each first strand 
synthesis sample, 130|il of second-strand mastermix was added. The tubes were mixed 
and centrifuged briefly and incubated for 2 hours at 16°C. After incubation, 2|il of T4 
DNA Polymerase was added to each sample, and incubated for 5 minutes at 16°C. To 
stop any further reaction, 10|il of EDTA (0.5M) was then added to each tube.
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cRNA was then synthesised and biotin-labelled using the ENZO BioArray HighYield 
RNA Transcript Labelling Kit (Affymetrix; 900182). For the IVT reaction the 
following reagents were added to the cDNA: 14|il RNase-free water; 4^1 10X IVT 
labelling buffer; 12|il labelling NTP mix and 4j j .1 IVT labelling enzyme mix. These 
reagents were mixed carefully and centrifuged briefly. The reaction tubes were then 
incubated for 16 hours at 37°C. Biotin-labelled cRNA was purified using the 
GeneChip Cleanup module Kit (Affymetrix; 900371) and quantified. A sample of 
biotin-labelled cRNA was taken for gel electrophoresis analysis. The labelled cRNA 
was then fragmented before hybridisation onto the Affymetrix GeneChip probe 
microarrays. The aliquot of fragmented sample RNA as stored at -20°C until ready to 
perform the hybridisation step.
Hybridisation of fragmented cRNA onto the Affymetrix GeneChip human microarrays 
HU133A was performed in the Conway Institute, University College Dublin, where 
the Affymetrix Hybridisation Oven and Fluidics Station is set up along with the 
Affymetrix GeneChip Scanner, which exported the data directly into the Affymetrix 
analysis software, Micro Array Suite 5.0 (MAS 5.0).
An initial microarray experiment on the two invasive DLKP parents (DLKP-1 and 
DLKP-2), the invasive TXT-2, the mildly invasive TXT-1 and the almost non-invasive 
VCR was carried out in this institute by Dr. Rasha Linehan as single samples for 
analysis. Further duplicate sets of the above samples were than prepared for microarray 
analysis, for this thesis. This generated a triplicate data set for the analysis of the 
DLKP invasive variants.
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2.15.3 Microarray Data Normalisation
The purpose of data normalisation is to minimise the effects of experimental and 
technical variation between microarray experiments so that meaningful biological 
comparisons can be drawn from the data sets and that real biological changes can be 
identified among multiple microarray experiments. Several approaches have been 
demonstrated to be effective and beneficial. However, most biologists use data scaling 
as the method of choice despite the presence of other alternatives. In order to compare 
gene expression results from experiments using microarrays, it is necessary to 
normalise the data obtained following the microarray chip scanning process. There are 
two main ways in which this type of normalisation is performed, the first of which is 
“per-chip” normalisation. This type of normalisation helps to reduce minor differences 
in probe preparation and hybridisation conditions which may potentially result in the 
high intensity of certain probe sets. These adjustments in probe intensity are made to 
set the average fluorescence intensity to some standard value, so that all the intensities 
on a given microarray chip increase or decrease to a similar degree. However, this type 
of normalisation should only be performed on microarrays using similar cell or tissue 
types. One drawback of this normalisation is that some aspects of the microarray data 
may potentially be obscured, such as whether the RNA samples or the probe 
preparation steps were equal for each sample. All data in this study were scaled to a 
value of 100.
The second way in which most biologists normalise their data sets is by using the “per 
gene” normalisation method. The aim of microarray experiments is to identify genes 
whose expression changes in different conditions, be that tracking gene changes across 
a temporal experiment or when comparing gene expression between an invasive and 
non-invasive sample. Therefore, it is necessary to normalise microarray data sets using 
“per gene” normalisation to find genes that have a similar expression pattern across an 
experiment. Analysis of raw data from microarray experiments is useful for identifying 
genes that are expressed at the same level, for example, genes that are highly abundant 
in the samples. In contrast to a time course investigation, there was no clear “control” 
sample to be used as a baseline in this experiment, so the median value for each gene 
was calculated and given a normalized value of one. This is known as normalisation to 
median.
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2.16 Overview of Bioinformatic Analysis
2.16.1 Quality Control
Scanned images of the Affymetrix™ U133A arrays were loaded into Affymetrix™ 
MAS software. Here, they were checked for damage and then analysed. The chips 
were scaled in MAS to make them comparable. Scaling is a linear process that adjusts 
all the values on an array so that all the arrays in the experiment have the same 
trimmed mean, 100 Affymetrix units.
QC output for the array data is graphed (Figure 3.1.1). Overall, the quality metrics 
should be looked at as a whole. These Quality Control Metrics graphs are an important 
part of the experimental record. To simplify visualisation of all the metrics on the same 
graph, some of the values are divided by constants to get the values in the same region 
of the graph.
Hierarchical clustering is used as an internal QC step within the Centre. Since the chips 
are scaled, no further normalisations were required for this QC step. This clustering 
allows the direct comparison of the different chips based on the profile of altered genes 
on each chip. The hierarchical clustering generated for this experiment is presented in 
Figures 3.1.2 and 3.1.3.
Since the array data was scaled in MAS, “per chip” normalization was not required in 
GeneSpring. A per gene normalization was then carried out. In contrast to a time 
course investigation, there is no clear “control” sample to be used as a baseline in this 
experiment, so the median value for each gene was calculated and given a normalized 
value of one. This is known as normalisation to median.
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2.16.2 Generating Genelists
2.16.2.1 Genelist 1
Initially the single 5 chips were analysed alone. In this case statistics were not used as 
the data was generated by one set of samples. For this analysis, multiple experiments 
were set up in GeneSpring™ with all possible pairs of samples. A filter was applied to 
remove any genes that were consistently flagged as absent. These “pairwise” 
comparisons were used to identify genes that were up and down regulated (using an 
arbitrary two fold cut off) between the five cell lines. These lists (which contained 
hundreds of genes each) were overlapped (using the Venn diagram function in 
GeneSpring™) to find genes that were consistently up or down regulated in invasive 
samples relative to non-invasive samples. Using this single data set, 31 genes came 
through the above analysis (Tables 3.1.1 and 3.1.2). A literature search was carried out 
on the 31 genes with 19 genes subsequently picked as candidates for RT-PCR to 
confirm array analysis.
2.16.2.2 Genelist 2
The second analysis was carried out using the same method as above except that the 
analysis was performed on the duplicate chips prepared subsequently to the initial 
single set, that is duplicate chips of the five cell lines (Table 3.1.3). Again, statistics 
were not used in this analysis. Using the same method as analysis 1, only nine genes 
came through and all were selected for confirmatory RT-PCR.
2.16.2.3 Genelist 3
The third analysis was the analysis of the 15 chips (that is the 5 cell lines in triplicate). 
The same method as analysis 1 and 2 was used to determine if any genes came through 
all of the 3 analyses. 40 genes came through this analysis (Table 3.1.4). RT-PCRs were 
not carried out on all 40 genes.
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2.16.2.4 Genelist 4
A further analysis was carried out, this time using a different approach on all fifteen 
chips. Genes that did not cross a two-fold threshold above or below the median in at 
least one cell line were removed from the analysis, as were genes that were 
consistently called absent by the Affymetrix software. A Welch ANOVA (analysis of 
variance) statistical test was used to find genes that were reliably differentially 
expressed between the five different cell lines. Subsequently, a further Welch ANOVA 
test was used to find genes in this list that were useful in discriminating between 
invasive and poorly invasive samples. This generated a gene list containing 45 genes, 
whose expression patterns (see heatmap Figure 3.1.4) were analysed visually to 
identify 18 possible invasion related genes (Table 3.1.5).
2.16.2.5 Genelist 5
Rather than grouping the samples into invasive and non-invasive, an arbitrary scale of 
invasion was applied to reflect the intermediate degrees of invasion displayed by the 
cell lines in the in vitro invasion assay. This arbitrary scale of invasiveness was put 
into the GeneSpring™ cell information, which allowed for analysis of the data based 
on relative invasiveness of he. The scale was as follows:
DLKP-1 5
TXT-2 5
DLKP-2 3.5
DLKP-TXT-1 1
DLKP-VCR 0
To analyse the data using the information above on the 15 chips, a ratio interpretation 
by analysis name was used. A filter was applied that included genes that were present 
or marginal in three out of 15 samples and also genes whose expression were 1.5 fold 
increased or decreased in three out of 15 samples. A genelist was made of the genes 
that passed these stipulations. A Welch ANOVA (settings: P-value; 0.01, no multiple 
testing correlation) was applied to this list using the invasion parameter (scale)
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mentioned above. 531 genes came through this statistical test and were referred to as 
consistently changing genes.
These 531 consistently changing genes were put into Self Organising Maps (SOMs). 
SOMs group together genes with similar expression pattern in clusters. The user 
defines the number of clusters into which the genes should be organised. The SOMs 
for the 531 changing genes related to invasiveness but a similar approach could be 
used to group genes related to drug resistance. A 7x6 SOM (log scale) was used to 
organize the 531 changing genes into clusters with similar expression patterns (Figure 
3.1.5).
2.16.3 Genomatix Software Suite
Genomatix provide software that allows users to explore published studies as well as 
combine sequence analysis, and genome annotation in order to help researchers to get 
a complete overview of their biological data (www.genomtix.de) The software offered 
by Genomatix is designed to help researchers gain a better understanding of gene 
regulation at the molecular level. The Genomatix software suite is comprised of six 
main tools: ElDorado, Gene2Promoter, BiblioSphere, GEMS Launcher, Matlnspector 
and Promoterlnspector. ElDorado is a gene orientated genome search engine which 
provides the user with information about functional genomic elements within a 
specific region of the genome. This piece of software compiles and integrates 
information on gene function and regulatory pathway. In addition, information on 
mRNAs, their exon/intron structure and coding sequences, single nucleotide 
polymorphisms (SNPs) and potential promoter regions may be retrieved using 
ElDorado. The hypothesis underlying this type of analysis is that genes with similar 
expression patterns may be co-regulated and therefore may be activated by the same 
transcriptional signals.
BiblioSphere is a data-mining solution for extracting and studying gene relationships 
from literature databases and genome-wide promoter analysis. Based on PubMed 
(www.ncbi.nlm.nih.gov), BiblioSphere currently searches over 14 million abstracts. 
The unique data-mining strategy allows you to find direct gene-gene co-citations and
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even yet unknown gene relations via interlinks. BiblioSphere data is displayed as 3D 
interactive view of gene relationships (Figure 3.1.6). Results can be classified by 
tissue, Gene Ontology and Medical Subject Headings (MeSH). Statistical rating by z- 
scores indicate over- and under-representation of genes in the various biological 
categories. BiblioSphere can be applied to single gene analysis, gene cluster analysis 
and analysis of gene regulatory mechanisms.
The 104 probe sets as selected from SOMs were pasted into BiblioSphere™ 
(Genomatix™ software) and a BiblioSphere was generated (Figure 3.1.6). A MeSH 
disease filter called “Neoplasm Invasiveness” (z-score = 19.2) (other filters could have 
been chosen) was applied to the BiblioSphere cluster and 11 genes from the cluster 
were related to this parameter.
Transcription factors were excluded assuming that an over-expressed TF may also be 
on a superior position in a regulative network and the identifiers for nine genes 
(excluding transcription factors) were copied into Gene2Promoter to retrieve the 
promoter sequences for these transcripts.
Since co-regulation of gene transcription often originates from common promoter 
elements the identification and characterisation of these elements provides a more in- 
depth analysis for the expression of microarray genelists. Gene2Promoter allows users 
to automatically extract groups of promoters for genes that may be of interest. This 
piece of Genomatix software provides access to promoter sequences of all genes 
annotated in available genomes.
Matlnspector is a tool that employs a library of matrix descriptions for transcription 
factor binding sites on a given promoter sequence. Graphical display of transcription 
factor binding sites common to a set of inputted promoters is obtained following 
Matlnspector analysis. These promoter sequences were then subjected to 
“FrameWorker” analysis. FrameWorker allows users to extract a common framework 
of elements from a set of DNA sequences. These elements are usually transcription 
factor binding sites since this tool is designed for the comparative analysis of promoter 
sequences. FrameWorker returns the most complex models that are common to the 
input sequences (and satisfying the user parameters). These are all elements that occur
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in the same order and in a certain distance range in all (or a subset of) the input 
sequences. The settings used for the framework analysis were as follows;
• A limit of 30% of nine input promoter sequences was used (denotes that only 
models are considered that occur in at least three of the nine sequences). Other 
percentage constraints were used but did not generate promoter models with 
more than two elements. (For a mixed set of input data (e.g. if it is not known if 
and how many of the promoter sequences share a common transcription model) 
this parameter should be lowered from 80% as above).
• Distance constraints of 5 and 50 (default settings, were used).
Once a model of transcription factor binding sites was generated using FrameWorker 
software, sequence databases were scanned for regulatory units that match the models, 
which were generated using Modellnspector. Model Inspector provides a library of 
experimentally verified promoter models against which transcription factor models 
may be scanned. The promoter models generated in this analysis were scanned against 
a library of experimentally verified human promoter models using Modellnspector. 
This generated a list of genes with the same promoter models from an experimentally 
verified human promoter database.
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2.17 RNA interference (RNAi)
RNAi using small interfering RNAs (siRNAs) was performed to silence specific genes. 
The siRNAs used were purchased from Ambion Inc. These siRNAs were 21-23 bps in 
length and were introduced to the cells via reverse transfection with the transfection 
agent siPORT™ TVeoFX™ (Ambion Inc., 4511).
2.17.1 Transfection optimisation
There were a number of different parameters that had to be determined to establish an 
optimised protocol for the siRNA transfection of DLKP and its variants. Initially, the 
transfection protocol itself was considered. In order to determine the optimal 
conditions for siRNA transfection, an optimisation with a siRNA for kinesin (Ambion 
Inc., 16704) was carried out for each cell line. Cell suspensions were prepared at 
1x10s; 3xl05 and 7xl05 cells per ml. Solutions of negative control and kinesin siRNAs
T W
at a final concentration of 30nM were prepared in optiMEM (Gibco , 31985). NeoFX 
solutions at a range of concentrations were prepared in optiMEM in duplicate and 
incubated at room temperature for 1 Omin. After incubation, either negative control or 
kinesin siRNA solution was added to each NeoFX concentration. These solutions were 
mixed well and incubated for a further 10 minutes at room temperature. 100 |il of the 
siRNA/neoFX solutions were added to each well of a 6-well plate. 1ml of the relevant 
cell suspensions were added to each well. The plates were mixed gently and incubated 
at 37°C for 24 hours. After 24hr, the transfection mixture was removed from the cells 
and the plates were fed with fresh medium. The plates were assayed for changes in 
proliferation at 72hr using the acid phosphatase assay (Section 2.7.1b). Optimal 
conditions for transfection were determined as the combination of conditions which 
gave the greatest reduction in cell number after kinesin siRNA transfection and also 
the least cell kill in the presence of transfection reagent. The optimised conditions for 
the cell lines were 2|il NeoFx to transfect 30nM siRNA in a cell density of 3xl05 per 
well of a 6-well plate.
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qPCR analysis of these early transfections demonstrated that mRNA knockdown was 
not being achieved, which led to the examination of cell line handling during the 
transfection process. It transpired that cell handling during the transfection protocol is 
particularly important. The following procedures were optimised for siRNA 
transfection in these cell lines:
• Cells should be in log/growth phase and in a healthy condition when used to
seed siRNA transfections and should be fed with fresh medium 24h prior to
transfection.
• The cell suspensions should be prepared in serum containing medium i.e. 
normal growth medium (as opposed to medium with reduced serum e.g. 
Optimem).
• Cells should be in suspension for as short a time as possible and maintained at
37°C to avoid heat shock while the siRNA complex is being prepared.
Five cell lines were too many cell lines to transfect with siRNA in any one 
transfection. The reasons for this are twofold; the cells are in suspension for longer 
time periods than if you were working with fewer cell lines. It was found that cells in 
suspension should be dispensed onto complexed siRNA/NeoFx solutions immediately 
following the complex incubation period (i.e. reverse transfection). Extended time 
periods lead to poor transfection efficiency and thereby poor target knockdown. We 
determined that three cell lines are the maximum number suitable in any single 
transfection experiment.
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2.17.2 Proliferation effects of siRNA transfection
Solutions of siRNA at a final concentration of 30nM were prepared in optiMEM 
(Gibco, 31985). NeoFX solution was prepared in optiMEM and incubated at room 
temperature for 10 minutes. After incubation, an equal volume of NeoFX solution was 
added to each siRNA solution. These solutions were mixed well and incubated for 10 
minutes at room temperature. Replicates of 100|al of the siRNA/NeoFX solutions were 
added to a 6 -well plate. 1ml of each cell suspension was added to at a concentration of 
3x105 per well. The plates were mixed gently and incubated at 37°C for 24 hours. After 
24 hours, the transfection mixture was removed from the cells and the plates were fed 
with fresh medium. The plates were assayed for changes in proliferation at 72 hours 
using the acid phosphatase assay (Section 2.7.1b).
Table 2.1.6 List of siRNAs used
Target name Ambion IDs
Scrambled Negative control #2
IGF-1R 74 (validated)
KCNJ8 7346, 7252
S100A13 42125, 263271,263272
SFN 17396
TFPI2 17988
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An additional assay format was used to investigate proliferation. Kinesin siRNA was 
included as a positive control for the transfection. Solutions of siRNA at a final 
concentration of 30nM were prepared in optiMEM (Gibco, 31985). NeoFX solution 
was prepared in optiMEM and incubated at room temperature for lOmin. After 
incubation, an equal volume of NeoFX solution was added to each siRNA solution. 
These solutions were mixed well and incubated for a further lOmin at room 
temperature. Replicates of 10|il of the siRNA/NeoFX solutions were added to a 96- 
well plate. Cell suspensions were overlayed to each well at densities of 2.5x103 and 
5xl03 per well. The plates were mixed gently and incubated at 37°C for 24hr. After 24 
hr, the transfection mixture was removed from the cells and the plates were fed with 
fresh medium. The plates were assayed for changes in proliferation at 72hr using the 
acid phosphatase assay (Section 2.7.1a).
2.17.3 Invasion analysis of siRNA transfected cells
To assay for changes in invasive capacity, siRNA experiments in 6-well plates were 
set up using 2[i\ NeoFx to transfect 30nM siRNA in a cell density of 3xl05 per well of 
a 6-well plate. Transfection medium was removed after 24hr and replaced with fresh 
growth medium. The transfected cells were assayed for changes in invasion capacity at 
72hr using the optimised in vitro invasion assay described in Section 2.7.2.
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2.18 Transfection of DLKP variants with Exogenous DNA
In order to understand the role of target genes more clearly, a vector, pSportô, 
containing the target cDNA sequence was transiently transfected into host cells to 
exogenously increase the level of expression of the target genes. Plasmids containing 
each target were purchased from OpenBiosystems in destination vectors and were sub­
cloned into the expression vector pSportô. Stock plasmid was produced by 
transforming competent JM109, growing up a large stock of these cells and isolating 
the plasmid from them. This isolated plasmid was then transfected into the chosen cell 
line. The plasmids used in this study are detailed in Table 2.1.7.
Table 2.1.7 Plasmids used in this study
Name Resistance to Catalogue no. Supplied
Vector
Expression
Vector
KCNJ8
CAM MHS1011-
59229 pOTB7 pCMV-
SPORT6
SFN
CAM MHS1011-
61174 pOTB7 pCMV-
SPORT6
S100A13
CAM MHS1011-
59294 pOTB7 pCMV-
SPORT6
TFPI2
CAM EHS1011-
4411426 pDNR-LIB pCMV-
SPORT6
GFP AMP - pEGFP-Cl pEGFP-Cl
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2 18 11 Transformation of JM109 Cells
A bacterial cell suspension (lOOfil) of competent JM109 (Promega, L2001) was mixed 
with 20ng DNA and placed on ice for 40min after which the mixture was heat-shocked 
at 42°C for 90s and then placed on ice for 3min LB broth (1ml) ((10g Tryptone 
(Oxoid, L42), 5g Yeast Extract (Oxoid, L21) 5g NaCl (Merck, K1880814))/litre LB, 
autoclaved before use) was added to the competent cell suspension and incubated at 
37°C for lhr Different volumes of this suspension was spread on a selecting agar 
plates (LB agar containing appropriate antibiotic concentration of ampicillin or 
chloramphenicol) and incubated overnight at 37°C Single colonies that grew on these 
selecting plates were incubated into 5ml LB broth containing appropnate selection 
antibiotic
Single colonies inoculated into 5ml LB broth (lOg Tryptone (Oxoid, L42), 5g Yeast 
Extract (Oxoid, L21), 5g NaCl (Merk, K1880814) per litre of LB, autoclaved before 
use) contaimng appropnate selection antibiotic and were grown for 8hr with shaking at 
37°C and were subject to a DNA mini preparation (Section 2 18 1 2) or Large Scale 
Preparation (Section 2 18 13) For a large scale DNA preparation this culture was then 
inoculated into 270ml LB broth contaimng 0 3ml ampicillin (lOOmg/ml) in 1L baffled 
flask with shaking overnight at 37°C
2.18 1 2 DNA Mmiprep of Plasmid DNA
Plasmid DNA was isolated from a 5ml culture grown in LB broth containing selection 
antibiotic ovemght with shaking at 37°C using the Qiagen Plasmid DNA Extraction 
Mim Kit (Qiagen, 12143) To determine and select the colomes contaimng the inserted 
DNA sequence, a mmiprep of the plasmid DNA was earned out Single colonies were 
selected off the selection plates and incubated in universals containing 5mls LB/Amp 
shaking at 180rpm at 37°C overnight After incubation, the cells were centnfuged at
2 18 1 Plasmid Preparation
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8,500rpm for 3 min Pelleted cells were resuspended in 250jil of buffer PI and the cell 
suspension was transferred to a microcentnfuge tube To this solution, 250jil buffer P2 
was added and mixed gently A volume of 350^1 buffer N3 was added to the solution 
and the tube was mixed immediately This mixture was centrifuged for 10mm at 
13,000 rpm The supernatant was applied to a QLAprep spin column and centrifuged 
for 60s The flow-through was discarded The column was washed by adding 500}il 
buffer PB and centrifuging for 60s The flow through was discarded This step was 
repeated with 750|il buffer PB The column was centrifuged for a further 60s to 
remove the entire wash buffer The column was then placed in a clean microcentnfuge 
tube To elute the DNA, 50|xl of buffer EB was added to the column The column was 
let stand for 60s and then centnfuged for 60s The DNA concentration was determined 
by measunng the OD260mn Plasmid was stored at -20°C until required
2 18 1.3 DNA Maxiprep of Plasmid DNA
Plasmid DNA was punfied using an endofree plasmid maxi kit (Qiagen, 12362) 
Following growth of plasmid culture in into 270ml LB broth containing 0 3ml 
ampicillin (lOOmg/ml) in 1L baffled flask with shaking overnight at 37°C, the culture 
was split into 2 x 250ml centnfuge bottles and spun at 3,500rpm for 15mm at 4°C 
Pellets were weighed and either frozen at -80°C until required or processed further
The bactenal pellet was resuspended in 10ml buffer PI To this, 10 ml buffer P2 was 
added, mixed gently and incubated at room temperature for 5min A volume of 10ml 
chilled buffer P3 was added to the lysate and mixed immediately and gently The 
lysate was poured into the barrel of the QLAfilter cartndge and incubated at room 
temperature for 10mm The cap from the QLA filter outlet nozzle was removed and the 
plunger was gently inserted in to the cartndge The cell lysate was filtered into a 50ml 
tube To the lysate, 2 5ml buffer ER was added and mixed by inverting repeatedly 
This was incubated on ice for 30min A qiagen-tip 500 was equilibrated by applying 
10ml buffer QBT and the column was allowed to empty by gravity flow The filtered 
lysate was then applied to the qiagen-tip and allowed to enter the resin by gravity flow 
The qiagen-tip was washed twice with 30ml buffer QC The DNA was eluted by
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addition of 15ml buffer QN and the eluate was collected in a 30ml tube The DNA was 
precipitated by adding 10 5ml isopropanol to the eluated DNA This was mixed and 
centrifuged at ~10,000rpm for 30min at 4°C The DNA pellet was washed with 5ml of 
70% ethanol and this was centrifuged at ~10,000rpm for 10mm The pellet was air- 
dned and dissolved in 500|il buffer TE The DNA concentration was determined by 
measuring the OD260nm
2.18 1 4 Sub-cloning
5jng of each plasmid from OpenBiosystems were digested with the appropriate 
restriction endonucleases (see table 2 1 8) for lhr at 37°C to remove the gene coding 
sequence for insertion into pSport6 expression vector
Table 2.1.8 Restriction Digestions of plasmids m their supplied vectors.
Target Restriction Enzymes 
used
Fragment size
KCNJ8 Ecorl/Xhol 1 7kb
S100A13 Ecorl/Xhol 0 5kb
SFN Ecorl/Xhol 1 3kb
TFPI2 Xbal/Sall 1 2kb
These restriction digests were analysed by TAE low melt 1% gel electrophoresis and 
the relevant fragment size excised from the gel using a fresh clean blade for each 
excision The DNA was purified from the gel by the addition of PB buffer (Qiagen Gel 
Purification Kit) to each gel slice, this was melted at 55°C for 10mm and applied under 
vacuum to a gel purification column The DNA was column was washed with 750^1 of 
PE buffer under vacuum and centrifuged at 13,000rpm for lmin to dry The pellet was
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re-dissolved in 15|il EB buffer and a portion of this run out on a 1% TAE agarose gel 
This ensured that the cDNA fragment was not contaminated and thus suitable for 
ligation
Each insert was ligated with pSport6 (digested with matching REs) at 15°C overnight 
in a mastermix typically contaimng expression vector (lOOng), target insert cDNA 
(300ng), water, 10X ligation buffer and T4 ligase (2 5U) in a total volume of 10|il 
Half of this ligation reaction was then transformed into JM109 competent cells as 
descnbed above (2 18 1 1) Single colonies that grew on the relevant selection plates 
were incubated into 5ml LB broth containing appropriate selection antibiotic and used 
for a DNA mini-preparation, a small volume was then digested and analysed by 1% 
TAE gel electrophoresis to ensure clean DNA preparations and confirm that bands 
obtained corresponded to the expected sizes of the expression vector and target 
fragments Once this was confirmed the plasmids were then sent for sequencing and 
used for maxi preparation of DNA stocks (2 18 13)
2.18.2 Plasmid DNA Sequencing
In order to fully confirm the orientation and the origin of the inserted DNA in the 
plasmids, each plasmid was sent to MWG-Biotech (Germany) for sequencing Once 
these parameters had been confirmed, transfection could be earned out
2 18 3 Optimisation of plasmid transient transfection protocol
The transient transfection protocol was optimised for each of the five DLKP cell lines 
used in the study To this end a cell suspension was generated at a concentration of 
4x10s cells/ml m complete growth medium and seeded 24hr before transfection 
Lipofectamine 2000 (Invitrogen, 11668019) and Green Flourescent Protein (GFP) 
plasmid DNA was prepared with the volumes of Lipofectamine 2000 and cDNA being 
vaned The conditions investigated to ascertain the most efficient transfection 
conditions were as follows,
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• 2fig GFP cDNA 5fil Lipofectamine 2000
• 4|ig GFP cDNA lOjil Lipofectamine 2000
Bnefly, the plasmid and optiMEM were incubated at room temperature for 5min 
During this time the Lipofectamine 2000 and optiMEM were also incubating at room 
temperature Both incubations were combined, mixed gently and formed complexes 
over 20min at room temperature 1ml of this complex was added per well and mixed 
gently The cells were viewed using a fluorescent microscope after 24hr and the 
optimum transfection efficiency determined for each cell line by comparing the 
number of cells that fluoresced green with the number of cells in a particular field 
(Section 3 5 6 2) The Lipofectamine 2000 had a toxic effect on the cells, thus the 
lowest volume of transfection reagent was used while maintaining high transfection 
efficiencies To this end 5jul Liofectamine 2000 was used to transfect 2|ig plasmid 
cDNA in all transient cDNA transfections m this study
2.18.4 Invasion analysis of cDNA transiently transfected cells
To assay for changes in invasive capacity, cDNA experiments in 6-well plates were set 
up using 5\i\ Lipofectamine 2000 to transfect 2jig plasmid cDNA in a cell density of 
4xl05 per well of a 6-well plate Transfection medium was removed after 24hr and 
replaced with fresh growth medium The transfected cells were assayed for changes in 
invasion capacity at 72hr using the optimised in vitro invasion assay descnbed in 
Section 2 7 2)
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Section 3.0: Results
I
3.1 Microarray analysis of DLKP and its invasive and
chemotherapeutic resistant variants
The gene-expression profiles of five human lung cancer cell lines with differing levels 
of invasion (as determined by an in vitro invasion assay) were analysed using 
expression microarray methodology Two invasive parental DLKP cell lines (DLKP-1 
and DLKP-2) were used along with an invasive Taxotere (TXT) resistant DLKP 
variant (DLKP-TXT-2) and a non-invasive TXT selected DLKP cell line that had lost 
it’s resistance to TXT (DLKP-TXT-1) This provided us with an in vitro model of 
invasion The aim of this microarray study was to identify genes involved in the 
development of an invasive phenotype in lung cancer cell lines These cell lines with 
differing levels of invasiveness (derived from the same parent) offered a unique 
opportunity to study the less-well characterised mechanisms of invasion
An important point to remember when considering this analysis is that there are 
potentially two ways to approach this data in that one could look at drug resistance 
and/or invasion The main focus in this thesis was to analyse differences between the 
invasive and poorly invasive cell lines Theoretically however, any differentially 
expressed genes identified by the microarray analysis could relate to drug resistance 
and/or invasion
3 11 GeneChip Quality Control
This section details the quality control measures were used in these microarray 
experiments before gene expression analysis began
3 1 1 1  Scale factor
Each array had varying image intensity, and this intensity, or brightness, was measured 
by the “scaling factor” In order to make an accurate comparison of multiple sets of 
array data the mean intensities of the arrays were brought to the same arbitrary set 
point, typically 100 This algorithm was performed using Microarray Suite 5 0 (MAS 
5 0) with a mathematical technique known as ‘scaling’ Scaling worked by calculating 
the overall intensity of an array and averaging every probe set on the array (with the 
exception of the top and bottom 2% of the probe set intensities) The average intensity
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of the array was then multiplied by the scaling factor to ensure that all of the intensities 
on the given array went up or down to a similar degree Therefore very dim chips 
typically have large scale factors Scaling allowed normalisation of several 
experiments to one target intensity For the experiments to be comparable, there must 
be no more than 3 fold difference between the scaling factors for each chip
3 1 1 2  Noise
“Noise” measured the pixel-to-pixel variation of probe cells on the array and is caused 
by small variations in the digital signal observed by the scanner as it sampled the array 
surface As each scanner has a unique electrical noise associated with its operation, 
noise values among scanners vary Therefore arrays that were scanned on the same 
scanner were expected to have similar noise values
3 1 1 3  Background
Affymetnx have found that typical background values range from 20 to 100 and that 
arrays being compared should have similar background The background values ranged 
from 47 to 66 for this set of arrays, which is acceptable High background can result 
from ethanol carryover during sample processing and result in a reduced percentage 
present call
3 1 1 4  Present call
The percentage of genes present relates to the number of probe sets present relative to 
the total number of probe sets on the array Replicate samples should have similar 
percentage present calls that typically vary between 40-60%, but this may be cell line 
dependent
1 0 0
3 1 1 5  3’:5’ ratio
All of the arrays used p actin and GAPDH to assess RNA sample and assay quality by 
having probes specific for the 3 \ middle and 5’end of these genes The ratio of signal
intensity from 37 probes to 5’probes was a measure of the number of cDNA synthesis
reactions that went to completion A ratio of 1 indicated full-length transcript and was 
considered ideal A cut-off value of 3 was applied, values above 3 indicated that either 
the in vitro transcription (IVT) reaction was not complete or that the RNA was 
degraded Values of less than 1 are also possible and indicate preferential binding of 55 
probes
3 1 1 6  Hybridisation controls
Spiked cRNAs were used as hybridization controls BioB, bioC and bioD represent 
genes in the biotin synthesis family of E coh, and Cre is the recombinase gene from 
the PI bacteriophage They were spiked in increasing concentrations and the average 
difference values were expected to be present in increasing amounts, bioB being the 
least and Cre the most Chips passed QC if MAS 5 0 deemed the BioB control 
“present”
3.11 7 Visual examination
After scanning the array, chips were inspected for the presence of image artefacts 
These include spots or regions on the chip with unusually high or low intensity, 
scratches or overall background All of the chips used passed visual inspection
The overall quality control for the duplicate array samples are visualised in Figure 
3 11 In order to visualise each quality control metric on one graph, values for 
background and percent present calls were divided by ten, and raw values were divided 
by 25
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Fig 3.1.1 Quality Control for the duplicate Aflymetrix Chips
This graph demonstrates that the U 133A duplicate array chips used for the duplicate 
analysis of the five DLKP variants were within the required quality control parameters 
recommended by Affymetrix.
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3 1 1 8 Quality control by unsupervised hierarchical clustering
Hierarchical clustering is used as an internal QC measure taken within the NICB when 
the chip run is deemed satisfactory Since the chips were scaled, no further 
normalisations were required for this QC step Unsupervised Hierarchical clustering 
grouped samples together based on similar expression levels of the genes analysed by 
the microarrays and identifies any bias m the system This clustering allowed the direct 
comparison of the different chips based on the profile of altered genes on each chip 
One would expect that chips used to analyse biological replicates should resemble each 
other more than chips used to analyse unrelated samples and would be grouped 
separately
The hierarchical cluster generated by GeneSpring for this experiment can be seen in 
Figure 3 1 2 Ideally, the five cell lines would group together in triplicates In this case 
however, the DLKP parents that were put on the array in duplicate clustered together 
but the single DLKP parent did not align beside them in the cluster Duplicate VCR 
samples also clustered together but did not align beside the single VCR sample The 
three TXT non-invasive samples did not cluster together at all and likewise for the 
TXT invasive samples This is not the optimal result for a hierarchical cluster 
However, the result is unsurprising since the initial sample generation and array 
processing on the two invasive DLKP parents, the invasive DLKP-TXT-2, and the 
poorly invasive DLKP-TXT-1 and DLKP-VCR was carried out by a different 
researcher, Dr Rasha Linehan in 2003 as single samples for analysis Further duplicate 
sets of the above samples were than prepared for microarray analysis, for this thesis 
This generated an overall triplicate data set for the statistical analysis of the DLKP 
invasive variants This is reflected in a further hierarchical cluster, where the samples 
cluster by researcher or by date of processing (Figure 3 1 3) Despite these anomalies 
in the hierarchical clustering, the results of this study indicate a useful microarray data 
set in terms of identifying genes involved m invasion and/or drug resistance, although 
it is likely that some data was lost due to the reduced reproducibility
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Figure 3.1.2 Hierarchical Cluster of DLKP and the variant samples in triplicate
Ideally, the five cell lines would group together into their biological triplicates. 
Coloured boxes represent replicate samples. Red/yellow bars indicate expression levels 
of genes used in generating cluster.
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Figure 3.1.3 Hierarchical Cluster of DLKP and the variant samples in triplicate
The samples cluster by researcher/date of sample processing. The red boxes are 
indicative of samples prepared by Dr. Rasha Linehan in 2003. The yellow boxes are 
indicative of samples processed in 2004 to generate an overall triplicate data set for the 
statistical analysis of the DLKP variants.
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3.1.2 Bioinformatic analysis -  generating genelists
A major aim of this work was to generate gene-lists from the raw array data that may 
potentially serve as a genotypic signature for invasiveness and/or drug resistance in the 
DLKP variants. Various methods were employed including using software such as 
GeneSpring, Bibliosphere (Genomatix), and promoter analysis using Gene2promoter, 
FrameWorker and Modellnspector (also from Genomatix). This is detailed in section 
2.16. Various analyses were used to compile the different genelists detailed in this 
section to increase confidence in the identification and selection of targets for further 
analysis. For example, the GeneSpring™ software was used to generate genelists one 
to five in this study. This allowed for the identification of genes that would otherwise 
have been missed had the data been interpreted in only one way, while identifying 
targets that consistently appeared on each genelist.
3.1.2.1 Genelist 1
For the generation of genelist 1 (Tables 3.1.1 and 3.1.2), multiple experiments were 
created in GeneSpring with all possible pairs of samples. A filter was applied to 
remove any genes that were consistently flagged as absent. These “pairwise” 
comparisons were used to identify genes that were up and down regulated (using an 
arbitrary two fold cut off) between the five cell lines. These lists (which contained 
hundreds of genes each) were overlapped (using the Venn diagram function in 
GeneSpring) to find genes that were consistently up or down regulated in invasive 
samples relative to poorly invasive samples. Using this single data set, 31 genes came 
through the above analysis. Genes emboldened were analysed by semi quantitative 
RT-PCR to confirm that the array results were reflective of gene expression across the 
DLKP cell model.
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Table 3.1.1 Genes 2X down-regulated on genelist 1
Common genes 2X down in Inv Parvs Non-inv Cell lines Common genes 2X down In InvTXT vs Non Inv cell lines
21584 
all genes
Figure 3.1.4 Genes Downregulated with respect to invasion from Pairwise 
analysis.
Pairwise comparisons were used to identify genes whose expression was different 
(using an arbitrary two fold cut off) between the five cell lines. These lists, containing 
hundreds of genes each, were overlapped using the Venn diagram function in 
GeneSpring to identify genes that were consistently down regulated in invasive 
samples relative to poorly invasive samples. Eleven genes were identified as having 
decreased expression in the invasive cell lines (there was two different probe sets 
reported for one of the genes).
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Symbol Gene Name Function (if known)
VAMP4 vesicle-associated membrane protein 4 Vesicle associated protein trafficking
HLA-DRB1 Major Histocompatibility Complex, 
Class II, Dr 3-1
MHC class II antigen
NRG1 neuregulin 1 Neurogenesis embryonic development cell 
differentiation
SLC4A7 solute carrier family 4, sodium 
bicarbonate cotransporter, member 7
Anion transport bicarbonate transport
SPP1 secreted phosphoprotein 1 (osteopontin, 
bone sialoprotein I, early T-lymphocyte 
activation 1)
anti-apoptosis cell-matrix adhesion, cell-cell 
signalling negative regulation of bone 
mineralization immune cell chemotaxis
TEM6/TENS
1
tensin-like SH2 domain containing 1 protein amino acid déphosphorylation 
intracellular signaling cascade
RANBP2 RAN binding protein 2 protein folding protein-nucleus import 
transport
GLI glioma-associated oncogene homolog 1 
(zinc finger protein)
regulation of transcription from Pol II 
promoter signal transduction development 
regulation of smoothened signaling pathway
SCHIP1 schwannomin interacting protein 1 unknown
ATP9A ATPase, Class II, type 9A cation transport metabolism
TFPI2 tissue factor pathway inhibitor 2 serine-type endopeptidase inhibitor activity 
extracellular matrix structural constituent 
protease inhibitor activity
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Table 3.1.2 Genes 2X up-regulated on genelist 1
Figure 3.1.5 Genes Upregulated with respect to invasion from Pairwise analysis.
Pairwise comparisons were used to identify genes whose expression was changing 
(using an arbitrary two fold cut off) between the five cell lines. These lists, containing 
hundreds of genes each, were overlapped using the Venn diagram function in 
GeneSpring to identify genes whose expression were consistently up regulated in 
invasive samples relative to poorly invasive samples. 23 genes were identified as 
having decreased expression in the invasive cell lines (Some of these 23 probe sets 
identified, reported increased expression for the same gene).
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Symbol Gene Name Function (if known)
PRLR
prolactin receptor anti-apoptosis, cell surface receptor linked 
signal transduction, transmembrane 
receptor protein, tyrosine kinase activation 
(dimerization)
GLP1R
glucagon-like peptide 1 receptor generation of precursor metabolites and 
energy G-protein coupled receptor protein, 
signaling pathway, adenylate cyclase 
activation
BCHE
butyrylcholinesterase beta-amyloid binding cholinesterase 
activity, serine esterase activity, hydrolase 
activity, enzyme binding
TLX1 T-cell leukemia, homeobox 1 unknown
loc51159 colon carcinoma related protein unknown
KCNJ8
potassium inwardly-rectifying channel, 
subfamily J, member 8
voltage-gated ion channel activity, 
potassium channel activity, ATP-activated 
inward rectifier potassium channel activity
TEM7
PLXDC1
plexin domain containing 1 Angiogenesis development
CYB5R2 cytochrome b5 reductase b5R.2 electron transport
DSCR6 Down syndrome critical region gene 6 unknown
MFAP2 microfibrillar-associated protein 2 extracellular matrix structural constituent
ICAM1
intercellular adhesion molecule 1 
(CD54), human rhinovirus receptor
cell-cell adhesion, transmembrane receptor 
activity, protein binding
SOX13
SRY (sex determining region Y)-box 
13
regulation of transcription, DNA dependent 
morphogenesis
SFN
stratifin regulation of cell cycle, negative regulation 
of protein kinase activity, signal 
transduction, cell proliferation
IGF-1R
Insulin-like growth factor 1 receptor regulation of cell cycle, protein amino acid 
phosphorylation, anti apoptosis, signal 
transduction, positive regulation of cell 
proliferation, insulin receptor signaling 
pathway
AKAP11 A kinase (PRKA) anchor protein 11 protein kinase cascade
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3.1.2.2 Genelist 2
Genelist 2 (Table 3 .1.3) was generated in a similar manner to genelist 1, except the raw 
data from the duplicate DLKP variant sample set was analysed. Again, pairwise 
comparisons were used to identify genes that were up and down regulated (using an 
arbitrary two fold cut off) between the five DLKP variants. These lists were compared 
using the Venn diagram function in GeneSpring and genes that were consistently up or 
down regulated in invasive samples relative to poorly invasive samples were 
identified. Genes emboldened were subject to RT-PCR confirmation of differential 
expression.
Table 3.1.3 Genelist 2
Symbol Gene Name Function (if known)
DHRS1
dehydrogenase/reductase (SDR family) 
member 1
metabolism
S100A13 S100 calcium binding protein A 13 cell differentiation, calcium ion binding
EFNB2
ephrin-B2 cell-cell signalling, neurogenesis, 
morphogenesis
TFPI2
tissue factor pathway inhibitor 2 serine-type endopeptidase inhibitor 
activity, extracellular matrix structural 
constituent, protease inhibitor activity
VEGF-C
vascular endothelial growth factor C regulation of cell cycle, angiogenesis, 
substrate-bound cell migration, signal 
transduction, cell proliferation, positive 
regulation of cell proliferation
MAP3K12 Signal transduction
MGC39900
hypothetical protein MGC39900 cytoskeleton organization and biogenesis, 
actin binding
SFN
stratifin regulation of cell cycle, negative regulation 
of protein kinase activity, signal 
transduction, cell proliferation
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3.1.2.3 Genelist3
Pairwise comparisons were also used to generate Genelist 3 (Table 3.1.4) in a manner 
similar to that used to generate gnelists 1 and 2, except that the triplicate DLKP variant 
microarray data set was included for analysis. RT-PCR was employed to investigate 
the expression of genes in bold to comfirm the trends indicated by the array data. 
Genelist 3 contained genes that were potentially differentially expressed in the invasive 
cell lines DLKP-1, DLKP-2 and DLKP-TXT-2, compared with the poorly invasive 
DLKP-TXT-1 and DLKP-VCR.
Table 3.1.4 Genelist 3
Symbol Gene Name Function (if known)
ABCG5
ATP-binding cassette, sub-family G 
(WHITE), member 5 (sterolin 1)
Transport cholesterol absorption
ADAM7
a disintegrin and metalloproteinase 
domain 7
proteolysis and peptidolysis 
metalloendopeptidase activity
ARHGAP8 Rho GTPase activating protein 8 GTPase activator activity
CACNALc
Calcium channel, voltage-dependent, 
L type, alpha 1C subunit
voltage-gated calcium channel activity, 
cation channel activity, calcium ion binding
C0R02B
coronin, actin binding protein, 2B actin cytoskeleton organization and 
biogenesis
CXCL13
chemokine (C-X-C motif) ligand 13 
(B-cell chemoattractant)
Chemotaxis, inflammatory response, 
positive regulation of cytosolic calcium ion 
concentration, cell-cell signaling
CYLC1
cylicin, basic protein of sperm head 
cytoskeleton 1
structural molecule activity
DLG5
discs, large homolog 5 (Drosophila) regulation of cell cycle, intracellular 
signaling cascade, cell-cell adhesion
flj 11467 Hypothetical protein FLJ 11467 unknown
flj22639 hypothetical protein FLJ22639 unknown
GAD1
glutamate decarboxylase 1 glutamate decarboxylase activity, protein 
binding lyase activity
GATA6
GAT A binding protein 6 transcription factor activity, zinc ion 
binding, transcriptional activator activity
GLI
glioma-associated oncogene homolog 
1 (zinc finger protein)
regulation of transcription from Pol II 
promoter, signal transduction,
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development, regulation of smoothened 
signaling pathway
GPT
glutamic-pyruvate transaminase 
(alanine aminotransferase)
Gluconeogenesis, nitrogen compound 
metabolism, biosynthesis
HEMK
HemK methyltransferase family 
member 1
DNA méthylation, protein amino acid 
méthylation
KCNK13
potassium channel, subfamily K, 
member 13
voltage-gated ion channel activity, 
potassium channel activity
KRT18 keratin 18 structural constituent of cytoskeleton
KRTAP1-1 keratin associated protein 1-1 structural constituent of epidermis
LAPTM5
lysosomal associated multispanning 
membrane protein 5
unknown
LY6G6E
lymphocyte antigen 6 complex, locus 
G6E
unknown
MBLL39 muscleblind-like 2 nucleic acid binding
MRPS6 Mitochondrial ribosomal protein S6 protein biosynthesis
0RM1 orosomucoid 1 transporter activity
PHF3
PHD finger protein 3 Transcription, regulation of transcription, 
DNA-dependent development
PIB5PA
phosphatidylinositol (4,5) 
bisphosphate 5-phosphatase, A
inositol or phosphatidylinositol 
phosphatase activity inositol-polyphosphate 
5 phosphatase activity hydrolase activity
PIK3R4
Phosphoinositide-3 -kinase, 
regulatory subunit 4, p i50
protein serine/threonine kinase activity, 
binding ATP binding, transferase activity
PLA2G2E
phospholipase A2, group IIE phospholipase A2 activity, calcium ion 
binding, hydrolase activity
PTK6
PTK6 protein tyrosine kinase 6 non-membrane spanning protein tyrosine 
kinase activity, ATP binding, transferase 
activity
PXR1 peroxisomal biogenesis factor 1 protein transport
TACSTD2
tumor-associated calcium signal 
transducer 2
cell surface receptor linked signal 
transduction, visual perception, cell 
proliferation
TFPÏ2
tissue factor pathway inhibitor 2 serine-type endopeptidase inhibitor 
activity, extracellular matrix structural 
constituent, protease inhibitor activity
TNS Tensin intracellular signaling cascade
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3.1.2.4 Genelist 4
The data was further analysed to generate genelist 4 (Table 3.1.5), this time using a 
different approach on all fifteen chips. Genes that did not cross a two-fold threshold 
above or below the median in at least one cell line were removed from the analysis, as 
were genes that were consistently called absent by the Affymetrix software. A Welch 
ANOVA statistical test was used to find genes that were reliably differentially 
expressed between the five different cell lines. Subsequently, a further Welch ANOVA 
test was used to find genes in this list that were useful in discriminating between 
invasive and non-invasive samples. This generated a gene list containing 45 genes, 
whose expression patterns (see heatmap Figure 3.1.6) were analysed visually to 
identify 18 possible invasion related genes i.e. genelist 4.
Table 3.1.5 Genelist 4
Symbol Gene Name Function (if known)
ATP9A ATPase, Class II, type 9A cation transport metabolism
CD34 Cd34 antigen Adhesion molecule
DPEP3 unknown
EFNB2
ephrin-B2 cell-cell signalling, neurogenesis, 
morphogenesis
flj23033 Hypothetical protein unknown
flj23091 Hypothetical protein
unknown
GDAP1L1
Ganglioside-induced differentiation- 
associated protein 1-like 1
GST-like protein
GLI
glioma-associated oncogene homolog 
1 (zinc finger protein)
regulation of transcription from Pol II 
promoter, signal transduction, 
development, regulation of smoothened 
signaling pathway
HGF
Hepatocyte growth factor regulation of cell cycle, substrate-bound 
cell migration, signal transduction, cell 
proliferation, positive regulation of cell 
proliferation
ICAM1
intercellular adhesion molecule 1 
(CD54), human rhinovirus rcceptor
cell-cell adhesion, transmembrane receptor 
activity, protein binding
JAG2 Jagged 2
Cell signalling
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mgc39900
hypothetical protein MGC39900 cytoskeleton organization and biogenesis, 
actin binding
PLXDC1
(tem7)
plexin domain containing 1 Angiogenesis development
S100A13 SI00 calcium binding protein A13
cell differentiation, calcium ion binding
SCHIP1 schwannomin interacting protein 1
unknown
SFN
stratifin regulation of cell cycle, negative regulation 
of protein kinase activity, signal 
transduction, cell proliferation
TLX1 T-cell leukemia, homeobox 1
unknown
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Fig 3.1.6 Heatmap of Gene-expression.
In this expression heatmap there is a gene on each row and the five columns represent 
our five cell lines. Genes are coloured red if they are upregulated relative to the median 
for that gene. A blue colour indicates downregulation. The gene tree to the left of the 
heatmap (in green) shows groups of genes with similar expression patterns (as grouped 
by the Pearson correlation). The genes on this heatmap are differentially expressed the 
in invasive versus poorly invasive DLKP variants and are detailed in Table 3.1.5 
above.
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3.1.2.5 Genelist 5
Rather than grouping the samples into invasive and non-invasive, an arbitrary scale of 
invasion was applied to reflect the intermediate degrees of invasion displayed by the 
cell lines in the in vitro invasion assay. The scale was as follows:
DLKP-1 = 5 
DLKP-2 = 3.5 
DLKP-TXT-1 = 1 
DLKP-TXT-2 = 5 
DLKP-VCR = 0
To analyse the data using this scale, a filter was applied that included genes that were 
present or marginal in three out of 15 samples and also genes whose expression were 
1.5 fold increased or decreased in three out of 15 samples. A genelist was made of the 
genes that passed these stipulations. A Welch ANOVA (settings: P-value; 0.01, no 
multiple testing correlation) was applied to this list using the invasion scale mentioned 
above. 531 genes came through this statistical test and are referred to as consistently 
changing genes.
These 531 consistently changing genes were put into Self Organising Maps (SOMs) 
(Figure 3.1.7). SOMs group together genes with similar expression pattern in clusters. 
The user defines the number of clusters into which the genes should be organised. The 
SOMs for the 531 changing genes relate to invasiveness only but a similar approach 
could be used to group genes related to drug resistance. A 7x6 SOM (log scale) was 
used to organise the 531 changing genes into clusters with similar expression patterns. 
Interesting expression patterns that may relate to invasion were chosen visually. The 
clusters picked for further analysis were (2,1), (5,1), (6,1), (3,7), (4,7), (5,7), (6,7) 
(where the 1st number relates to the cluster and the second number relates to the row 
the cluster is on). These reflect genes which either generally increase or generally 
decrease with invasion i.e. genelist 5 (Tables 3.1.6 and 3.1.7).
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Y-3xij; 15 chips invasive norm median, Lo9 by invasion details
Split by: 7>:fì SOM tor 15 chips invasive norm medi a n (Log by invasion details)
Oene List: uuelch ANOVA on PorM in 3outa15 and 1.5f UD (531)
Figure 3.1.7 7x6 SOMs for the 531 changing genes based on the invasion scale 
derived from invasion assay.
Interesting expression patterns that may relate to invasion were chosen visually. The 
clusters picked for further analysis were (2,1), (5,1), (6,1), (3,7), (4,7), (5,7), (6,7) 
(where the 1st number relates to the cluster and the second number relates to the row 
the cluster is on). These reflect genes that either generally increase or generally 
decrease with invasion.
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Table 3.1.6 Genelist 5; Genes with negative correlation to invasion from SOMs
Symbol Gene Name Function (if known)
ARK5
AMP-activated protein kinase 
family member 5
protein kinase activity, protein 
serine/threonine kinase activity, ATP 
binding transferase activity
BEX1 brain expressed, X-linked 1 unknown
CD24
CD24 antigen (small cell lung 
carcinoma cluster 4 antigen)
humoral immune response
CRYAB
crystallin, alpha B protein folding, muscle contraction, visual 
perception
CSRP2
cysteine and glycine-rich protein 2 muscle development, cell proliferation, cell 
growth, cell differentiation
ENC1
ectodermal-neural cortex (with 
BTB-like domain)
actin binding, protein binding, 
development, neurogenesis
flj 10097 Hypothetical protein unknown
FN1
fibronectin 1 acute-phase response, cell adhesion, 
metabolism, response to wounding, cell 
migration
FSTL1 follistatin-like 1 calcium ion binding, heparin binding
GAS1
growth arrest-specific 1 cell cycle arrest, negative regulation of cell 
proliferation, negative regulation of S 
phase of mitotic cell cycle
GPC3 glypican 3 morphogenesis
HIST1H2BK
histone 1, H2bk nucleosome assembly, chromosome 
organization and biogenesis
IFIT1
interferon-induced protein with 
tetratricopeptide repeats 1
immune response
IGFBP7
insulin-like growth factor binding 
protein 7
regulation of cell growth, negative 
regulation of cell proliferation, insulin-like 
growth factor binding
ISL1
ISL1 transcription factor, 
LIM/homeodomain, (islet-1)
regulation of transcription, DNA-dependent
KCTD12
potassium channel tetramerisation 
domain containing 12
voltage-gated potassium channel activity
kiaa0992 palladin unknown
LAMB1
laminin, beta 1 cell adhesion, structural molecule activity, 
protein binding
LRRN3 leucine rich repeat neuronal 3 unknown
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MDM1
Mdm4, transformed 3T3 cell 
double minute 1, p53 binding 
protein
unknown
MT1F
metallothionein IF copper ion binding, zinc ion binding, 
cadmium ion binding, metal ion binding
MT1H metallothionein 1H metal ion binding
MT1X metallothionein IX metal ion binding
NELL2
NEL-like 2 cell adhesion, structural molecule activity, 
calcium ion binding
OASL 2'-5'-oligoadenylate synthetase-like protein modification, immune response
OIPIO6
0GT(0-Glc-NAc transferase)- 
interacting protein 106 KDa
protein binding
PCDH7 BH-protocadherin cell adhesion, homophilic cell adhesion
PHLDA1
pleckstrin homology-like domain, 
family A, member 1
unknown
PI 15
protease inhibitor 15 peptidase activity, trypsin inhibitor 
activityF
PPM ID
protein phosphatase ID 
magnesium-dependent, delta 
isoform
regulation of cell cycle, protein amino acid 
dephosphorylation, negative regulation of 
cell proliferation, response to radiation
PRSS12 protease, serine, 12 proteolysis and peptidolysis
RAP1B
RAP IB, member of RAS oncogene 
family
intracellular protein transport, small 
GTPase mediated signal transduction
SFRP4
secreted frizzled-related protein 4 signal transduction, embryo implantation, 
Wnt receptor signaling pathway
SGK
serum/glucocorticoid regulated 
kinase
protein serine/threonine kinase activity, 
ATP binding, transferase activity
SPP1
secreted phosphoprotein 1 cytokine activity, integrin binding, protein 
binding, growth factor activity
TBX2
T-box 2 regulation of transcription, DNA- 
dependent, development
TITF1 thyroid transcription factor 1 regulation of transcription, DNA-dependent
TNFSF10
tumor necrosis factor (ligand) 
superfamily, member 10
Apoptosis, induction of apoptosis, immune 
response, signal transduction, cell-cell 
signalling, positive regulation of I-kappaB 
kinase/NF-kappaB cascade
TNNC1 troponin C, slow calcium ion binding
ZFPM2 zinc finger protein, multitype 2 regulation of transcription, DNA-dependent
ARK5 AMP-activated protein kinase protein kinase activity, protein
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family member 5 serine/threonine kinase activity, ATP 
binding, transferase activity
BEX1 brain expressed, X-linked 1 unknown
CRYAB
crystallin, alpha B protein folding, muscle contraction, visual 
perception
CSRP2
cysteine and glycine-rich protein 2 muscle development, cell proliferation, cell 
growth, cell differentiation
DAB2
disabled homolog 2, mitogen- 
responsive phosphoprotein
cell proliferation
dkfzp586a0522
DKFZP586A0522 protein S-adenosylmethionine-dependent 
methyltransferase activity, transferase 
activity
EGF
epidermal growth factor epidermal growth factor receptor activating 
ligand activity, calcium ion binding, growth 
factor activity
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Table 3.1.7 Genelist 5; Genes with positive correlation to invasion from SOMs
Symbol Gene Name Function (if known)
ARHGAP4
Rho GTPase activating protein 4 cytoskeleton organization and biogenesis, 
Rho protein signal transduction SH3/SH2 
adaptor protein activity, Rho GTPase 
activator activity
CAMK1
calcium/calmodulin-dependent 
protein kinase I
protein serine/threonine kinase activity, 
calcium- and calmodulin-dependent protein 
kinase activity, calmodulin binding, ATP 
binding, transferase activity
CD34 CD34 antigen cell adhesion, protein binding
CDH10
cadherin 10, type 2 (T2-cadherin) homophilic cell adhesion, calcium ion 
binding, protein binding
CDH2
cadherin 2, type 1, N-cadherin cell adhesion calcium ion binding, protein 
binding
CUGBP2
CUG triplet repeat, RNA binding 
protein 2
RNA binding
EFHC1
EF-hand domain (C-terminal) 
containing 1
calcium ion binding
HOXAIO
homeo box A 10 regulation of transcription, DNA- 
dependent, development
HOXA2
homeo box A2 regulation of transcription, DNA- 
dependent, development
HOXA9
homeo box A9 Transcription, regulation of transcription, 
DNA-dependent, development
IGF-1R
Insulin-like growth factor 1 
receptor
regulation of cell cycle, protein amino acid 
phosphorylation, anti-apoptosis, signal 
transduction, positive regulation of cell 
proliferation, insulin receptor signaling 
pathway
1GFBP3
insulin-like growth factor binding 
protein 3
regulation of cell growth, negative 
regulation of signal transduction, positive 
regulation of apoptosis, positive regulation 
of myoblast differentiation, insulin-like 
growth factor binding, protein tyrosine 
phosphatase activator activity, metal ion 
binding
IRS1 insulin receptor substrate 1 signal transduction from IGF-1R
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KCNJ8
potassium inwardly-rectifying 
channel, subfamily J, member 8
voltage-gated ion channel activity, 
potassium channel activity, ATP-activated 
inward rectifier potassium channel activity
MMP3
matrix metalloproteinase 3 
(stromelysin 1, progelatinase)
stromelysin 1 activity, calcium ion binding, 
zinc ion binding hydrolase activity
MRPS10
mitochondrial ribosomal protein 
S10
protein biosynthesis
NRG1
neuregulin 1 receptor binding, growth factor activity, 
transmembrane receptor protein tyrosine 
kinase activator activity, receptor tyrosine 
kinase binding
PDE4B
phosphodiesterase 4B, cAMP- 
specific
signal transduction
PLCB4
phospholipase C, beta 4 phosphoinositide phospholipase C activity, 
signal transducer activity, calcium ion 
binding, hydrolase activity
PLXNC1 Plexin Cl cell adhesion, development
PROCR
protein C receptor, endothelial 
(EPCR)
receptor activity
RGC32
response gene to complement 32 regulation of cyclin dependent protein 
kinase activity
SCG2 secretogranin II calcium ion binding
SMS
spermine synthase spermidine synthase activity, transferase 
activity, spermine synthase activity
SSX1 synovial sarcoma, X breakpoint 1 regulation of transcription, DNA-dependent
SSX2
synovial sarcoma, X breakpoint 2 regulation of transcription, DNA- 
dependent, G-protein coupled receptor 
protein signaling pathway,
SSX4 synovial sarcoma, X breakpoint 4 regulation of transcription, DNA-dependent
TACSTD1
tumor-associated calcium signal 
transducer 1
unknown
TCF4
transcription factor 4 regulation of transcription from Pol II 
promoter
TLE4
transducin-like enhancer of split 4 
(E(spl) homolog, Drosophila)
regulation of transcription, DNA- 
dependent, frizzled signaling pathway
TLX1 T cell homeobox 1 unknown
VEGF
vascular endothelial growth factor regulation of cell cycle, angiogenesis, 
vasculogenesis, response to stress, signal
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transduction, neurogenesis, cell 
proliferation, positive regulation of cell 
proliferation, cell migration, positive 
regulation of vascular endothelial growth 
factor receptor signaling pathway, negative 
regulation of apoptosis, induction of 
positive chemotaxis
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3.1.3 Data analysis using Genomatix software suite
Genomatix provide software that allows users to explore published studies as well as 
combine sequence analysis, and genome annotation in order to help researchers to get 
a complete overview of their biological data fwww. genomtix.de) The software offered 
by Genomatix is designed to help researchers gain a better understanding of gene 
regulation at the molecular level. The Genomatix software suite is comprised of six 
main tools: ElDorado, Gene2Promoter, BiblioSphere, GEMS Launcher, Matlnspector 
and Promoterlnspector. ElDorado is a gene orientated genome search engine that 
provides the user with information about functional genomic elements within a 
specific region of the genome. This piece of software compiles and integrates 
information on gene function and regulatory pathway. In addition, information on 
mRNAs, their exon/intron structure and coding sequences, single nucleotide 
polymorphisms (SNPs) and potential promoter regions may be retrieved using 
ElDorado. The hypothesis underlying this type of analysis is that genes with similar 
expression patterns may be co-regulated and therefore may be activated by the same 
transcriptional signals.
BiblioSphere is a data-mining solution for extracting and studying gene relationships 
from literature databases and genome-wide promoter analysis. Based on PubMed 
(www.ncbi.nlm.nih.gov), BiblioSphere currently searches over 14 million abstracts. 
The unique data-mining strategy allows direct gene-gene co-citations and even yet 
unknown gene relations to be found via interlinks. BiblioSphere data is displayed as 
3D interactive view of gene relationships (Figure 3.1.8). Results can be classified by 
tissue, Gene Ontology and Medical Subject Headings (MeSH). Statistical ratings by z- 
scores indicate over- and under-representation of genes in the various biological 
categories. BiblioSphere can be applied to single gene analysis, gene cluster analysis 
and analysis of gene regulatory mechanisms.
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to invasion from the SOM expression clusters.
The cluster contains all input genes. The dark blue spheres relate to the neoplasm
invasiveness MeSH filter. The faded blue spheres represent genes that do not relate to 
this disease filter. Genes that have a grey line linking them are co-cited genes in 
relation to this filter. A green line from a sphere labelled “TF” signifies a transcription
factor-binding site in the promoter of that gene.
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The Genomatix analysis generated (as described in section 2.16.3) two promoter 
models each containing 5 elements involving three genes, VEGF, FSTL1 and FN1 
(Figures 3.1.9 and 3.1.10). Since co-regulation of gene transcription often originates 
from common promoter elements the identification and characterisation of these 
elements provides a more in-depth analysis for the expression of microarray genelists. 
Gene2Promoter allows users to automatically extract groups of promoters for genes 
that may be of interest. The FW score for these models is 0.75. These scores allow to 
assess the quality of a model generated by FrameWorker: The higher the scores, the 
more specific is the extracted model. A very low FW-score (<0.5) indicates a model 
that is likely to match very often in random DNA sequences. The promoter models 
generated suggest possible co-regulation of these three genes, VEGF, FSTL1 and FN1. 
These promoter models are comprised of the zinc binding protein factor family 
(ZBPF), the myeloid zinc finger 1 factors (MZF1) and the GC-box factors SP1/GC 
(SP1F). Searches were made for genes to which any of these family members bind to 
in the genelist of the 531 consistently changing genes. Only the SP1F transcription 
factors KLF5 and TIEG2 were found in this data set. Both transcription factors appear 
to be downregulated with increasing invasiveness based on the values for the genes in 
the array data.
To determine if VEGF, FSTL1 and FN1 might be co-regulated, RT-PCR analysis was 
performed in our cell model for those gene. The RT-PCR results did not demonstrate 
differential expression of these genes with invasion and were therefore not subject to 
further investigation.
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Figure 3.1.9 Promoter model 1 from Genomatix analysis.
Dashed lines signify genomic region upstream of gene sequence. Angled arrows 
denote transcriptional start sites; thick arrows indicate start of coding region. Coloured 
shapes signify TF binding sites with putative promoter modules shaded.
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Figure 3.1.10 Promoter model 2 from Genomatix analysis.
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3.2 RT-PCR confirmation of array data analysis
The genelists generated from the various bioinformatic analyses of the microarray data 
were subject to further scrutiny before final targets for functional analysis were chosen. 
In Section 3.1.2, genes highlighted in bold were subject to RT-PCR analysis in the five 
DLKP cell lines comprising our cell model to confirm the trends indicated by the array 
data.
Twenty-eight genes were selected, based on literature searches and on proposed 
functions for a given gene, for RT-PCR analysis across the five cell lines. The PCR 
was performed on the following RNA samples,
1 RNA used for the original single array experiment.
2 RNA used for the subsequent duplicate experiment.
3 RNA from a fresh culture of the five cell lines that were not analysed by
microarray. This was to ensure that results from the array data were not an 
anomaly and reflected gene expression in an independent batch of the cell 
lines, separate to those harvested for microarray analysis.
4 RNA from the five DLKP cell lines over increasing passage number. This
was to ensure that results from the array data were true for cells over a 
specific time period i.e. ten passages.
An overview of the results from the RT-PCR study is detailed in Tables 3.2.1 and 
3.2.2. The actual gels representing each PCR are available for examination in the 
Appendices.
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Table 3.2.1 Summary of RT-PCR results for genes with increased expression in
invasive cell lines
Gene
Symbol
Band Size 
(kb)
Agrees with array data Pick as 
Target
AKAP11 233 No obvious expression differences in 
PCR
No
BCHE 180 Trend agrees with array data Yes
CYB5R2 172 Decreased expression in VCR only, not 
TXT-1
No
EFNB2 220 Fluctuations in different sample sets, No
GLP1R 228 Initial trend matches, check other 
samples
ICAM1 245 Trend agrees with array data Yes
IGF1R 241 Trend agrees with array data Yes
KCNJ8 210 Trend agrees with array data Yes
LOC5119 249 Not increased in invasive cell lines No
MFAP2 422 check in other samples.
MGC3900 219 No clear-cut expression differences in 
PCR
No
MMP3 214 Trend agrees with array data, need to 
rpt some samples
Yes
S100A13 219 Trend agrees with array data, check 
passaged samples.
Yes
SFN 195 Trend agrees with array data Yes
TCF4 204 Trend agrees with array data, very, low 
expression in VCR samples
Yes
TEM7 239 Trend fluctuating in sets of PCR 
samples
No
TLX1 201 Trend agrees with array data Yes
VEGFA 186 Optimised, No clear-cut expression 
differences in PCR
No
VEGFC 249 Trend agrees with array data Yes
130
Table 3.2.2 Summary of RT-PCR results for genes with decreased expression
in invasive cell lines
Gene
Symbol
Band Size 
(kb)
Agrees with array data Pick as 
Target
FN1 230 Consistently high expression in 
VCR compared to other cell lines
Yes
FSTL1 242 Slight expression differences in 
PCR can rpt.
No
MAP3K12 240 No obvious expression differences 
in PCR
No
NRG1 190 No expression differences in PCR No
RANBP2 218 No clear-cut expression differences 
in PCR
No
SCHIP1 355 Trend fluctuating in sets of PCR 
samples
No
SPP1 244 Consistently high expression in 
VCR compared to other cell lines
Yes
TEM6 199 No obvious expression differences 
in PCR
No
TFPI2 183 Trend agrees with array data Yes
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3.3 Invasion assay confirmation of in vitro invasive capacity of 
DLKP variants
The invasion assay used to monitor in vitro invasion was optimised for use within this 
cell model. Commercial invasion assay kits containing inserts pre-coated with matrigel 
were used for analysis. This eliminated the risk of batch-to-batch variation possible 
when manually coating inserts with matrigel.
The inserts were placed in medium containing 5% serum. Cell suspensions were 
prepared in medium containing 1% serum and 100(il of a lxlO6 cells/ml suspension 
was added to each insert. This provided serum gradient in the assay. The cells were 
incubated at 37°C for 24hr. After this time, the underside of the insert stained with 
crystal violet and allowed to air dry.
The invasion assay was validated by analysing fresh cultures of the DLKP variants 
using the optimised conditions outlined above over increasing passage number. This 
confirmed that the trend of invasive capacity for each cell line was consistent over ten 
passages (Figures 3.3.1-3.3.1.5). In order to verify that that batch-to-batch variation 
was negligible between the commercial kits, cells with the same passage number and 
from the same cell suspension were applied to two different kits with different batch 
and lot numbers (Figure 3.3.1.2). RT-PCR was also used for a number of selected 
genes to determine if gene expression patterns were consistent with the invasive 
capacities of the cell lines as determined using the invasion assay.
The overall trend for the DLKP cell lines is as follows, starting from the most to least 
invasive; TXT-2 > DLKP-1 > DLKP-2 > TXT-1 > VCR. This validation study 
demonstrated reproducible results over ten passages for the cell lines and confirmed 
the suitability of the cell lines in conjunction with the optimised invasion assay as a 
model system suitable for use in subsequent investigations into the molecular 
mechanisms of invasion. For the purposes of simplicity in subsequent Results and 
Discussion sections, these five cell lines will be split into two groups broadly referred 
to as “invasive” (TXT-2, DLKP-1, DLKP-2) and less or non-invasive lines (TXT-1 
and VCR).
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3.3.1 Graphical Representations of measurement of relative DLKP variant 
invasive capacity with increasing passage number
Fresh stocks of the DLKP variants were thawed and analysed by invasion assay over 
increasing passage number using commercial invasion assay kits, a serum gradient and 
equal cell number over 24hr. The underside of each insert was stained and the cells 
counted. Averaging counts from 10 fields of view with 20X magnification generated 
final counts, which were included in each graphical representation of the invasion 
assay results. Each condition was analysed using at least two inserts. The overall trend 
is as follows, starting from the most to least invasive; TXT-2 > DLKP-1 > DLKP-2 > 
TXT-1 > VCR. This set of experiments demonstrate reproducible trends of DLKP 
variant invasion capacity and verify the suitability of these cell lines for use as a cell 
model to study invasion using these defined parameters over ten passages
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DLKP-1 DLKP-2 TXT-1 TXT-2 VCR RPMI-2650 RPMI-Mel
Cell Line
Figure 3.3.1 Measurement of relative invasion using 24hr Boyden
chamber assay.
The DLKP variants are compared by invasion assay over 24hr. Counts from ten fields 
of view at 20X magnification per insert were averaged. At least two inserts per 
condition were included in each analysis and counted and the average of each insert 
calculated. This generated figures for the number of cells invading and allowed 
graphical representation of relative invasion. Counts for RPMI-2650 (non-invasive 
parental) and RPMI-Melphalan (RPMI-Mel) selected human nasal carcinoma cell line 
are included as negative and positive invasion assay controls in this study.
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DLKP-1 p.43 DLKP-2 p.27 TXT-1 p. 47 TXT-2 p . 26 VCR p.32 RPMI-2650 RPMI-Mel
p. 80
Cell line and Passage number
Figure 3.3.1.1 Measurement of relative DLKP invasive capacity from early
passage in culture (i.e. the cells are at passage 1 in culture).
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DLKP-1 DLKP-2 TXT-1 p.49 TXT-2 p.28 VCR p.34 RPMI-2650 RPMI-Mel
p.45 p.29 p.82
Cell line and passage number
Figure 3.3.1.2 Measurement of relative DLKP invasive capacity from 
passage 2 in culture and comparing different invasion assay kit lot numbers to 
ensure consistent results.
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Figure 3.3.1.3 Measurement of relative DLKP invasive capacity from
passage 3 in culture
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DLKP-1 p.48 DLKP-2 p.32 TXT-1 p.52 TXT-2 p.31 VCR p.37 RPMI-2650 RPMI-Mel
p. 85
Cell line and passage number
Figure 3.3.1.4 Measurement of relative DLKP invasive capacity from
passage 5 in culture
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DLKP-1 p.49 DLKP-2 p.33 TXT-1 p.53 TXT-2 p.32 VCR p.38 RPMI-2650 RPMI-Mel
p. 86
Cell line and passage number
Figure 3.3.1.5 Measurement of relative DLKP invasive capacity from
passage 6 in culture
Figure 3.3.1.6 Invasion assay controls.
Photographic representation of the negative invasion control RPMI-2650 (A) and the 
positive invasion control RPMI-Melphalan (Mel) (B) at 10X.
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3.3.2 RT-PCR validation of consistent gene expression in 
conjunction with consistent invasion assay results.
The mRNA expression of a number of selected genes was analysed by RT-PCR to 
determine if relative gene expression patterns remained consistent in parallel with the 
relative invasive capacities of the cell lines over a number of passages. The genes 
selected for RT-PCR analysis to investigate if the invasive capacities of the cell lines 
correlated with differential gene expression (i.e. increased/decreased mRNA 
expression in the invasive cell lines compared with the non-invasive cell lines) were 
consistent as the cell lines were cultured are detailed in Table 3.3.1. The results 
demonstrated that mRNA was not differentially expressed between the invasive and 
non-invasive cell lines for EFNB2, VEGF-C, FN1 and FSTL1. These genes were not 
selected for further functional analysis as a result. The trends in mRNA expression for 
the remaining genes were consistently differentially expressed between the invasive 
and non-invasive cell lines as the cell lines were cultured.
Table 3.3.1 Genes selected for RT-PCR analysis to ensure that mRNA 
expression correlated with invasion assay results over time.
Gene Symbol
IGF-1R
TLX-1
SFN
KCNJ8
ICAM1
EFNB2
VEGF-C
TCF4
MMP3
FN1
FSTL1
TFPI2
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3.4 Investigation into role of IGF-1R in invasion in an in vitro cell 
model
3.4.1 Aims of experiments
IGF-1R was identified as a gene potentially involved in invasion in our microarray 
study. The microarray data analysis revealed that IGF-1R expression was increased in 
the more invasive cell lines compared to the lesser invasive cell lines. The aims of this 
set of experiments was as follows:
1. To confirm by PCR that IGF-1R was differentially expressed between the
DLKP cell lines.
2. To quantify endogenous IGF-1R levels in the cell model by qRT-PCR and
western blot.
3. To demonstrate transfection efficiency of the siRNA sequence
immunofluorescence.
4. To decrease IGF-1R expression by transfecting a validated siRNA to the
IGF-1R sequence using optimised transfection conditions.
5. To demonstrate IGF-lR-specific siRNA knockdown at mRNA and protein
level.
6. To evaluate the effect of IGF-1R knockdown on proliferation.
7. To evaluate the effect of IGF -1R knockdown on invasion.
8. To compare the effect of treatment using an IGF-1R blocking antibody
(aIR3) on invasion, with the effect of IGF-1R siRNA knockdown on 
invasion.
To summarise the results detailed in this section, it was found that IGF-1R was 
differentially expressed in the panel of cell lines studied, correlating with array data. 
Conditions for the transfection of siRNA sequences were optimised for these cell lines. 
Decreasing IGF-1R expression had no effect on proliferation, but did decrease 
invasion substantially, as determined by in vitro invasion assays. Treatment of the cells
rr
with a blocking antibody to IGF-1R, aIR3, also decreased invasion.
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3.4.2 RT-PCR confirmation of differential IGF-1R mRNA expression 
in the DLKP variants
RT-PCR was utilised to confirm that IGF-1R expression changes in the array data 
were reflected in the cell lines studied.
RNA samples from the preliminary Affymetrix array study by Dr. Rasha Linehan in 
2003 (Figure 3.4.2.1), RNA from the duplicate array samples 2004 (Figure 3.4.2.2), 
RNA from a fresh set of cultures harvested separately to those for array analysis 
including RNA from three samples analysed on the Agilent array platform (Figure 
3.4.2.3) were included in this analysis. The Agilent data was not analysed for inclusion 
in this work due to limitations in data analysis capabilities at the time. This was to 
ensure that results from the array study matched to independent analysis of the cell 
lines.
In all of the Figures in this section P-actin was used as an endogenous control to 
normalise for RNA quantities added to each reaction. The reactions were analysed by 
gel electrophoresis (GE) on a 2% agarose gel. The band size for IGF-1R is 241 bp. 
PCR negative controls consisted of consisted of PCR master mix to which no cDNA 
template was added. cDNA negative control (cDNA neg) consisted of PCR master mix 
with cDNA but without addition of Taq enzyme. Densitometric analysis was 
performed and Figures were generated by dividing IGF-1R intensity values by P-actin 
intensity values and were plotted for each sample. The gels included in this section are 
representative of at least two independent repeats.
This analysis by semi quantitative PCR demonstrates a trend of increased IGF-1R 
expression in the more invasive cell lines DLKP-1, DLKP-2 and TXT-2, compared to 
the lesser invasive cell lines TXT-1 and VCR. This correlates with the array IGF-1R 
data.
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Figure 3.4.2.1 RT-PCR of IGF-1R mRNA expression from RNA used in array 
samples 2003.
RNA used for this PCR was analysed on the 2003 arrays. P-actin was used as an 
endogenous control to normalise for RNA quantities added to each reaction. The 
reaction was analysed by gel electrophoresis (GE) on a 2% agarose gel. A PCR 
Negative (PCR Neg) control was included in the analysis and consisted of PCR master 
mix to which no cDNA template was added. Figures for the densitometry values were 
generated by dividing IGF-1R intensity values by P-actin intensity values and were 
graphed for each sample. The trend indicates decreased IGF-1R mRNA expression in 
the poorly invasive cell lines compared to invasive cell lines.
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Figure 3.4.2.2 RT-PCR of IGF-1R mRNA expression from RNA used in duplicate 
array samples 2004.
RNA for this PCR was analysed in the duplicate array analysis of the DLKP cell lines 
in 2004. p-actin was used as an endogenous control. The reaction was analysed by GE 
on a 2% agarose gel. PCR negative (PCR Neg) and cDNA negative controls were 
included in the analysis. Densitometry values were generated by dividing IGF-1R 
intensity values by p-actin intensity values and were graphed for each sample. IGF-1R 
mRNA expression is decreased in the poorly invasive cell lines compared to invasive 
cell lines.
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Figure 3.4.2.3 RT-PCR of IGF-1R mRNA in a separate sample set and Agilent 
samples.
RNA for this analysis was from a separate batch of DLKP variant cultures not 
harvested or processed for Affymetrix array analysis. Also included were three 
samples analysed on the Agilent array platform but which were not investigated 
further. P-actin was used as an endogenous control. The reaction was analysed by GE 
on a 2% agarose gel. Densitometry values were generated by dividing IGF-1R 
intensity values by P-actin intensity values and were graphed for each sample.
This PCR demonstrates high IGF-1R expression in TXT-1, which is one of the poorly 
invasive cell lines and is an unexpected result. However, the endogenous levels on 
IGF-1R were subsequently determined by qPCR and confirm the array results.
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3.4.3 Endogenous IGF-1R mRNA and protein levels in the DLKP cell 
lines
Quantitative real time PCR (qPCR) gives a more accurate measurement of mRNA 
expression than the trends identified by semi-quantitative RT-PCR. qPCR was used to 
determine endogenous IGF-1R mRNA expression using a commercial TaqMan IGF- 
1R probe and normalised using P-actin as an endogenous control (Figure 3.4.3.1). 
Forty cycles of 15s at 95°C were used in the reaction.
Endogenous IGF-1R protein expression in the DLKP variants was determined by 
western blot, a-tubulin and GAPDH antibodies were used to demonstrate even loading 
between the samples (Figure 3.4.3.2).
These results correlate with the array results and demonstrate differential IGF-1R 
expression, where there is higher expression in the invasive cell lines, DLKP-2 and 
TXT-2 and lower expression in the lowly invasive cell line VCR. DLKP-1 and TXT-1, 
unexpectedly, have similar IGF-1R protein levels despite DLKP-1 being more invasive 
than TXT-1.
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Figure 3.4.3.1 qRT-PCR of endogenous IGF-1R mRNA levels.
Endogenous IGF-1R mRNA expression in the DLKP variants was examined by qRT- 
PCR using a commercial TaqMan IGF-1R probe and normalised for RNA content 
using p-actin as an endogenous control. The data represents IGF-1R expression 
relative to DLKP-1, which was set to 1 for the analysis. This result demonstrates 
higher expression in the invasive cell lines, DLKP-2 and TXT-2 and lower expression 
in the poorly invasive cell line VCR. DLKP-1 and TXT-1, unexpectedly, have similar 
IGF-1R mRNA levels despite DLKP-1 being more invasive than TXT-1.
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a  Tubulin 
GAPDH
Figure 3.4.3.2 Western blot analysis of endogenous IGF-1R protein levels.
Endogenous IGF-1R protein expression in the DLKP variants was determined by 
western blot, a-tubulin and GAPDH antibodies were used to demonstrate even loading 
between the samples. This result correlates with the endogenous qPCR results above, 
and demonstrate differential IGF-1R expression, where there is higher expression in 
the invasive cell lines, DLKP-2 and TXT-2 and lower expression in the mildly 
invasive cell line VCR. DLKP-1 and TXT-1, unexpectedly, have similar IGF-1R 
protein levels despite DLKP-1 being more invasive than TXT-1. This is a 
representative picture of at least 3 independent analyses.
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3.4.4 siRNA Transfection Optimisation for the DLKP cell lines
3.4.4.1 Summary of siRNA transfection optimisation
There were a number of different parameters that had to be determined to establish an 
optimised protocol for the siRNA transfection of DLKP and its variants. Initially, only 
the transfection protocol itself was considered. 2|al of NeoFx transfection reagent per 
well of a 6-well plate was used to transfect 30nM of target siRNA into the cells. These 
were amounts recommended by Ambion. qPCR analysis of these early transfections 
demonstrated that mRNA knockdown was not being achieved, which led to the 
examination of cell line handling during the transfection process. It transpired that cell 
handling during the transfection protocol is particularly important. The following 
procedures were optimised for siRNA transfection in these cell lines:
• Cells should be in log/growth phase and in a healthy condition when used to
seed siRNA transfections and should be fed with fresh medium 24h prior to
transfection.
• The cell suspensions should be prepared in serum containing medium i.e. 
normal growth medium (as opposed to medium with reduced serum e.g. 
OptiMEM).
• Cells should be in suspension for as short a time as possible and maintained at 
37°C to avoid heat shock while the siRNA complex is being prepared.
• Five cell lines are too many cell lines to transfect with siRNA in any one 
transfection. The reasons for this are twofold; the cells are in suspension for 
longer time periods than if you were working with fewer cell lines. It was 
found that cells in suspension should be dispensed onto complexed 
siRNA/NeoFx solutions immediately following the complex incubation period 
(i.e. reverse transfection). Extended time periods lead to poor transfection 
efficiency and thereby poor target knockdown. We determined that three cell 
lines are the maximum number suitable in any single transfection experiment.
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• A protocol was also optimised for the analysis of a target siRNA specific effect 
on invasion. This was of particular importance since the transfection agent 
itself, NeoFx, caused a decrease in invasion as determined by in vitro invasion 
assay In addition, it was found that allowing the transfected cells more time to 
recover following siRNA transfection minimised the non-specific effect of the 
transfection on invasion. To this end, siRNA transfected cells were analysed by 
in vitro invasion assay 72h post-transfection.
148
A validated IGF-1R siRNA sequence was transfected into the DLKP variants. The 
effect on invasion was determined by invasion assay 48h post-siRNA transfection 
(Figure 3.4.4.1). Non treated and scrambled siRNA transfected cell lines were the 
controls for this experiment. RPMI-Mel and RPMI-2650 are included as positive 
and negative invasion assay controls respectively. Each condition was examined 
using at least two invasion kit inserts. Ten random fields per insert were counted at 
20X and average and the average of the inserts per condition calculated. While a 
specific decrease in invasion could be attributed to the IGF-1R siRNA for DLKP- 
1, there was no related decrease in invasion in the other four samples. Also, there 
was a considerable non-specific decrease in invasion in the scrambled siRNA 
treated cells compared with the non-treated cells. This was most likely due to the 
transfection process and not the scrambled siRNA, since the scrambled siRNA was 
one of only three sequences that Ambion sells as a transfection control as they do 
not target any RNA sequence.
It was decided to allow the cells to recover from the transfection for as long as 
possible before invasion analysis, in order to minimise the non-specific 
transfection effect on invasion. To this end the invasion assay was performed 48 
and 72h post-transfection (Figure 3.4.4.2). From these results, it appeared that 
performing the invasion assay 72h post siRNA transfection allowed more recovery 
time for the cells and decreased the non-specific transfection effect on invasion. 
This was the time point at which all-further invasion analysis of siRNA transfected 
samples were performed. Fig 3.4.4.3 and 3.4.4.7 demonstrate that IGF-1R 
expression was eliminated in IGF-1R siRNA transfected samples.
3.4.4.2 Optimisation of in vitro invasion analysis following siRNA
transfection
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Figure 3.4.4.1 Determination of the effect of IGF-1R siRNA transfection on 
invasion.
The invasion assay was performed 48h post-siRNA transfection. Non treated and 
scrambled siRNA transfected cell lines are the controls for this experiment. RPMI- 
Mel and RPMI-2650 are included as positive and negative invasion assay controls 
respectively. Ten random fields per insert were counted at 20X. Each condition 
was examined using at least two invasion kit inserts and the counts averaged. Only 
a slight IGF-lR-specific siRNA related decrease in invasion was observed for the 
DLKP-1 sample, with no related decrease in the other four DLKP cell lines. There 
was also a considerable non-specific decrease in invasion in the scrambled siRNA 
treated cells compared with the non-treated cells. This was probably due to the 
transfection process and not the scrambled siRNA, since the scrambled siRNA is 
one of only three sequences that Ambion markets as a transfection control as they 
do not target any RNA sequence.
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Figure 3.4.4.2 Minimisation of non-specific transfection effect on invasion.
An additional IGF-1R siRNA transfection was performed and analysed by invasion 
assay at 48 and 72h post-transfection. Non treated and scrambled siRNA 
transfected cell lines are the controls for this experiment. RPMI-Mel and RPMI- 
2650 are included as positive and negative invasion assay controls respectively. 
Ten random fields per insert were counted at 20X. Each condition was examined 
using at least two invasion kit inserts and the counts averaged and graphed. These 
results suggest that performing the invasion assay 72h post siRNA transfection 
allows more recovery time for the cells and decreases the non-specific transfection 
effect on invasion. This was the time point at which all-further invasion analysis of 
siRNA transfected samples were performed.
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3.4.4.3 Evaluation of siRNA transfection efficiency
siRNA transfection efficiency was evaluated using immunofluoresence and confocal 
microscopy (Figure 3.4.4.3) and was also visualised photographically in Figure 
3.4.4A
Figure 3.4.4.3 Evaluation of transfection efficiency using
immunofluorescence and confocal microscopy.
Immunofluorescent localisation of IGF-1R expression in the invasive TXT-2 cell line 
(A), and following siRNA knockdown (B). FAM labelled IGF-1R siRNA can be seen 
as punctuate fluorescence in the cytoplasm of transfected TXT-2 (C). Untransfected 
cells (D) are presented as a control. The nuclei were stained with DAPI in all cases.
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Figure 3.4.4.4 Photographic representation of effect of siRNA targeting IGF-1R 
and Kinesin on DLKP variant cell growth.
Scrambled siRNA transfection has a slight toxic effect on the cells. This was also 
observed in our invasion analysis optimisation. However, from the pictures above it is 
clear that an siRNA targeting IGF-1R does not induce additional toxic effects on the 
cells than caused by the transfection process itself. The effect of an efficient kinesin 
transfection is visualised above as the typical rounded morphology associated with 
cells arrested in mid cell division.
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3.4.4.4 IGF-1R- specific siRNA decrease in IGF-1R mRNA and 
Protein levels
A validated IGF-1R specific siRNA sequence was transfected into the DLKP variants 
and a decrease in IGF-1R mRNA and protein expression was confirmed by qPCR and 
western blot respectively.
Relative IGF-1R mRNA expression was measured using a commercial TaqMan IGF- 
1R probe and normalised using P-actin as an endogenous control (Figure 3.4.4.5).
IGF-1R protein expression in the DLKP variants and their IGF-1R siRNA transfected 
counterparts was determined by western blot. Cells were transfected with a scrambled 
siRNA sequence as a control to ensure that the transfection process did not affect 
target protein expression. An a-tubulin antibody was used to demonstrate even loading 
between the samples (Figure 3.4.4.6).
These qPCR results do not show a substantial decrease in IGF-1R mRNA expression 
in response to IGF-1R siRNA transfection. However, the western blots demonstrate 
close to 100% decrease in IGF-1R protein expression in IGF-1R siRNA transfected 
cells compared to the non-treated and scrambled siRNA transfected cells. This 
indicates that the siRNA might be acting like a microRNA (miRNA) and blocking 
translation rather than directing target mRNA degradation.
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Figure 3.4.4.5 qRT-PCR of IGF-1R 48h post siRNA transfection.
IGF-1R mRNA expression was examined by qRT-PCR using a commercial TaqMan 
IGF-1R probe and normalised for RNA content using P-actin as an endogenous 
control. The data represents IGF-1R expression relative to DLKP-1, which was set to 1 
for the analysis. A slight decrease in IGF-1R mRNA expression was observed in the 
IGF-1R siRNA treated samples 48h post-transfection compared to the scrambled 
control, except for TXT-1. IGF-1R mRNA expression was increased in scrambled 
siRNA transfected cells compared with the non-treated cells.
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Figure 3.4.4.6 Western blot of IGF-1R 72h post siRNA transfection.
Protein was harvested 72h post-transfection and used to determine an IGF-lR-siRNA 
specific decrease at protein level in response to siRNA transfection by western blot. 
An a-tubulin antibody was used to demonstrate even loading between the samples. 
The above figure demonstrates an IGF-1R siRNA specific decrease close to 100% in 
IGF-1R protein levels compared with scrambled and non-treated samples. This is a 
representative picture of at least 3 independent analyses.
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The effect of IGF-1R siRNA transfection on proliferation was examined using two cell 
densities a “low density” of 2.5 x 103 cells/well of a 96-well plate (Figure 3.4.4.7), and 
a “high density” of 5 x 103 cells/well of a 96-well plate (Figure 3.4.4.8). Cell number 
was determined using the acid phosphatase assay. An siRNA sequence to Kinesin was 
transfected as a positive control and acts by preventing cell doubling thus kinesin 
siRNA transfected cells do not increase in number compared with the non-treated, 
scrambled siRNA- and IGF-1R siRNA- transfected cells.
3.4.5 Evaluation of IGF-1R siRNA effect of DLKP variant
proliferation
157
140 -,
120 -
DLKP-1 DLKP-2 TXT-1 TXT-2 VCR
Sample
Figure 3.4.4.7 Effect of siRNA targeting IGF-1R and Kinesin on DLKP
variant cell number at lower seeding density.
The cells were seeded at a “low density” of 2.5 x 103 cells/well of a 96-well plate. 
Relative cell number was measured using the acid phosphatase assay. IGF-1R siRNA 
treatment does not appear to affect proliferation compared with the scrambled siRNA 
and non-treated cells. The kinesin results indicate effective siRNA transfection.
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Figure 3.4.4.8 Effect of siRNA targeting IGF-1R and Kinesin on DLKP variant 
cell number at higher seeding density.
The cells were seeded at a “high density” of 5 x 103 cells/well of a 96-well plate. A 
decrease in cell number for the kinesin treated cells demonstrates act as a positive 
control for the siRNA transfection. IGF-1R siRNA treatment does not affect 
proliferation compared with the scrambled siRNA and non-treated cells when seeded 
at a high cell density.
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3.4.6 Evaluation of IGF-1R siRNA effect on invasion
The effect of IGF-1R knockdown on DLKP variant invasive capacity was examined. 
Invasion assay analysis was performed 72h post transfection. Commercial invasion 
assay kits containing inserts pre-coated with matrigel were used for analysis and a 
serum gradient was used in the assay. The cells were incubated at 37°C for 24h. After 
this time, the underside of the insert stained with crystal violet and allowed to air dry. 
The inserts were then photographed using 10X magnification. Ten fields of view were 
counted per insert at 20X magnification and averaged. At least two inserts were used 
for the analysis of each condition. The counts per number of inserts used were then 
also averaged and this figure used to generate graphs of relative invasive capacity per 
cell line per condition.
Two sets of representative photographs were included (Figure 3.4.4.9 and 3.4.4.11) in 
this section and clearly show a decrease in invasion in IGF-1R siRNA transfected 
cells. Invasion assay results are also presented graphically (Figures 3.4.4.10 and 
3.4.4.12) as percentage invasion normalised to the scrambled siRNA for each cell line..
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Figure 3.4.4.9 Photographic representation of invasion assay results 72h
post IGF-1R siRNA transfection I.
The invasion assay was performed 72h post-transfection. Untransfected- and 
scrambled siRNA transfected- cell lines were the controls for this experiment. 
Representative photographs at 10X are shown above. Invasion was decreased in IGF- 
1R siRNA transfected cells compared with the scrambled siRNA and non-treated cells.
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Figure 3.4.4.10 Graphic representation of invasion assay results 72h post 
IGF-1R siRNA transfection I.
The invasion assay was performed 72h post-transfection. Scrambled siRNA 
transfected- cell lines are the controls for this experiment. Ten random fields were 
counted at 20X. Each condition was examined using at least two invasion kit inserts. 
Counts per insert were averaged and plotted as percentage invasion normalised to the 
scrambled siRNA for each cell line. Invasion was decreased in IGF-1R siRNA 
transfected DLKP-2 (P<0.001), TXT-1 and TXT-2 (P<0.005) compared with the 
scrambled siRNA control. There was a decrease in invasion in DLKP-1 IGF-1R 
siRNA transfected cells also, albeit insignificant. This may be attributed to poor 
transfection efficiency in this cell line.
Scale: PO.Ol = *, P< 0.005 = **, P<0.001 = ***
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Figure 3.4.4.11 Photographic representation of invasion assay results 72hr 
post IGF-1R siRNA transfection II.
The invasion assay was performed 72h post-transfection. Untransfected- and 
scrambled siRNA transfected- cell lines are the controls for this experiment. 
Representative photographs at 1 OX are shown above. Invasion was decreased in IGF- 
1R siRNA transfected cells compared with the scrambled siRNA and non-treated cells.
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Figure 3.4.4.12 Graphic representation of invasion assay results 72hr post 
IGF-1R siRNA transfection II.
The invasion assay was performed 72h post-transfection. Untransfected- and 
scrambled siRNA transfected- cell lines are the controls for this experiment. Ten 
random fields were counted at 20X. Each condition was examined using at least two 
invasion kit inserts. Counts per insert were averaged and plotted as percentage invasion 
normalised to the scrambled siRNA for each cell line. Invasion was decreased in IGF- 
1R siRNA transfected cells (PO.OOl), compared with the scrambled siRNA control. 
Invasion was unaffected in VCR IGF-1R siRNA transfected cells, however this cell 
line is considered non-invasive in the first instance and does not express endogenous 
IGF-1R.
Scale: P<0.01 = *, P< 0.005 = **, PO.OOl = ***
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The effect of an additional method of preventing IGF-1R expression on invasion was 
investigated (Figure 3.4.4.13). To this end, only the invasive DLKP variants DLKP-1, 
DLKP-2 and TXT-2 were treated with lOOOng/ml of aIR3 monoclonal antibody for 
24h.
The cell lines were seeded from 80% confluency for invasion analysis with or without 
the addition of lOOOng/ml aIR3 monoclonal antibody. After 24h incubation, the 
invading cells on the underside of the insert were stained with crystal violet and 
allowed to air dry. Each condition was examined using at least two invasion kit inserts. 
Ten random fields per insert were counted at 20X. Counts per insert were averaged and 
graphed above. RPMI-Mel and RPMI-2650 are included as positive and negative 
invasion assay controls respectively.
A shortcoming in this experiment was the lack of a control antibody to confirm the 
specificity of the aIR3 antibody on IGF-1R activity and its subsequent effect on the 
invasive capacity of the DLKP variants. This would be included in future experiments. 
It would also have been interesting to evaluate the amount of IGF-1R being blocked by 
the antibody. This could have been achieved by taking a sample of aIR3 treated and 
non-treated cells and using protein G sepharose to pull down the IGF-1R and compare 
the treated versus non-treated IGF-1R quantities in each sample. The decrease in IGF- 
1R amounts could then be correlated with the effect on invasion. Nevertheless, 
invasion was decreased in aIR3 treated cells compared with the non-treated cells at 
similar levels to those achieved using an siRNA strategy to decrease IGF-1R 
expression.
3.4.7 Evaluation of IGF-1R blocking antibody, aIR3 effect on
invasion
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Figure 3.4.4.13 Graphic representation of IGF-1R blocking antibody. aIR3, 
treatment on DLKP variant invasion.
The above cell lines were seeded for invasion analysis with or without the addition of 
lOOOng/ml aIR3 monoclonal antibody. After 24h incubation, the invading cells on the 
underside of the insert were stained with crystal violet and allowed to air dry. Each 
condition was examined using at least two invasion kit inserts. Ten random fields per 
insert were counted at 20X. Counts per insert were averaged and graphed above. 
RPMI-Mel and RPMI-2650 are included as positive and negative invasion assay 
controls respectively. Invasion was decreased in aIR3 treated cells compared with the 
non-treated cells (P0.001).
Scale: P<0.01 = *, P< 0.005 = **, PO.OOl = ***
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3.5 Investigation into role of KCNJ8 in invasion in our cell model
3.5.1 Aims of KCNJ8 experiments
KCNJ8 was identified as a gene potentially involved in invasion in the microarray 
study. The data indicated that KCNJ8 expression was higher in the more invasive cell 
lines compared to the lesser invasive cell lines. The aims of this set of experiments 
were as follows:
1. To confirm by PCR that KCNJ8 was differentially expressed across the 
DLKP cell line panel.
2. To decrease KCNJ8 expression by transfecting two independent siRNA 
sequences to KCNJ8 into the invasive cell lines DLKP-1, DLKP-2 and 
TXT-2.
3. To demonstrate KCNJ8 siRNA-specific knockdown at mRNA level.
4. To evaluate the effect of KCNJ8 knockdown on proliferation.
5. To evaluate the effect of decreased KCNJ8 expression on invasion.
6. To determine cDNA transfection efficiency using Green Fluorescent 
Protein (GFP).
7. To increase KCNJ8 expression by transfecting a pSport6 plasmid 
containing the KCNJ8 sequence into the lesser or poorly invasive cell lines 
TXT-1 and VCR.
8. To confirm an increase in KCNJ8 cDNA transfected cells at protein level.
9. To evaluate the effect of increasing KCNJ8 expression on invasion.
To summarise the results detailed in this section, it was found that KCNJ8 was 
differentially expressed in the panel of cell lines studied, in agreement with array data. 
Decreasing KCNJ8 expression had no effect on proliferation, but did increase invasion. 
This was an unexpected result. Increasing KCNJ8 expression had no effect on invasion 
in the non-invasive cell lines. However, western blots for KCNJ8 overexpression were 
not conclusive.
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3.5.2 RT-PCR investigation of KCNJ8 mRNA expression
Semi quantitative RT-PCR was used to confirm that KCNJ8 expression changes in the 
array data were reflected in the cell lines studied.
To ensure that results from the array study matched to independent analysis of the cell 
lines, RNA samples from the preliminary Affymetrix array study by Dr. Rasha 
Linehan in 2003 (Figure 3.5.2.1), RNA from the duplicate array samples 2004 (Figure 
3.5.2.2), RNA from a fresh set of cultures harvested separately to those for array 
analysis including RNA from three samples analysed on the Agilent array platform 
(Figure 3.5.2.3) were included in this analysis. The Agilent data was not analysed 
further in this work.
In all of the PCRs in this section P-actin was used as an endogenous control to 
normalise for RNA quantities added to each reaction. The reactions were analysed by 
gel electrophoresis (GE) on a 2% agarose gel. The band size for KCNJ8 was 210bp. 
cDNA negative control (cDNA neg) consisted of PCR master mix with cDNA but 
without addition of Taq enzyme. PCR negative controls consisted of consisted of PCR 
master mix to which no cDNA template was added. Densitometric values were 
normalised by dividing KCNJ8 intensity values by P-actin intensity values and were 
graphed for each sample. The gels included in this section are representative of at least 
two independent repeats.
This analysis by semi quantitative PCR demonstrates a trend of increased KCNJ8 
expression in the more invasive cell lines DLKP-1, DLKP-2 and TXT-2, compared to 
the poorly invasive cell lines TXT-1 and VCR. This correlates with the array KCNJ8 
data.
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Figure 3.5.2.1RT-PCR of KCNJ8 expression from RNA used in array samples 
2003.
RNA used for this PCR was analysed on the 2003 arrays. P-actin was used as an 
endogenous control to normalise for RNA content in each reaction. The PCR was 
analysed by gel electrophoresis (GE) on a 2% agarose gel. A PCR Negative (PCR 
Neg) control was included in the analysis and consisted of PCR master mix to which 
no cDNA template was added. The trend indicates lower KCNJ8 mRNA expression in 
the poorly invasive cell lines TXT-1 and VCR compared to invasive cell lines.
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Figure 3.5.2.2 RT-PCR of KCNJ8 mRNA expression from RNA used in duplicate 
array samples 2004.
RNA for this reaction was analysed in the duplicate array analysis of the DLKP cell 
lines in 2004. P-actin was used as an endogenous control. The reaction was analysed 
by GE on a 2% agarose gel. PCR negative (PCR Neg) and cDNA negative controls 
(cDNA neg consisted of PCR master mix with cDNA but without addition of Taq 
enzyme) were included in the analysis. KCNJ8 mRNA expression is decreased in the 
poorly invasive cell lines compared to invasive cell lines.
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Figure 3.5.2.3 RT-PCR of KCNJ8 mRNA in a separate sample set and Agilent 
samples.
RNA for this analysis was from a separate batch of DLKP variant cultures not 
harvested or processed for Affymetrix array analysis. Also included were three 
samples analysed on the Agilent array platform but which were not investigated 
further. (3-actin was used as an endogenous control. The reaction was analysed by GE 
on a 2% agarose gel. Densitometry values were normalised by dividing KNCJ8 
intensity values by P-actin intensity values and were graphed for each sample.
This PCR demonstrates elevated KCNJ8 expression in TXT-1, which is one of the less 
invasive cell lines and lower KCNJ8 mRNA expression in DLKP-1. This is an 
unexpected result. However, KCNJ8 levels in VCR remain low.
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3.5.3 KCNJ8 siRNA transfection in the invasive DLKP variants
3.5.3.1 Summary of KCNJ8 siRNA experimental plan
Since array data and RT-PCR results indicated that KCNJ8 mRNA expression was 
higher in the invasive compared with the mildly invasive DLKP lines, it was decided 
to decrease KCNJ8 expression using two independent siRNA sequences in the 
invasive cell lines DLKP-1, DLKP-2 and TXT-2 to investigate any impact on an 
invasive phenotype. Initial experiments were performed using KCNJ8 siRNA 1. A 
repeat was then performed using KCNJ8 siRNA 1 and the additional KCNJ8 siRNA 2 
sequence. 2|il of NeoFx transfection reagent per well of a 6-well plate was used to 
transfect 30nM of target siRNA into the cells. Transfections were performed using the 
optimum procedures identified in Section 3.4.4.1. KCNJ8 siRNA specific knockdown 
was confirmed by PCR and the effect of this knockdown on proliferation and invasion 
investigated. Counter to what was expected; KCNJ8 knockdown appeared to enhance 
the invasive nature of the cell lines.
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3.5.3.2 KCNJ8-specific siRNA decrease in mRNA levels
KCNJ8-specific siRNA sequences were transfected into the invasive DLKP cell lines 
and a decrease in mRNA expression examined by semi quantitative RT-PCR and 
qPCR respectively.
Timecourse analysis of KCNJ8 knockdown was investigated using RT-PCR (Figures 
3.5.3.2 to 3 5.3.4). P-actin was included as an endogenous control to normalise for 
RNA quantities added to each reaction. The PCRs were analysed by gel 
electrophoresis (GE) on a 2% agarose gel. The band size for KCNJ8 was 210bp. 
cDNA negative control (cDNA neg) consisted of PCR master mix with cDNA but 
without addition of Taq enzyme. PCR negative controls consisted of PCR master mix 
to which no cDNA template was added. Densitometric values were calculated by 
dividing KCNJ8 intensity values by P-actin intensity values and were graphed for each 
sample. The gels included in this timecourse study are representative of at least two 
independent repeats. These results suggest that RT-PCR is not sensitive enough to 
accurately monitor KCNJ8 expression but indicates an overall trend from the data that 
KCNJ8 siRNA transfection did not deplete KCNJ8 mRNA expression. There is a 
possibility that the KCNJ8 siRNA 1 is acting like a miRNA.
Relative KCNJ8 mRNA expression was measured using a commercial TaqMan 
KCNJ8 probe and was normalised using P-actin as an endogenous control (Figure
3.5.3.1). An investigation into the timecourse of mRNA expression in KCNJ8 siRNA 
transfected samples was measured by qPCR (Figures 3.5.3.5 to 3.5.3.7). The results 
show that KCNJ8 knockdown was achieved at mRNA level, although the decrease was 
not striking in some case. There is the possibility that the KCNJ8 siRNA sequences act 
in a manner similar to that observed with the IGF-1R siRNA, whereby the changes in 
mRNA expression in response to siRNA transfection were small but expression of the 
IGF-1R protein was almost entirely diminished. However, this theory remains 
inconclusive due to the lack of a suitable KCNJ8 antibody to detect changes at the 
protein level.
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Figure 3.5.3.1 qPCR analysis of KCNJ8 siRNA experiment (I) at 24h.
KCNJ8 mRNA expression was examined by qRT-PCR using a commercial TaqMan 
KCNJ8 probe and normalised for RNA content using (3-actin as an endogenous 
control. RNA was harvested 24h post-transfection and used to determine a KCNJ8- 
siRNA specific decrease in mRNA in response to siRNA transfection. This graph is a 
composite of three biological repeats. The data represents KCNJ8 expression relative 
to DLKP-1 KCNJ8 siRNA, which was set to 1 for the analysis and was the lowest 
expresser in the qPCR data set. A decrease in KCNJ8 mRNA expression was observed 
in the DLKP-2 and TXT-2 KCNJ8 siRNA treated samples. KCNJ8 expression in 
DLKP-1 was not decreased compared to untreated cells although this may be due to 
noise in the data.
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Figure 3.5.3.2 Timecourse analysis of KCNJ8 mRNA knockdown (I) by semi- 
quantitative RT-PCR in DLKP-1.
KCNJ8 siRNA was transfected into DLKP-1. RNA for the analysis of KCNJ8 mRNA 
was harvested at 24, 48, 72 and 96h. P-actin was used as an endogenous control to 
normalise for RNA content in each PCR. Figures for the densitometry values were 
normalised by dividing KCNJ8 intensity values by P-actin intensity values and were 
graphed for each sample. KCNJ8 mRNA expression was only slightly affected at 
certain time points by KCNJ8 siRNA transfection.
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Figure 3.5.3.3 Timecourse analysis of KCNJ8 mRNA knockdown (I) by semi- 
quantitative RT-PCR in DLKP-2.
KCNJ8 siRNA was transfected into DLKP-2 and KCNJ8 mRNA analysed at 24, 48, 
72 and 96h. P-actin was used as an endogenous control to normalise for RNA content 
in each PCR. cDNA negative control (cDNA neg) consisted of PCR master mix with 
cDNA but without addition of Taq enzyme. KCNJ8 mRNA expression was only 
slightly affected at certain time points by KCNJ8 siRNA transfection in DLKP-2.
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Figure 3.5.3.4 Timecourse analysis of KCNJ8 mRNA knockdown (I) by semi- 
quantitative RT-PCR in TXT-2.
KCNJ8 siRNA was transfected into TXT-2 and KCNJ8 mRNA measured at 24, 48, 72 
and 96h. (3-actin was used as an endogenous control to normalise for RNA content in 
each PCR. PCR negative control contained PCR master mix without addition of 
cDNA. Figures for the densitometry values were normalised by dividing KCNJ8 
intensity values by P-actin intensity values and were graphed for each sample. KCNJ8 
mRNA expression was only slightly affected by KCNJ8 siRNA transfection in TXT-2.
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Figure 3.5.3.5Timecourse analysis of KCNJ8 mRNA knockdown (II) in DLKP-1 
by qPCR.
Two independent KCNJ8 siRNA sequences were transfected into DLKP-1. KCNJ8 
mRNA expression in these samples was analysed by qPCR at 24, 48 and 72h using a 
commercial TaqMan KCNJ8 probe and normalised for RNA content using P-actin as 
an endogenous control. The data represents KCNJ8 expression relative to the lowest 
KCNJ8 expresser in this data set, DLKP-1 KCNJ8 siRNA 2 48h sample, which was set 
to 1 for the analysis. KCNJ8 mRNA expression was reduced by KCNJ8 siRNA 
transfection in all siRNA transfected samples with the exception of the DLKP-1 
KCNJ8 siRNA 1 48h sample.
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Figure 3.5.3.6Timecourse analysis of KCNJ8 mRNA knockdown (II) in DLKP-2 
by qPCR.
Two independent KCNJ8 siRNA sequences were transfected into DLKP-2. KCNJ8 
mRNA expression in these samples was analysed by qPCR at 24, 48 and 72h using a 
commercial TaqMan probe. (3-actin was used as an endogenous control. The data 
represents KCNJ8 expression relative to the lowest KCNJ8 expresser in this data set, 
DLKP-2 KCNJ8 siRNA 1 24h sample, which was set to 1 for the analysis. KCNJ8 
knockdown using the KCNJ8 siRNA sequences was not achieved at mRNA level in 
DLKP-2 but was achieved for the 24 and 72h transfected samples. It is possible that 
the efficiency of the 48h transfected samples were poor than those achieved for the 24 
and 72h cells.
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Figure 3.5.3.7Timecourse analysis of KCNJ8 mRNA knockdown (II) in TXT-2 by 
qPCR.
Two independent KCNJ8 siRNA sequences were used to target KCNJ8 in TXT-2. 
KCNJ8 mRNA expression in these samples was analysed by qPCR at 24, 48 and 72h 
using a commercial TaqMan KCNJ8 probe and normalised for RNA content using (3- 
actin as an endogenous control. The data represents KCNJ8 expression relative to the 
lowest KCNJ8 expresser in this data set, TXT-2 KCNJ8 siRNA 2 48h sample, which 
was set to 1 for the analysis. A decrease in KCNJ8 mRNA expression was attained in 
all KCNJ8 siRNA transfected samples with the exception of TXT-2 KCNJ8 siRNA 1 
72h.
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The effect of KCNJ8 siRNA transfection on proliferation was investigated by 
transfecting cells seeded at 3 x 105 cells/well of a 6-well plate (Figure 3.5.4.1). 
Relative cell number was determined using the acid phosphatase assay at 72h post 
transfection. Cell numbers were measured to determine what functional effect, if any, a 
decrease in KCNJ8 expression was having on proliferation.
Transfection with KCNJ8 siRNA sequences did not affect proliferation compared with 
non-treated and scrambled siRNA transfected cells.
3.5.4 Evaluation of KCNJ8 siRNA effect on DLKP variant
proliferation
Effect of KCNJ8 siRNA transfection on proliferation
140 -1 
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Figure 3.5.4.1 Effect of siRNA targeting KCNJ8 on DLKP variant cell number.
The cells were seeded at a 3 x 105 cells/well of a 6-well plate. Cell number was 
measured using the acid phosphatase assay at 72h post transfection. KCNJ8 siRNA 
transfection does not appear to significantly affect proliferation compared with the 
scrambled siRNA and non-treated cells.
183
3.5.5 Evaluation of KCNJ8 knockdown on DLKP variant invasion
The effect of KCNJ8 knockdown on DLKP variant invasion was investigated Invasion 
assay analysis was performed 72h post transfection, using commercial invasion assay 
kits containing inserts pre-coated with matngel in conjunction with a serum gradient 
The cells were incubated at 37°C for 24h after which, the underside of the inserts were 
stained with crystal violet and allowed to air dry The inserts were then photographed 
using 10X magnification Ten fields of view were counted per insert at 20X 
magnification and averaged At least two inserts were used for the analysis of each 
condition The counts per number of inserts used were then also averaged and this 
figure was used to generate graphs of relative invasive capacity per cell line per 
condition
One set of representative photographs was included (Figure 3 5 5 1) in this section and 
clearly shows an increase in invasion in KCNJ8 siRNA transfected cells Invasion 
assay results are also presented graphically (Figures 3 5 5 2 and 3 5 5 3)
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Figure 3.5.5.1 Photographic representation of invasion assay results 72h
post KCNJ8 siRNA transfection (I).
The invasion assay was performed 72h post-transfection. Untransfected- and 
scrambled siRNA transfected- cell lines were the controls for this experiment. 
Representative photographs at 10X are shown above. Invasion was increased in 
KCNJ8 siRNA transfected cells compared with the scrambled siRNA and non-treated 
cells.
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Figure 3.5.5.2 Graphic representation of invasion assay results 72h post
KCNJ8 siRNA transfection (I).
The invasion assay was performed 72 hours post-transfection. Untransfected- and 
scrambled siRNA transfected- cell lines were the controls for this experiment. Ten 
random fields were counted at 20X. Each condition was examined using at least two 
invasion kit inserts. Counts per insert were averaged and plotted as percentage invasion 
normalised to the scrambled siRNA for each cell line. Invasion was increased in 
KNCJ8 siRNA transfected cells compared with the scrambled siRNA control 
(P<0.001), except in the case of DLKP-2, which may be due to poor transfection 
efficiency in this cell line.
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Figure 3.5.5.3 Graphic representation of invasion assay results 72h post
KCNJ8 siRNA transfection (II).
The invasive cell lines DLKP-1, DLKP-2 and TXT-2 were transfected with scrambled 
siRNA and two independent siRNA sequences to KCNJ8. The effect of decreasing 
KCNJ8 expression on invasion was examined 72h post transfection. Ten random fields 
were counted at 20X. Each condition was examined using at least two invasion kit 
inserts. Counts per insert were averaged and plotted as percentage invasion normalised 
to the scrambled siRNA for each cell line. An increase was observed in invasion in 
both of the KCNJ8 siRNA transfected samples compared with the scrambled siRNA 
control (P<0.001).
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3.5.6 KCNJ8 cDNA transfection in the less- or non-invasive DLKP 
variants
3.5 6.1 Summary of KCNJ8 cDNA experimental plan
Since array data and RT-PCR results indicated that KCNJ8 mRNA expression was 
higher in the invasive compared with the less invasive DLKP lines, it was decided to 
increase KCNJ8 expression by transfecting the expression vector pSport6 containing 
the cDNA sequence to KCNJ8 into the mildly/non-invasive cell lines TXT-1 and 
VCR This would help determine whether increasing KCNJ8 expression in poorly 
invasive cell lines could induce an invasive phenotype Western blot (not fully 
optimised) was used to examine KCNJ8 expression in the cDNA transfected samples
3.5.6.2 Evaluation of cDNA transient transfection efficiency
using GFP
Two cell lines, TXT-1 and VCR, were transiently transfected with Green Fluorescent 
Protein (GFP) expression plasmid using different conditions in order to achieve 
optimal transfection efficiency (Figures 3 5 6 1  to 3 5 6  4) Cells were seeded at 5 x 
105 cells/well of a six-well plate and transfected using 2 or 4jug GFP plasmid with 5 or 
lOjil of Lipofectamine 2000, transfection reagent Transfection efficiency was 
evaluated by estimating the number of green fluorescent cells per field of vision
Using 2fig GFP with 5|il Lipofectamine 2000, approximately 80% efficiency was 
achieved for TXT-1, while approximately 60% was achieved for VCR There was a 
toxic effect attributed to the use of Lipofectamine 2000, so 2[ig plasmid DNA 5|j,l 
Lipofectamine 2000 were the conditions chosen for all cDNA transient transfections 
used in this study
188
Figure 3.5.6.1 Evaluation of cDNA transfection efficiency I.
TXT-1 transfected using 2|ig GFP with 5(0.1 Lipofectamine 2000 and viewed under 
normal and fluorescent view. Transfection efficiency here is approximately 80%.
Figure 3.5.6.2 Evaluation of cDNA transfection efficiency II.
TXT-1 transfected using 4fj,g GFP with 10|il Lipofectamine 2000 and viewed under 
normal and fluorescent view. Transfection efficiency here is approximately 60%.
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Figure 3.5.6.3 Evaluation of cDNA transfection efficiency III.
VCR transfected using 2|ig GFP with 5\jl\ Lipofectamine 2000 and viewed under 
normal and fluorescent view. Transfection efficiency here is approximately 60%.
Figure 3.5.6.4 Evaluation of cDNA transfection efficiency IV.
TXT-1 transfected using 4|ig GFP with 10|il Lipofectamine 2000 and viewed under 
normal and fluorescent view. Transfection efficiency here is approximately 40%.
190
3.S.6.3 Western blot analysis of KCNJ8 cDNA transient
transfection
Considerable effort was made to determine KCNJ8 protein expression in the poorly 
invasive DLKP variants and their KCNJ8 cDNA transfected counterparts by western 
blot Cells transfected with a pSport6 empty vector were used as a control to ensure 
that the transfection process did not affect target protein expression (Figures 3 5 6 5 
and 3 5 6 6)
The polyclonal anti-kir6 1 (KCNJ8) CAF-1 antibody used in these experiments was a 
gift from Prof William A Coetzee (NYU School of Medicine) and was raised in 
chickens Blots were incubated using a 1/200 dilution of this antibody which 
reportedly generates a 44kDa band specific to KCNJ8 as well as other non-specific 
bands The western blot was not fully optimised and one cannot draw any conclusions, 
as there was no obvious increase at the 44kDa size or any clearly identifiable band 
One strategy to overcome this limitation could include the utilisation of HA tags to 
quantify the KCNJ8 protein Alternatively, an in-house antibody to KCNJ8 could be 
developed to aid more sensitive KCNJ8 protein detection, although previous studies by 
Yoshida et a l , (2004) demonstrate the difficulties in developing a specific and 
sensitive antibody to this protein
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Figure 3.5.6.5 Western blot analysis of KCNJ8 cDNA transient
transfection in TXT-1.
The polyclonal anti-kir6.1 (KCNJ8) CAF-1 antibody used in this experiment was a gift 
from Prof. William A. Coetzee (NYU School of Medicine) and was raised in chickens. 
Blots were incubated using a 1/200 dilution of this antibody and generates a 44kDa 
band specific to KCNJ8. Due to the number of non-specific bands on the blot it is one 
cannot conclude if KCNJ8 cDNA transfection increased protein expression in TXT-1 
or not. Ideally, this protocol would be optimised further.
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Figure 3.5.6.6 Western blot analysis of KCNJ8 cDNA transient 
transfection in VCR.
Blots were incubated using a 1/200 dilution of the CAF-1 antibody. The expected size 
of KCNJ8 is 44kDa. Due to the number of non-specific bands on the blot one cannot 
conclude that KCNJ8 cDNA transfection increased KCNJ8 protein expression in VCR. 
Ideally, this protocol would be optimised further.
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The effect of increasing KCNJ8 expression in the poorly invasive DLKP variants was 
examined Invasion assay analysis was performed 72h post transfection, using 
commercial invasion assay kits containing inserts pre-coated with matngel in 
conjunction with a serum gradient The ceils were incubated at 37°C for 24 hours after 
which, the underside of the inserts were stained with crystal violet and allowed to air 
dry The inserts were then photographed using 10X magnification Ten fields of view 
were counted per insert at 20X magnification and averaged At least two inserts were 
used for the analysis of each condition The counts per number of inserts used were 
then also averaged and this figure was used to generate graphs of relative invasive 
capacity per cell line per condition
One set of representative photographs were included (Figure 3 5 6 7) in this section 
and do not clearly demonstrate any changes in the invasive capacities of TXT-1 or 
VCR in response to KCNJ8 cDNA transfection These invasion assay results are also 
presented graphically (Figures 3 5 6 8) However, one cannot conclude that increasing 
KCNJ8 expression impacts on invasion since the increase m KCNJ8 protein 
expression was unconfirmed
3.5.6 4 Evaluation of KCNJ8 cDNA transient transfection on
invasion
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Figure 3.5.6.7 Photographic representation of invasion assay results 72h
post KCNJ8 cDNA transfection.
The invasion assay was performed 72h post-transfection. Untransfected- and pSport6 
empty vector transfected- cell lines are the controls for this experiment. Ten random 
fields were counted per insert at 20X. An increase in invasion was observed in the 
KCNJ8 cDNA transfected TXT-1 cell line (P<0.001). No effect on invasion was 
observed in KCNJ8 cDNA transfected VCR cells compared with the empty vector and 
non-treated cells. This may be because there was no increase in KCNJ8 expression in 
KCNJ8 cDNA transfected VCR cell line, or that increased KCNJ8 expression is itself 
insufficient to induce an invasive phenotype in mildly invasive cells. This result is 
inconclusive.
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Figure 3.5.6.8 Graphic representation of invasion assay results 72 hrs post
KCNJ8 cDNA transfection.
An increase in invasion was observed in the KCNJ8 cDNA transfected TXT-1 cell line 
(P<0.001). No effect on invasion was observed in KCNJ8 cDNA transfected VCR 
cells compared with the empty vector control cells. This may potentially be attributed 
to poor transfection efficiency in this cell line. This result is inconclusive as no 
increase in KCNJ8 protein expression was confirmed by western blot.
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3 6 Investigation into role of S100A13 m invasion m the DLKP 
vanants
3.6.1 Aims of S100A13 experiments
S100A13 was identified as a gene potentially involved m invasion from the microarray 
analysis The data indicated that S100A13 expression was increased in the more 
invasive cell lines compared with the poorly invasive DLKP variants The aims of this 
set of experiments was as follows
1 To confirm by PCR that S100A13 is differentially expressed between the 
DLKP cell lines
2 To decrease S100A13 expression by transfecting three independent siRNA 
sequences to S100A13 into the invasive cell lines DLKP-1, DLKP-2 and 
TXT-2
3 To demonstrate S100A13-specific siRNA knockdown at mRNA level
4 To evaluate the effect of S100A13 knockdown on proliferation
5 To evaluate the effect of decreased S100A13 expression on invasion
6 To increase S100A13 expression by transfecting a pSport6 plasmid
containing the S100A13 sequence into the mildly invasive cell lines TXT-1 
and VCR
7 To demonstrate an increase in S100A13 protein expression in cDNA 
transfected cells
8 To evaluate the effect of increasing S100A13 expression on invasion
To summarise the results detailed in this section, it was found that S100A13 was 
differentially expressed m the panel of cell lines studied, correlating with array data 
Decreasing S100A13 expression had no effect on proliferation but did decrease 
invasion, as determined by in vitro invasion assays Increasing S100A13 expression 
had no effect on invasion in the less/non-invasive cell lines, despite a measurable 
increase in protein expression following transient transfection
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3.6.2 RT-PCR validation of differential S100A13 mRNA expression
Semi-quantitative RT-PCR was used to confirm that S100A13 mRNA expression was 
higher in the invasive DLKP variants compared with the poorly invasive variants and 
were reflective of array data.
RNA from the duplicate array samples 2004 (Figure 3.6.2.1), RNA from a fresh set of 
cultures harvested separately to those for array analysis including RNA from three 
samples analysed on the Agilent array platform (Figure 3.6.2.2) were subject to this 
analysis. The Agilent data was not analysed further in this work. The aim of using 
different batches of RNA samples was to ensure that results from the array study 
matched to independent analysis of the cell lines.
P-actin was used as an endogenous control to normalise for RNA quantities added to 
each S100A13 PCR. The reactions were analysed by gel electrophoresis (GE) on a 2% 
agarose gel. The band size for S100A13 was 219bp. PCR negative controls consisted 
of consisted of PCR master mix to which no cDNA template was added. cDNA 
negative control (cDNA neg) contained PCR master mix with cDNA but without 
addition of Taq enzyme. Densitometric values were normalised by dividing S100A13 
intensity values by P-actin intensity values and were graphed for each sample. The gels 
included in this section are representative of at least two independent repeats.
This analysis by semi-quantitative PCR demonstrates a trend towards higher S100A13 
expression in the more invasive cell lines DLKP-2 and TXT-2, compared to the mildly 
invasive cell lines TXT-1 and VCR. This correlates with the results from the array 
data. DLKP-1 did not follow the expected trend.
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Figure 3.6.2.1RT-PCR of S100A13 mRNA expression from RNA used in 
duplicate array samples 2004.
RNA for this reaction was analysed in the duplicate array analysis of the DLKP cell 
lines in 2004. P-actin was used as an endogenous control to normalise for RNA content 
in each reaction. The PCR was analysed by gel electrophoresis (GE) on a 2% agarose 
gel. PCR negative (PCR Neg was comprised of PCR master mix withour cDNA 
template) and cDNA negative controls (cDNA neg consisted of PCR master mix with 
cDNA but without Taq) were included in the PCR. Densitometry was used to measure 
of band intensity. Densitometry values were normalised by dividing S100A13 intensity 
values by p-actin intensity values and were graphed for each sample. This PCR 
demonstrates increased S100A13 expression in the more invasive cell lines DLKP-2 
and TXT-2, compared to the lesser invasive cell lines TXT-1 and VCR. Surprisingly, 
low S100A13 mRNA levels were obtained in DLKP-1.
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Figure 3.6.2.2 RT-PCR of S100A13 mRNA in a separate sample set and Agilent 
samples.
RNA for this analysis was from a separate batch of DLKP variant cultures not 
harvested or processed for Affymetrix array analysis. Also included were three 
samples analysed on the Agilent array platform but which were not investigated 
further. P-actin was used as an endogenous control to normalise for RNA content. The 
reaction was analysed by GE on a 2% agarose gel. Densitometry values were 
normalised by dividing S100A13 intensity values by P-actin intensity values and were 
graphed for each sample. This PCR demonstrates a trend towards increased S100A13 
expression in the more invasive cell lines DLKP-1, DLKP-2 and TXT-2, compared to 
the lesser invasive cell lines TXT-1 and VCR. This result agrees with the array data.
2 0 0
3.6.3 S100A13 siRNA transfection in the invasive DLKP variants
3.6.3.1 Summary of S100A13 siRNA experimental plan
Array data and RT-PCR results indicated that S100A13 mRNA expression was higher 
in the invasive compared with the less invasive DLKP lines, thus it was decided to 
knockdown S100A13 expression using three independent siRNA sequences in the 
invasive cell lines DLKP-1, DLKP-2 and TXT-2 and determine any functional effect 
on invasion Initial experiments were performed using S100A13 siRNA 1 A repeat 
was then performed using S100A13 siRNA 1 and the additional S100A13 siRNA 2 
and S100A13 siRNA 3 sequences 2\x\ of NeoFx transfection reagent per well of a 6- 
well plate was used to transfect 30nM of target siRNA into the cells Transfections 
were performed according to the optimum procedures identified in Section 3 4 4 1 
S100A13-specific knockdown was confirmed by qPCR and the effect S100A13 
knockdown on proliferation and invasion investigated
2 0 1 i
3.6.3.2 S100A13-speciflc siRNA decrease in mRNA levels
Three S100A13-specific siRNA sequences were transfected into the invasive DLKP 
cell lines and a decrease in mRNA expression examined by semi quantitative RT-PCR 
and qPCR respectively
Timecourse analysis of S100A13 knockdown was examined using RT-PCR (Figures 
3 6 3 2  to 36 3  4) P-actin was included as an endogenous control to normalise for 
RNA content in each reaction The PCRs were analysed by gel electrophoresis (GE) on 
a 2% agarose gel The band size for S100A13 was 219bp cDNA negative control 
(cDNA neg) consisted of PCR master mix with cDNA but without addition of Taq 
enzyme PCR negative controls consisted of PCR master mix to which no cDNA 
template was added Figures for the densitometry values were normalised by dividing 
S100A13 intensity values by P-actin intensity values and were plotted for each sample 
The gels included in this timecourse study are representative of at least two 
independent repeats These results demonstrate that RT-PCR is not sensitive enough to 
accurately monitor S100A13 expression but indicates an overall trend from the data 
that S100A13 siRNA transfection did affect S100A13 mRNA expression
A commercial TaqMan probe to S100A13 was used to more accurately measure 
relative S100A13 mRNA expression The data was normalised using P-actin as an 
endogenous control (Figure 3 6 3 1) An investigation into the timecourse of mRNA 
expression in S100A13 siRNA transfected samples was measured by qPCR (Figures 
3 6 3 5  to 3 6 3  7) The results confirm that S100A13 knockdown was achieved at the 
mRNA level
2 0 2
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Figure 3.6.3.1 qPCR analysis of S100A13 siRNA experiment (I) at 24h.
S100A13 mRNA expression was examined by qRT-PCR using a commercial TaqMan 
S100A13 probe and normalised for RNA content using P-actin as an endogenous 
control. RNA was harvested 24h post-transfection and used to determine an S100A13- 
siRNA specific decrease in mRNA in response to siRNA transfection. The data 
represents S100A13 expression relative to DLKP-1 S100A13 siRNA, which was set to 
1 for the analysis and was the lowest expresser in the qPCR data set. A decrease in 
S100A13 mRNA expression was observed in the DLKP-2 and TXT-2 S100A13 
siRNA transfected samples. S100A13 expression in DLKP-1 was not decreased.
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Figure 3.6.3.2 Timecourse analysis of S100A13 mRNA knockdown (I) by 
semi-quantitative RT-PCR in DLKP-1.
S100A13 siRNA was transfected into DLKP-1. RNA for the analysis of S100A13 
mRNA was harvested at 24, 48, and 72h. P-actin was used to normalise for RNA 
content in each PCR. Figures representing the densitometry values graphed above were 
normalised by dividing S100A13 intensity values by P-actin intensity values. S100A13 
mRNA levels were decreased at 24, 48 and 72h respectively, in comparison to the non­
treated and scrambled siRNA transfected samples.
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Figure 3.6.3.3 Timecourse analysis of S100A13 mRNA knockdown (I) by
semi-quantitative RT-PCR in DLKP-2.
S100A13 siRNA was transfected into DLKP-2 and S100A13 mRNA expression 
analysed at 24, 48, 72 and 96h. P-actin was used as an endogenous control to 
normalise for RNA content in each PCR. Figures for the densitometry values were 
normalised by dividing S100A13 intensity values by P-actin intensity values and were 
graphed for each sample. S100A13 mRNA levels were decreased at 24, and 72h 
respectively, in comparison to the non-treated and scrambled siRNA transfected 
samples.
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Figure 3.6.3.4 Timecourse analysis of S100A13 mRNA knockdown (I) by
semi-quantitative RT-PCR in TXT-2.
S100A13 siRNA was transfected into TXT-2 and S100A13 mRNA expression 
measured at 24, 48, 72 and 96h. ß-actin was used to normalise for RNA content in 
each PCR. Densitometrie values were normalised by dividing S100A13 intensity 
values by ß-actin intensity values and were graphed for each sample. S100A13 mRNA 
levels were decreased at 24, 48 and 72h respectively, in comparison to the non-treated 
and scrambled siRNA transfected samples.
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Figure 3.6.3.5 Timecourse analysis of S100A13 mRNA knockdown (II) in 
DLKP-1 by qPCR.
Three independent S100A13 siRNA sequences were transfected into DLKP-1. 
S100A13 mRNA expression in these samples was analysed by qPCR at 24, 48 and 72h 
using a commercial TaqMan probe to S100A13 and normalised for RNA content using 
P-actin as an endogenous control. The data represents S100A13 expression relative to 
the lowest S100A13 expresser in this data set, DLKP-1 S100A13 siRNA 3 48h 
sample, which was set to 1 for the analysis. A decrease in S100A13 mRNA expression 
was observed for all three siRNA’s at 24 and 48h. This decrease was more pronounced 
at 72h.
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Figure 3.6.3.6 Timecourse analysis of S100A13 mRNA knockdown (H) in 
DLKP-2 by qPCR.
Three independent S100A13 siRNA sequences were transfected into DLKP-2. 
S100A13 mRNA expression in these samples was analysed by qPCR at 24, 48 and 
72h. P-actin was used as an endogenous control. The data represents S100A13 
expression relative the lowest S100A13 expresser in this data set, DLKP-2 S100A13 
siRNA 2 24h sample, which was set to 1 for the analysis. S100A13 knockdown was 
observed for all three S100A13 siRNA’s at all timepoints compared with the 
scrambled siRNA samples.
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Figure 3.6.3.7 Timecourse analysis of S100A13 mRNA knockdown (II) in 
TXT-2 by qPCR.
Three independent S100A13 siRNA sequences were transfected into TXT-2. S100A13 
mRNA expression in these samples was analysed by qPCR at 24, 48 and 72h using a 
commercial TaqMan S100A13 probe and normalised for RNA content using (3-actin as 
an endogenous control. The data represents S100A13 expression relative to the lowest 
S100A13 expresser in this data set, TXT-2 S100A13 siRNA 2 72h sample, which was 
set to 1 for the analysis. S100A13 knockdown was observed for all three S100A13 
siRNA’s at all timepoints compared with the scrambled siRNA samples.
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The effect of transfecting S100A13 siRNA sequences on proliferation was 
investigated. Cells seeded at 3 x 105 cells/well of a 6-well plate (Figure 3.6.4.1), which 
was the cell number used to seed all the siRNA transfections in six-well plates. 
Relative cell number was determined using the acid phosphatase assay at 72h post 
transfection. Cell numbers were measured to determine what functional effect, if any, a 
decrease in S100A13 expression was having on proliferation.
Transfection with any of the siRNA sequences did not have a dramatic affect on 
proliferation compared with non-treated and scrambled siRNA transfected cells.
3.6.4 Evaluation of S100A13 siRNA effect on DLKP variant
proliferation
Effect of S100A13 siRNA transfection on proliferation
140 -I 
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Figure 3.6.4.1 Effect of siRNA targeting S100A13 on DLKP variant cell number.
The cells were seeded at a 3 x 105 cells/well of a 6-well plate. Proliferation was 
measured by the acid phosphatase assay at 72h post transfection. There is a slight 
decrease in proliferation observed due to the transfection. S100A13 siRNA treatment 
does not appear to increase/decrease proliferation in any cell line.
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3.6 5 Evaluation of S100A13 siRNA effect on DLKP variant invasion
The effect of decreasing S100A13 expression on DLKP variant invasion was 
investigated Invasion assay analysis was performed 72h post transfection, to allow the 
cells to recover from the transfection procedure, using commercial invasion assay kits 
containing inserts pre-coated with matngel in conjunction with a serum gradient The 
cells were incubated at 37°C for 24h after which, the underside of the inserts were 
stained with crystal violet and allowed to air dry The inserts were then photographed 
using 10X magnification Ten fields of view were counted per insert at 20X 
magnification and averaged At least two inserts were used for the analysis of each 
condition The counts per number of inserts used were then also averaged and this 
figure was used to generate graphs of relative invasive capacity per cell line per 
condition
One set of representative photographs was included (Figure 3 6 5 1) in this section and 
clearly demonstrate decreased invasion in S100A13 siRNA transfected cells Invasion 
assay results are also presented graphically (Figures 3 6 5 2 and 3 6 5 3) Results for 
DLKP-2 are not included in Figure 3 6 5 1 and 3 6 5 2 due to a technical error, but are 
included in Figure 3 6 5 3
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Figure 3.6.5.1 Photographic representation of invasion assay results 72h
post S100A13 siRNA transfection (I).
The invasion assay was performed 72h post-transfection and was of 24h duration. 
Untransfected- and scrambled siRNA transfected- cell lines were the controls for this 
experiment. Representative photographs at 10X are shown above. Invasion was 
decreased in S100A13 siRNA transfected cells compared with the scrambled siRNA 
and non-treated cells (P<0.001).
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Figure 3.6.5.2 Graphic representation of invasion assay results 72h post S100A13 
siRNA transfection (I).
The invasion assay was performed 72h post-transfection. Scrambled siRNA 
transfected- cell lines are the controls for this experiment. Ten random fields were 
counted at 20X. Each condition was examined using at least two invasion kit inserts. 
Counts per insert were averaged and plotted as percentage invasion normalised to the 
scrambled siRNA for each cell line. Invasion was decreased in S100A13 siRNA 
transfected cells compared with the scrambled siRNA control (P<0.001).
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Figure 3.6.5.3 Graphic representation of invasion assay results 72h post S100A13 
siRNA transfection (II).
The invasive cell lines DLKP-1, DLKP-2 and TXT-2 were transfected with scrambled 
siRNA and three independent siRNA sequences to S100A13. The effect of S100A13 
expression knockdown on invasion was examined 72h post transfection. Scrambled 
siRNA transfected- cell lines were the controls for this experiment. Ten random fields 
were counted per insert at 20X. Each condition was examined using at least two 
invasion kit inserts. Counts per insert were averaged and plotted as percentage invasion 
normalised to the scrambled siRNA for each cell line. Invasion was decreased in 
S100A13 siRNA transfected cells compared with the scrambled siRNA control 
(PO.OOl).
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3.6.6 S100A13 cDNA transfection in the non-invasive DLKP vanants
3.6.6.1 Summary of S100A13 cDNA expenmental plan
Array and RT-PCR results indicated that S100A13 mRNA expression was increased in 
the invasive compared with the poorly invasive DLKP lines, it was decided to 
overexpress S100A13 by transfecting the vector pSport6 containing the cDNA 
sequence to S100A13 into the mildly/non-invasive cell lines TXT-1 and VCR This 
would help determine whether increasing S100A13 expression in poorly invasive cell 
lines could induce an invasive phenotype Western blotting was used to confirm 
exogenous S100A13 expression in the cDNA transfected samples
3.6.6.2 Western Blot analysis of S100A13 cDNA transient 
transfection
S100A13 protein expression in the poorly invasive DLKP cell lines and their S100A13 
cDNA transfected counterparts was determined by western blotting Cells were 
transfected with a pSport6 empty vector as a control to ensure that the transfection 
process did not affect S100A13 protein expression (Figures 3 6 6 1 and 3 6 6 2)
The polyclonal anti-S100A13 antibody used in these experiments was a gift from Prof 
Claus Heizmann and was raised in rabbit An 1 lkDa band is specific to S100A13 An 
a-tubulin antibody was used to demonstrate even loading between the samples 
S100A13 protein expression was increased in response to S100A13 cDNA transient 
transfection in both TXT-1 and VCR
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Figure 3.6.6.1 Western blot analysis of S100A13 cDNA transient transfection in 
TXT-1.
The polyclonal anti-S100A13 antibody used in this experiment was a gift from Prof. 
Claus Heizmann and was raised in rabbit. An llkDa band is specific to S100A13. 
S100A13 expression is increased in S100A13 cDNA transfected samples in TXT-1 
and was sustained over 72h.
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Figure 3.6.6.2 Western blot analysis of S100A13 cDNA transient transfection in 
VCR.
The polyclonal anti-S100A13 antibody used in this experiment was a gift from Prof. 
Claus Heizmann and was raised in rabbit. An llkDa band is specific to S100A13. 
S100A13 expression is increased in S100A13 cDNA transfected samples in VCR at all 
timepoints.
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The effect of overexpressing S100A13 in the poorly invasive DLKP variants was 
examined. Invasion assay analysis was performed 72h post transfection, using 
commercial invasion assay kits containing inserts pre-coated with matrigel in 
conjunction with a serum gradient. The cells were incubated at 37°C for 24h after 
which, the underside of the inserts were stained with crystal violet and allowed to air 
dry. The inserts were then photographed using 10X magnification. Ten fields of view 
were counted per insert at 20X magnification and averaged. At least two inserts were 
used for the analysis of each condition. The counts per number of inserts used were 
then also averaged and this figure was used to plot graphs of relative invasive capacity 
per cell line per condition.
One set of representative photographs were included (Figure 3.6.6.3) in this section 
and do not demonstrate any obvious alteration in the invasive capacities of TXT-1 or 
VCR in response to increased S100A13 expression. These invasion assay results are 
also presented graphically (Figures 3.6.6.4) and demonstrate a decrease in invasion in 
S100A13 cDNA transfected cells compared with the empty vector, however this 
decrease was significant for the TXT-1 S100A13 cDNA transfected cells (P<0.01) 
only. This indicates that an increase in S100A13 expression is insufficient to induce an 
invasive phenotype in poorly or non-invasive cell lines.
3.6.6.3 Evaluation of S100A13 cDNA transient transfection on
invasion
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Figure 3.6.6.3 Photographic representation of invasion assay results 72h post 
S100A13 cDNA transfection.
The invasion assay was performed 72h post-transfection. Untransfected- and pSport6 
empty vector transfected- cell lines are the controls for this experiment. Ten random 
fields were counted per insert at 20X. No effect on invasion was apparent in S100A13 
cDNA transfected cells compared with the empty vector and non-treated cells. This 
indicates that increased S100A13 expression is itself insufficient to induce an invasive 
phenotype in mildly invasive cells. Surprisingly, when the counts were statistically 
examined, a decrease in invasion was observed in S100A13 cDNA transfected cells 
compared with the empty vector, however this decrease was significant for the TXT-1 
S100A13 cDNA transfected cells (P<0.01) only.
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Figure 3.6.6.4 Graphic representation of invasion assay results 72h post S100A13 
cDNA transfection.
The invasion assay was performed 72h post-transfection. pSport6 empty vector 
transfected- cell lines were the controls for this experiment. Ten random fields were 
counted at 20X. Counts per insert were averaged and plotted as percentage invasion 
normalised to the empty vector pSport6 cDNA for each cell line. A decrease in 
invasion was observed in S100A13 cDNA transfected cells compared with the empty 
vector, however this decrease was significant for the TXT-1 S100A13 cDNA 
transfected cells (P<0.01) only. This indicates that increased S100A13 expression is 
itself insufficient to induce an invasive phenotype in lowly invasive cells.
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3.7 Investigation into role of Stratifin (SFN) in invasion in the 
DLKP cell model
3.7.1 Aims of SFN experiments
SFN was identified being differentially expressed across the cell lines in our model of 
invasion by array expression analysis. Higher expression correlated with a greater 
degree of invasion. The aims of these experiments were as follows.
1. To confirm by PCR that SFN is differentially expressed across the DLKP
cell line model of invasion.
2. To decrease SFN expression by transfecting an siRNA sequence to SFN
using optimised transfection conditions into the invasive cell lines DLKP-1, 
DLKP-2 and TXT-2.
3. To demonstrate SFN-specific knockdown at mRNA level.
4. To evaluate the effect of decreased SFN expression on invasion.
5. To increase SFN expression by transfecting a pSport6 plasmid containing 
the SFN sequence into the poorly/non-invasive cell lines TXT-1 and VCR.
6. To demonstrate an increase in SFN protein expression in cDNA transfected
cells.
7. To evaluate the effect of exogenous SFN expression on invasion.
To summarise the results detailed in this section, it was found that SFN was 
differentially expressed in the panel of cell lines studied where higher expression was 
associated with an increased capacity to invade. This correlated with array data. SFN 
knockdown was marginal in the DLKP-1 and DLKP-2 cell lines. The knockdown in 
TXT-2 was greater. Where knockdown was minimal no effect on invasion was 
observed. However, decreased SFN expression in TXT-2 increased invasion in this cell 
line. Overexpressing SFN had no effect on invasion in the less/non-invasive cell lines.
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3.7.2 RT-PCR investigation of differential SFN mRNA expression
Semi-quantitative RT-PCR was used to confirm that SFN mRNA expression was 
higher in the invasive DLKP variants compared with the less invasive variants and 
were reflective of array data
To ensure that results from the array study matched to independent analyses of the cell 
lines, RNA samples from the preliminary Affymetnx array study by Dr Rasha 
Linehan in 2003 (Figure 3 7 2 1), RNA from the duplicate array samples 2004 (Figure 
3 7 2 2), RNA from a fresh set of cultures harvested separately to those for array 
analysis including RNA from three samples analysed on the Agilent array platform 
(Figure 3 7 2 3) were included in this analysis The Agilent data was not analysed 
further in this work
P-actin was used as an endogenous control to normalise for RNA content in each SFN 
PCR The reactions were analysed by gel electrophoresis (GE) on a 2% agarose gel 
and visualised by ethidium bromide staining The band size for SFN was 195bp PCR 
negative controls consisted of consisted of PCR master mix to which no cDNA 
template was added cDNA negative control (cDNA neg) contained PCR master mix 
with cDNA but without addition of Taq enzyme Densitometry values were normalised 
by dividing SFN intensity values by P-actin intensity values and were plotted for each 
sample The gels included in this section are representative of at least two independent 
repeats
This analysis by semi-quantitative PCR demonstrated a trend towards higher SFN 
expression in the more invasive cell lines DLKP-1 and TXT-2, compared to the less 
invasive cell lines TXT-1 and VCR This correlates with the array data
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Figure 3.7.2.1 RT-PCR of SFN mRNA expression from RNA used in array
samples 2003.
RNA used for this PCR was analysed on the 2003 arrays. P-actin was used as an 
endogenous control to normalise for RNA content in each reaction. The PCR was 
analysed by gel electrophoresis (GE) on a 2% agarose gel. A PCR Negative (PCR 
Neg) control was included in the analysis and consisted of PCR master mix to which 
no cDNA template was added. Densitometry values were normalised by dividing SFN 
intensity values by P-actin intensity values and were graphed for each sample. SFN 
mRNA expression is highest in the invasive DLKP-1 cell line followed by TXT-2. 
Surprisingly, SFN is expressed at low levels in DLKP-2.
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Figure 3.7.2.2 RT-PCR of SFN mRNA expression from RNA used in 
duplicate array samples 2004.
RNA for this reaction was analysed in the duplicate array analysis of the DLKP cell 
lines in 2004. (3-actin was used as an endogenous control. A PCR negative (PCR Neg) 
control was included in the analysis. Densitometry values were normalised by dividing 
SFN intensity values by P-actin intensity values and were graphed for each sample. 
This PCR demonstrates higher SFN expression in the more invasive cell lines DLKP- 
1, DLKP-2 and TXT-2, compared to the poorly invasive cell lines TXT-1 and VCR. 
This result agrees with the array data.
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Figure 3.7.2.3 RT-PCR of SFN mRNA in a separate sample set and Agilent 
samples.
RNA for this analysis was from a separate batch of DLKP variant cultures not 
harvested or processed for Affymetrix array analysis. Also included were three 
samples analysed on the Agilent array platform but which were not investigated 
further. P-actin was used as an endogenous control. The reaction was analysed by GE 
on a 2% agarose gel. Densitometry values were normalised by dividing SFN intensity 
values by P-actin intensity values and were plotted for each sample. This PCR 
demonstrates increased SFN expression in DLKP-2 and TXT-2, with lower expression 
in TXT-1 and VCR. SFN mRNA levels were also low in DLKP-1 in this analysis.
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3.7.3 SFN siRNA transfection in the invasive DLKP variants
3.7.3.1 Summary of SFN siRNA experimental plan
SFN was identified being differentially expressed across the cell lines in our model of 
invasion by array expression analysis. Higher expression correlated with a greater 
degree of invasion. This finding was confirmed by semi-quantitative RT-PCR, except 
in the case of DLKP-1. This correlation prompted us to investigate the impact of SFN 
knockdown using a commercial siRNA sequence on the invasive phenotype. 
Successful knockdown was confirmed by PCR and the phenotypic effect assessed by 
in vitro invasion assay. Western blot analysis of protein levels indicated that 
endogenous SFN levels were below the level of detection.
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3.7.3.2 SFN-specific siRNA knockdown of mRNA levels
An SFN-specific siRNA sequence was transfected into the invasive DLKP cell lines 
and a decrease in mRNA expression examined by qPCR and semi-quantitative RT- 
PCR.
A commercial TaqMan probe to SFN was used to quantify relative SFN mRNA 
expression. The data was normalised using (3-actin as an endogenous control (Figure
3.7.3.1). An siRNA-dependent decrease in SFN mRNA was observed for samples at 
24h.
Timecourse analysis of SFN knockdown was examined by RT-PCR (Figures 3.7.3.2 to 
3.7.3.4). (3-actin was included as an endogenous control to normalise for RNA content 
in each reaction. The PCRs were analysed by gel electrophoresis (GE) on a 2% agarose 
gel and visualised with ethidium bromide staining. The band size for SFN was 195bp. 
cDNA negative control (cDNA neg) consisted of PCR master mix with cDNA but 
without addition of Taq enzyme. PCR negative controls consisted of PCR master mix 
to which no cDNA template was added. Densitometric values were normalised by 
dividing SFN intensity values by P-actin intensity values and were graphed for each 
sample. The gels included in this timecourse study are representative of at least two 
independent repeats. These results demonstrate the limited value of semi-quantitative 
RT-PCR timecourse analysis. However, the data does suggest an overall trend in that 
SFN siRNA transfection had a marginal effect on mRNA expression that warranted 
further investigation.
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Figure 3.7.3.1 qPCR analysis of SFN siRNA experiment at 24h.
RNA was harvested 24h post-transfection and used to determine an SFN-siRNA 
specific decrease in mRNA in response to siRNA transfection. SFN mRNA expression 
was examined by qRT-PCR using a commercial TaqMan SFN probe and normalised 
for RNA content using P-actin as an endogenous control. The data represents SFN 
expression relative to TXT-2 SFN siRNA, which was set to 1 for the analysis and was 
the lowest expresser in the qPCR data set. A SFN siRNA specific decrease in mRNA 
was observed for all samples at 24h.
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Figure 3.7.3.2 Timecourse analysis of SFN mRNA knockdown by semi- 
quantitative RT-PCR in DLKP-1.
SFN siRNA was transfected into DLKP-1. RNA for the analysis of SFN mRNA was 
harvested at 24, 48, 72 and 96h. P-actin was used to normalise for RNA content in 
each PCR. Densitometric values graphed above were normalised by dividing SFN 
intensity values by P-actin intensity values. The trend here indicates that SFN mRNA 
levels were marginally decreased at 24 and 96h respectively, in comparison to the non­
treated and scrambled siRNA transfected samples.
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Figure 3.7.3.3 Timecourse analysis of SFN mRNA knockdown by semi- 
quantitative RT-PCR in DLKP-2.
A SFN siRNA sequence was transfected into DLKP-2 and SFN mRNA expression 
analysed at 24, 48, 72 and 96h. P-actin was used as an endogenous control to 
normalise for RNA content in each PCR. Figures for the densitometry values were 
normalised by dividing SFN intensity values by P-actin intensity values and were 
plotted for each sample. SFN mRNA levels were decreased, albeit slightly, at 48, 72 
and 96h samples compared to the non-treated and scrambled transfected samples.
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Figure 3.7.3.4 Timecourse analysis of SFN mRNA knockdown by semi- 
quantitative RT-PCR in TXT-2.
SFN siRNA was transfected into TXT-2 and SFN mRNA expression measured at 24, 
48, 72 and 96h. (3-actin was used to normalise for RNA content in each PCR. Figures 
for the densitometry values were normalised by dividing SFN intensity values by P- 
actin intensity values and were graphed for each sample. SFN mRNA levels were 
slightly decreased in the 24, 48 and 72h sample compared to the non-treated and 
scrambled transfected samples.
231
3.7 4 Evaluation of SFN siRNA effect on DLKP variant invasion
The impact of SFN knockdown on DLKP variant invasion was investigated Invasion 
assay analysis was performed 72h post transfection, using commercial invasion assay 
kits containing inserts pre-coated with matngel in conjunction with a serum gradient 
The cells were incubated at 37°C for 24h after which, the underside of the inserts were 
stained with crystal violet and allowed to air dry The inserts were then photographed 
using 10X magnification Ten fields of view were counted per insert at 20X 
magnification and averaged At least two inserts were used for the analysis of each 
condition The counts per number of inserts used were then also averaged and this 
figure was used to plot graphs of relative invasive capacity per cell line per condition
One set of representative photographs was included (Figure 3 7 4 1) in this section 
Invasion assay results are also presented graphically (Figures 3 7 4 2) SFN 
knockdown had a negligible effect on the invasive capacity of DLKP-1 However, 
SFN knockdown in DLKP-2 and TXT-2 increased invasion (P<0 001) These results 
do not clarify the potential role of SFN in invasion and require further investigation
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Figure 3.7.4.1 Photographic representation of invasion assay results 72h post SFN 
siRNA transfection.
The invasion assay was performed 72h post-transfection over 24h. Untransfected- and 
scrambled siRNA transfected- cell lines were the controls for this experiment. 
Representative photographs at 10X are shown above. Invasion was increased in SFN 
siRNA transfected cells in the DLKP-2 and TXT-2 cell lines compared with the 
scrambled siRNA and non-treated cells. No effect was observed in the DLKP-1 cell 
line.
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Figure 3.7.4.2 Graphic representation of invasion assay results 72h post SFN 
siRNA transfection
The invasion assay was performed 72h post-transfection over 24h. Untransfected- and 
scrambled siRNA transfected- cell lines were the controls for this experiment. Ten 
random fields were counted per insert at 20X. Each condition was examined using at 
least two invasion kit inserts. Counts per insert were averaged and plotted as 
percentage invasion normalised to the scrambled siRNA for each cell line. Invasion 
was increased in SFN siRNA transfected DLKP-2 and TXT-2 cells compared with the 
scrambled siRNA control (PO.OOl).
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3.7.5 SFN cDNA transfection in the non-invasive DLKP variants
3.7.5.1 Summary of SFN cDNA experimental plan
Both microarray and RT-PCR analysis of SFN expression indicated an increase in SFN 
expression of invasive cell lines. To investigate the effect of overexpression of 
exogenous SFN on the invasive status of the cells we transiently transfected an 
expression vector containing the SFN cDNA sequence under the control of a strong 
viral promoter (pSport6). Transient transfection of this vector into the poorly/non- 
invasive cell lines TXT-1 and VCR resulted in SFN overexpression as determined by 
western blotting. However, this had no measurable effect on the invasive abilities of 
these cell lines.
3.7.5.2 Western Blot analysis of SFN cDNA transient transfection
SFN overexpression by transient transfection was confirmed by western blotting. Cells 
were transfected with a pSport6 empty vector as a control to ensure that the 
transfection process did not affect SFN protein expression (Figures 3.7.5.1 and
3.7.5.2).
A 30kDa band is specific to SFN. A a-tubulin antibody was used to demonstrate even 
loading between the samples. SFN protein expression was increased in response to 
SFN cDNA transient transfection in both TXT-1 and VCR.
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Figure 3.7.5.1 Western blot analysis of SFN cDNA transient transfection in TXT-
A 30kDa band is specific to SFN. SFN expression is increased in SFN cDNA 
transfected samples over the 72h timecourse.
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Figure 3.7.5.2 Western blot analysis of SFN cDNA transient transfection in VCR.
A 30kDa band is specific to SFN. SFN expression is increased in SFN cDNA 
transfected samples in VCR over a 72h period.
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3.7.6 Evaluation of SFN cDNA transient transfection on invasion
The effect of exogenously overexpressing SFN in the poorly invasive DLKP variants, 
TXT-1 and VCR was examined. Invasion assay analysis was performed 72h post 
transfection, using commercial invasion assay kits containing inserts pre-coated with 
matrigel in conjunction with a serum gradient, and was of 24h duration. After this time 
the underside of the inserts were stained with crystal violet and allowed to air-dry. The 
inserts were then photographed using 10X magnification. Ten fields of view were 
counted per insert at 20X magnification and averaged. At least two inserts were used 
for the analysis of each condition. The counts per number of inserts used were then 
also averaged and this figure was used to plot graphs of relative invasive capacity per 
cell line per condition.
One set of representative photographs were included (Figure 3.7.6.1) in this section 
and do not demonstrate any alteration in the invasive abilities of TXT-1 or VCR in 
response to increased SFN expression. These invasion assay results are also presented 
graphically (Figures 3.7.62). This indicates that exogenously increasing SFN 
expression is insufficient to induce an invasive phenotype in these poorly or non- 
invasive cell lines.
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Figure 3.7.6.1 Photographic representation of invasion assay results 72h post SFN 
cDNA transfection.
The invasion assay was performed 72h post-transfection. Untransfected- and pSport6 
empty vector transfected- cell lines were the controls for this experiment. Ten random 
fields were counted at 20X. No effect on invasion was observed in SFN cDNA 
transfected cells compared with the empty vector and non-treated cells. This indicates 
that increased SFN expression is itself insufficient to induce an invasive phenotype in 
poorly invasive cells.
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Figure 3.7.6.2 Graphic representation of invasion assay results 72h post SFN 
cDNA transfection.
Ten random fields were counted at 20X. Counts per insert were averaged and plotted 
as percentage invasion normalised to the pSport6 empty vector cDNA for each cell 
line. No effect on invasion was observed in SFN cDNA transfected cells compared 
with the empty vector transfected cells. This indicates that increasing SFN expression 
by transient transfection cannot induce an invasive phenotype in mildly invasive cells.
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3.8 Investigation into role of Tissue Factor Pathway Inhibitor-2
(TFPI2) in invasion in the DLKP variants
3.8.1 Aims of TFPI2 experiments
TFPI2 was identified as a gene potentially involved in invasion as it was identified as 
being differentially expressed across the cell lines in our model of invasion by array 
expression analysis The data showed that TFPI2 expression was lower in the invasive 
cell lines than the less/non-invasive cell lines The aims of this set of experiments were 
as follows
1 To confirm by PCR that TFPI2 is differentially expressed across the DLKP
cell line model of invasion
2 To decrease TFPI2 expression by transfecting an independent siRNA
sequence to TFPI2 into the non-invasive cell lines TXT-1 and VCR
3 To demonstrate TFPI2-specific siRNA knockdown at mRNA level
4 To evaluate the effect of decreased TFPI2 expression on invasion
5 To increase TFPI2 expression by transiently transfecting an expression
vector containing the TFPI2 sequence into the invasive cell lines DLKP-1, 
DLKP-2 and TXT-2
6 To demonstrate an increase in TFPI2 protein expression in cDNA
transfected cells by western blot
7 To evaluate the effect of TFPI2 cDNA transfection on proliferation
8 To evaluate the effect of increasing TFPI2 expression on invasion
To summarise the results detailed in this section, TFPI2 mRNA was differentially 
expressed in the panel of cell lines studied, with decreased invasive ability correlating 
with higher expression This concurs with array data analysis Decreasing TFPI2 
expression had no effect on invasion in the non-invasive cell lines Increasing TFPI2 
expression exogenously by transient cDNA transfection had no effect on proliferation, 
but did decrease invasion dramatically
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3.8.2 RT-PCR investigation of differential TFPI2 mRNA expression
Semi-quantitative RT-PCR was used to confirm that TFPI2 mRNA expression was 
lower in the invasive DLKP variants compared with the poorly invasive variants and 
was reflective of array results.
To ensure that results from the array study matched to independent analysis of the cell 
lines, RNA samples from the preliminary Affymetrix array study by Dr. Rasha 
Linehan in 2003 (Figure 3.8.2.1), RNA from the duplicate array samples 2004 (Figure
3.8.2.2), RNA from a fresh set of cultures harvested separately to those for array 
analysis including RNA from three samples analysed on the Agilent array platform 
(Figure 3.8.2.3) were included in this analysis.
P-actin was used as an endogenous control to normalise for RNA content in each SFN 
PCR. The reactions were analysed by gel electrophoresis (GE) on a 2% agarose gel 
and visualised by ethidium bromide staining. The band size for TFPI2 was 183bp. 
cDNA negative control (cDNA neg) contained PCR master mix with cDNA but 
without addition of Taq enzyme. PCR negative controls consisted of consisted of PCR 
master mix to which no cDNA template was added. Densitometric values were 
normalised by dividing TFPI2 intensity values by P-actin intensity values and were 
graphed for each sample. The gels included in this section are representative of at least 
two independent repeats.
This analysis by semi-quantitative PCR demonstrates a trend of lower TFPI2 
expression in the more invasive cell lines DLKP-1, DLKP-2 and TXT-2, compared to 
the less invasive cell lines TXT-1 and VCR. This correlates with the array data.
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Figure 3.8.2.1RT-PCR of TFPI2 mRNA expression from RNA used in array 
samples 2003.
RNA used for this PCR was analysed on the 2003 arrays. (3-actin was used as an 
endogenous control to normalise for RNA content in each reaction. The PCR was 
analysed by gel electrophoresis (GE) on a 2% agarose gel and visualised by ethidium 
bromide staining. A PCR Negative (PCR Neg) control was included in the analysis and 
consisted of PCR master mix to which no cDNA template was added. Densitometry 
values were normalised by dividing TFPI2 intensity values by P-actin intensity values 
and were plotted for each sample. This PCR demonstrates increased TFPI2 expression 
in the mildly invasive cell lines TXT-1 and VCR, although there is high TFPI2 
expression in DLKP-2 also. Considering that DLKP-2 is in the middle of the scale of 
invasion, it is not too surprising that TFPI-2 expression would be higher in this sample 
than DLKP-1 or TXT-2.
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Figure 3.8.2.2 RT-PCR of TFPI2 mRNA expression from RNA used in duplicate 
array samples 2004.
RNA for this reaction was analysed in the duplicate array analysis of the DLKP cell 
lines in 2004. P-actin was used as an endogenous control. A PCR negative (PCR Neg) 
and cDNA negative (cDNA Neg) control was included in the analysis. Densitometry 
values were normalised by dividing TFPI2 intensity values by P-actin intensity values 
and were plotted for each sample. This PCR demonstrates high TFPI2 expression in 
the lesser invasive cell lines TXT-1 and VCR, although mRNA levels in DLKP-1 and 
DLKP-2 are also high. TFPI2 expression is lowest in the most invasive cell line TXT-
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Figure 3.8.2.3 RT-PCR of TFPI2 mRNA in a separate sample set and Agilent 
samples.
RNA for this analysis was from a separate batch of DLKP variant cultures not 
harvested or processed for Affymetrix array analysis. Also included were three 
samples analysed on the Agilent array platform but which were not investigated 
further. P-actin was used as an endogenous control. The reaction was analysed by GE 
on a 2% agarose gel. Densitometry values were normalised by dividing TFPI2 
intensity values by P-actin intensity values and were displayed graphically for each 
sample. This PCR demonstrates lowest TFPI2 mRNA expression in TXT-2, which is 
the most invasive cell line in the panel studied.
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3.8.3 TFPI2 siRNA transfection in the non-invasive DLKP variants
3.8.3.1 Summary of TFPI2 siRNA expenmental plan
TFPI2 was identified being differentially expressed across the cell lines in our model 
of invasion by array expression analysis Lower TFPI2 expression correlated with a 
greater degree of invasion This correlation was confirmed by RT-PCR though it was 
not as apparent However, it was decided to examine the impact of TFPI2 knockdown 
using a commercial siRNA sequence on the less invasive phenotype Successful 
knockdown was confirmed by PCR and the phenotypic effect assessed by in vitro 
invasion assay Western blot analysis of protein levels indicated that endogenous 
TFPI2 levels were below the level of detection
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3.8.3.2 TFPI2 siRNA specific decrease m mRNA levels
An siRNA sequence to TFPI2 was transfected into the poorly invasive DLKP cell 
lines, TXT-1 and VCR qPCR and semi quantitative RT-PCR was used to examine the 
effect of TFPI2 knockdown on mRNA expression
A commercial TaqMan probe to TFPI2 was used to quantify relative TFPI2 mRNA 
expression The data was normalised using P-actin as an endogenous control (Figure 
3 8 3 1) Knockdown was achieved in VCR, but not to the same extent, at mRNA 
level, in TXT-1
Timecourse analysis of TFPI2 knockdown was examined by RT-PCR (Figures 3 8 3 2 
to 3 8 3 3) P-actin was included as an endogenous control to normalise for RNA 
content in each reaction The PCRs were analysed by gel electrophoresis (GE) on a 2% 
agarose gel and visualised with ethidium bromide staining The band size for TFPI2 
was 183bp cDNA negative control (cDNA neg) consisted of PCR master mix with 
cDNA but without addition of Taq enzyme PCR negative controls consisted of PCR 
master mix to which no cDNA template was added Densitometry values were 
normalised by dividing TFPI2 intensity values by P-actin intensity values and were 
visualised graphically for each sample The gels included in this timecourse study are 
representative of at least two independent repeats These results demonstrate the 
limited value of semi-quantitative RT-PCR timecourse analysis However, it does 
suggest an overall trend from the data that TFPI2 siRNA transfection decreased 
mRNA expression in the VCR cell line but not to any great extent in TXT-1 cell line
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Figure 3.8.3.1 qPCR analysis of TFPI2 siRNA experiment at 24h.
RNA was harvested 24h post-transfection and used to determine a TFPI2-siRNA 
specific decrease in mRNA in response to siRNA transfection. TFPI2 mRNA 
expression was examined by qRT-PCR using a commercial TaqMan probe to TFPI2 
was and normalised for RNA content using P-actin as an endogenous control. This 
graph is a composite of three biological repeats. The data represents TFPI2 expression 
relative to the VCR TFPI2 siRNA sample, which was set to 1 for the analysis and was 
the lowest expresser in the qPCR data set. A TFPI2 siRNA specific decrease in mRNA 
was observed for samples at 24h.
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Figure 3.8.3.2 Timecourse analysis of TFPI2 mRNA knockdown by semi- 
quantitative RT-PCR in TXT-1.
TFPI2 siRNA was transfected into TXT-1. RNA for the analysis of TFPI2 mRNA was 
harvested at 24, 48, 72 and 96h. ß-actin was used to normalise for RNA content in 
each PCR. Densitometrie analysis assigned an arbitrary figure to each band as a 
measure of band intensity. Figures representing the densitometry values graphed above 
were calculated by dividing TFPI2 intensity values by ß-actin intensity values.
TFPI2 mRNA levels were decreased at 24, 72 and 96h respectively, in comparison to 
the non-treated and scrambled siRNA transfected samples.
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Figure 3.8.3.3 Timecourse analysis of TFPI2 mRNA knockdown by semi- 
quantitative RT-PCR in VCR.
TFPI2 siRNA was transfected into VCR. RNA for the analysis of TFPI2 mRNA was 
harvested at 24, 48, 72 and 96h. P-actin was used as an endogenous control to 
normalise for RNA content in each PCR. Figures for the densitometry values were 
normalised by dividing TFPI2 intensity values by P-actin intensity values and were 
plotted for each sample. TFPI2 mRNA levels were decreased at 24, 48, 72 and 96h 
respectively, in comparison to the non-treated and scrambled siRNA transfected 
samples.
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3.8.4 Invasion assay analysis of TFPI2 siRNA transfection
The impact of TFPI2 knockdown on the invasive capacity of the poorly invasive 
DLKP variants was examined Invasion assay analysis was performed 72h post 
transfection, using commercial invasion assay kits containing inserts pre-coated with 
matngel in conjunction with a serum gradient The cells were incubated at 37°C for 24 
hours after which, the underside of the inserts were stained with crystal violet and 
allowed to air dry The inserts were then photographed using 10X magnification Ten 
fields of view were counted per insert at 20X magnification and averaged At least two 
inserts were used for the analysis of each condition The counts per number of inserts 
used were then also averaged and this figure was used to plot graphs of relative 
invasive capacity per cell line per condition
One set of representative photographs was included (Figure 3 8 4 1) in this section 
Invasion assay results are also presented graphically (Figures 3 8 4 2) TFPI2 
knockdown did not impact the invasive capacity of TXT-1 and VCR These results 
suggest that decreasing TFPI2 expression does not induce an invasive phenotype in 
poorly invasive cell lines
251
■  I
I- ■ I I
1  I  
1  1
v , *■ * .-v.’
S*.' * • : •? £'■■■ ’ • ’t
'•» . -v • ;
Tv* • • • *»* - * * * ~ »
- .
j. •..» '• f - '1 «?}.
TXT-1 lOxNotmt TXT-1 lOx Scrm siRNA TXT-1 lOx TFPI2 siRNA
H I
VCR lOx No tint VCRlOx Scrm siRNA VCR lOx TFPI2 siRNA
Figure 3.8.4.1 Photographic representation of invasion assay results 72h post 
TFPI2 siRNA transfection.
The invasion assay was performed 72h post-transfection. Untransfected- and 
scrambled siRNA transfected- cell lines are the controls for this experiment. 
Representative photographs at 10X are shown above. No obvious effect on invasion 
was observed in TFPI2 siRNA transfected cells compared with the scrambled siRNA 
transfected and non-treated cells. This indicates that decreased TFPI2 expression is 
itself insufficient to induce an invasive phenotype in mildly invasive cells.
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Figure 3.8.4.2 Graphic representation of invasion assay results 72h post TFPI2 
siRNA transfection.
The invasion assay was performed 72h post-transfection. Scrambled siRNA 
transfected- cell lines were the controls for this experiment. Counts per insert were 
averaged and plotted as percentage invasion normalised to the scrambled siRNA for 
each cell line. Invasion was increased in TFPI2 siRNA transfected VCR cells 
compared with the scrambled siRNA control (P<0.005). However, no effect on 
invasion was observed in TFPI2 siRNA transfected TXT-1 cells compared with the 
scrambled siRNA transfected control cells. These data indicate that decreased TFPI2 
expression is itself insufficient to induce a highly invasive phenotype in mildly 
invasive cells.
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3.8.5 TFPI2 cDNA transfection in the invasive DLKP vanants
3.8.5.1 Summary of TFPI2 cDNA expenmental plan
Array and RT-PCR results indicated that TFPI2 mRNA expression was increased in
■o
the poorly invasive compared with the invasive DLKP lines To investigate the effect 
of overexpression of exogenous TFPI2 on the invasive status of the cells we transiently 
transfected the vector pSport6 containing the cDNA sequence to TFPI2 into the 
invasive cell lines DLKP-1, DLKP-2 and TXT-2 Transient transfection of this vector 
into the invasive cell lines increased TFPI2 protein expression as determined by 
western blotting Exogenous overexpression of TFPI2 dramatically decreased the 
invasive capacities of the invasive DLKP variants
3.8.5.2 Western Blot analysis of TFPI2 cDNA transient transfection
An increase in TFPI2 protein expression in response to TFPI2 cDNA transfection was 
determined by western blotting Cells were transfected with a pSport6 empty vector as 
a control to ensure that the transfection process did not affect TFPI2 protein expression 
(Figures 3 8 5 1 to 3 8 5 3) Each blot in this section is representative of at least two 
independent repeats
The polyclonal anti-TFPI2 antibody used in these experiments was a gift from Prof 
Walt Kisiel and was raised in rabbit The bands specific for TFPI2 are a triplet of 33, 
31 and 27kDa respectively A a-tubulin antibody was used to demonstrate even 
loading between the samples TFPI2 protein expression was increased in response to 
TFPI2 cDNA transient transfection in both TXT-1 and VCR
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Figure 3.8.5.1 Western blot analysis of TFPI2 cDNA transient transfection in 
DLKP-1.
The polyclonal anti-TFPI2 antibody used in this experiment was a gift from Prof Walt 
Kisiel and was raised in rabbit. The bands specific for TFPI2 are a triplet of 33, 31 and 
27kDa respectively. TFPI-2 protein expression is increased in response to TFPI-2 
cDNA transfection over 72h in DLKP-1.
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Figure 3.8.5.2 Western blot analysis of TFPI2 cDNA transient transfection in 
DLKP-2.
TFPI-2 protein expression is increased in DLKP-2 in response to TFPI-2 cDNA 
transfection over 72h.
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Figure 3.8.5.3 Western blot analysis of TFPI2 cDNA transient transfection in 
TXT-2.
TFPI-2 protein expression is increased in response to TFPI-2 cDNA transfection over 
72h in TXT-2.
257
The effect of increasing TFPI2 expression on proliferation was investigated. Cells 
seeded at 4 x 105 cells/well of a 6-well plate (Figure 3.8.5.4), which was the cell 
number used to seed all the cDNA transfections in six-well plates. Relative cell 
number was determined using the acid phosphatase assay at 72h post transfection. Cell 
numbers were measured to determine what functional effect, if any, an increase in 
TFPI2 expression was having on proliferation.
Exogenously TFPI2 expression did not have a dramatic affect proliferation compared 
with pSport6 empty vector -transfected and non-treated cells.
3.8.5.3 Investigation of effect of TFPI-2 cDNA transient transfection
on proliferation.
Effect of TFPI-2 transient transfection on proliferation
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Figure 3.8.5.4 Effect of TFPI2 cDNA transfection on DLKP variant cell number.
The cells were seeded at a 4 x 105 cells/well of a 6-well plate. Proliferation was 
measured by the acid phosphatase assay at 72h post transfection. There is a decrease in 
proliferation observed due to the transfection. TFPI2 cDNA transfection does not 
appear to affect proliferation in the cell lines compared with the empty vector-pSport6 
and non-transfected cells.
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The effect of exogenously increasing TFPI2 expression on the invasive abilities of the 
invasive DLKP variants was investigated Invasion assay analysis was performed 72h 
post transfection, using commercial invasion assay kits containing inserts pre-coated 
with matrigel in conjunction with a serum gradient The cells were incubated at 37°C 
for 24h after which, the underside of the inserts were stained with crystal violet and 
allowed to air dry The inserts were then photographed using 10X magnification Ten 
fields of view were counted per insert at 20X magnification and averaged At least two 
inserts were used for the analysis of each condition The counts per number of inserts 
used were then also averaged and this figure was used to generate graphs of relative 
invasive capacity per cell line per condition
One set of representative photographs was included (Figure 3 8 5 5) in this section and 
clearly demonstrate decreased invasion in TFPI2 cDNA transfected cells Invasion 
assay results are also presented graphically (Figures 3 8 5 6 and 3 8 5 7)
3.8.5.4 Evaluation of effect of TFPI2 cDNA transient transfection on
DLKP variant invasion
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TXT-2 lOx No tint TXT-2 lOx pSport6 cDNA TXT-2 lOx TFPI2 cDNA
Figure 3.8.5.5 Photographic representation of invasion assay results 72h post 
TFPI2 cDNA transient transfection (I).
The invasion assay was performed 72h post-transfection. Untransfected- and empty 
vector pSport6 transfected- cell lines are the controls for this experiment. 
Representative photographs at 1 OX are shown above. Invasion was decreased in TFPI2 
cDNA transfected cells compared with the empty vector and non-treated cells.
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Figure 3.8.5.6 Graphic representation of invasion assay results 72h post TFPI2 
cDNA transient transfection (I).
The invasion assay was performed 72h post-transfection. pSport6 empty vector 
transfected- cell lines were the controls for this experiment. Counts per insert were 
averaged and plotted as percentage invasion normalised to the empty vector transfected 
cells for each cell line. Invasion was decreased in TFPI2 cDNA transfected cells 
compared with the pSport6 empty vector control transfected cells (P<0.001). A 
decrease of 50% or greater was observed in invasion in TFPI2 cDNA transfected 
samples compared with the empty vector controls.
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Figure 3.8.5.7 Graphic representation of invasion assay results 72h post TFPI2 
cDNA transient transfection (II).
The invasion assay was performed 72h post-transfection. pSport6 empty vector 
transfected- cell lines were the controls for this experiment. Counts per insert were 
averaged and plotted as percentage invasion normalised to the empty vector transfected 
cells for each cell line. Invasion was decreased in TFPI2 cDNA transfected cells 
compared with the pSport6 empty vector control transfected cells (P<0.001).
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3.9 PCR analysis of cDNA transient transfections
Exogenous cDNA transfections were part of the functional investigations of the role of 
many of the targets in this study including KCNJ8, S100A13, SFN and TFPI2 The 
results in this section give an example of some of the challenges met when analysing 
the mRNA of cDNA transfected samples by RT-PCR
RNA was harvested at 24, 48, 72 and 96h post cDNA transfection for each of the 
targets mentioned above and used to determine a target specific increase in mRNA in 
response to the cDNA transfection by PCR Initial PCR analysis did not have a band 
for P-actin (endogenous control) in target cDNA transfected samples at any of the 
timepoints (Figure 3 9 1) this may possibly be attributed to competition for PCR 
components in the master mix The result of this missing band for the endogenous 
control was that one could not definitively conclude that the increase in target band 
density was as a result of increased target expression and was possibly caused by 
cDNA carryover in the RT reaction
To investigate the possibility of cDNA carryover affecting the RT reaction and 
consequently the PCR results, RT negative controls for the empty vector transfected 
and target cDNA transfected samples were included in the analysis RT negative 
controls consisted of RNA, RT master mix but without the addition of MMLV 
enzyme This identified cDNA carryover in the cDNA transfected samples This 
cDNA carryover needed to be removed if an accurate increase in target mRNA due to 
transfection of target cDNA was to be measured
To eliminate the cDNA carryover in the cDNA transfected samples we digested the 
cDNA in the RNA samples using Qiagen RNAse free DNAsel (Figures 3 9 2 and 
3 9 3) This digestion eliminated the cDNA carryover from the RT reaction However, 
it also degraded the RNA in the process (Figure 3 9 4)
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Figure 3 9 1 Tunecourse analysis by semi-quantitative RT-PCR using S100A13 
cDNA transient transfection in TXT-1 as an example.
S100A13 cDNA was transiently transfected into TXT-1 RNA for the analysis of 
S100A13 mRNA was harvested at 24, 48, 72 and 96h post transfection Negative RT 
controls, which consisted of mRNA, RT master mix, but no MMLV, were included in 
the PCR analysis of this transfection This showed that there was cDNA carryover 
from the transfection process biasing the results of the RT-PCR This cDNA carryover 
needed to be removed if an accurate increase in S100A13 mRNA due to transfection of 
S100A13 cDNA was to be measured
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S100A13
Figure 3 9 2 DNAse I digestion of pSportó empty vector and S100A13 cDNA 
transfected samples
2|ig of pSportó empty vector and S100A13 cDNA transfected RNA samples were 
subject to Qiagen RNAse free DNAse I digestion using 2U RNAse free DNAse I per 
juig RNA at 37°C for 30mms These samples, including RT negative controls, were then 
analysed by RT-PCR PCR analysis revealed that cDNA carryover in the RT reaction 
was eliminated following this procedure since RT negative controls showed no bands 
specific to S100A13
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Figure 3.9 3 DNAse I digestion of ail samples from the S100A13 cDNA transient 
transfection
S100A13 cDNA was transiently transfected into TXT-1 RNA for the analysis of 
S100A13 mRNA was harvested at 24, 48, 72 and 96h 2[ig of pSport6 empty vector 
and S100A13 cDNA transfected RNA samples were subject to Qiagen RNAse free 
>DNAse I digestion using 2U RNAse free DNAse I per fig RNA at 37°C for 30mins 
PCR analysis revealed that cDNA carryover in the RT reaction was eliminated 
following this procedure since RT negative controls showed no bands specific to 
S100A13 However, while a strong band was obtained for the S100A13 transfected 
samples at 24, 48, 72 and 96h samples, no other band for S100A13 or p-actin was 
obtained
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Figure 3.9.4 Analysis of RNA pre- and post- DNAse I digestion using the Agilent 
Bioanalyser.
2|ig of various cDNA transfected RNA samples were subject to Qiagen RNAse free 
DNAse I digestion using 2U RNAse free DNAse I per jag RNA at 37°C for 30mins. A 
sample of this RNA was also used for the analysis of RNA integrity pre-DNAse I 
digestion. The Bioanalyser analysis of the RNA pre- and post- DNAse I digestion 
revealed that RNA was degraded post digestion in all samples irrespective of the 
cDNA used in the transfection. This explains why RT-PCR analysis post DNAse I 
digestion was unsuccessful.
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Section 4.0: Discussion
The work described in this thesis was undertaken to increase our understanding of the
molecular nature of invasion in human lung cancer cell lines using the following
approaches
1 The gene-expression profiles of five human lung cancer cell lines with different 
invasive capacities (as determined by an in vitro invasion assay) were analysed 
using expression microarray methodology Two invasive, parental DLKP cell 
lines (DLKP-1 and DLKP-2) were used along with an invasive Taxotere (TXT) 
resistant DLKP variant (TXT-2) and a poorly invasive TXT selected DLKP 
cell line that had lost its resistance to TXT (TXT-1) A Vincristine (VCR) 
resistant DLKP cell line that was less or non-invasive was included in the 
analysis This provided us with a cell model to study in vitro invasion
2 Bioinformatic analysis was performed on the raw microarray data that 
generated lists containing genes that potentially serve as a transcriptional 
signature for invasiveness in these cell lines
3 An RT-PCR validation study was employed to confirm that the array results 
were a true reflection of gene expression in the cell lines studied
4 The invasive abilities of each of the cell lines studied were validated by an in 
vitro invasion analysis of the cell lines over ten passages and using different 
invasion assay kit lot numbers To further validate the invasion assay results 
RT-PCR was used to confirm that there was consistent differential gene 
expression between the invasive and non-invasive cell lines for the test genes 
over those ten passages
5 siRNA technology was utilised to investigate the functional role of chosen 
genes from the microarray analysis
6 cDNA transient transfection was also employed to investigate the functional 
role of the microarray gene targets in the invasive phenotype
These results are discussed here in the context of previously published reports
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4.1 Microarray analysis of DLKP and its invasive and 
chemotherapeutic resistant variants
A major obstacle in the use of chemotherapy for cancer treatment is the development 
of resistance Consequently, a better understanding of the mechanisms of drug 
resistance would help to overcome this obstacle Intrinsic and acquired drug resistance 
are believed to cause treatment failure in over 90% of patients with metastatic cancer 
(Longley & Johnston, 2005) Some tumours are initially sensitive to an anticancer 
agent and, over time, develop a resistance to it and this is referred to as acquired 
resistance Whereas, other tumours are resistant before treatment and this is known as 
intrinsic resistance One of the major factors leading to drug resistance is decreased 
drug accumulation This is caused by decreased drug influx or enhanced drug efflux, 
both of which result in the chemotherapeutic agent not exerting its effect on the 
tumour Drug resistance can also be caused by modified drug activation, drug 
inactivation, alterations m DNA repair mechanisms and altered response to apoptosis 
Treatment with one agent can often lead to associate resistance to a number of 
unrelated agents The development of resistance to a variety of unrelated 
chemotherapeutic drugs is called multiple drug resistance (MDR) MDR is caused by a 
variety of changes m the cancer cells and is almost always multifactonal
Metastasis is the spread of cancer from a primary tumour to distant sites in the body A 
distinguishing feature of malignant cells is their capacity to invade surrounding normal 
tissues and metastasise through the blood and lymphatic systems to distant organs 
This process of metastasis is the most devastating aspect of cancer Current therapies 
fail to eradicate metastasis for three major reasons Firstly, when initially diagnosed, 
most tumours are well advanced and metastasis has already occurred Secondly, 
specific organ environment can modify the response of a metastatic tumour cell to 
systemic therapy and alter the efficiency of anticancer agents The third reason and the 
greatest obstacle to the success of therapy, is the heterogeneous composition of 
tumours, where highly metastatic cells can escape from the effect of therapeutic 
agents Invading tumour cells appear to have lost the control mechanisms that which 
prevents normal cells from invading neighbouring tissue at inappropriate times and 
places Thus, the fundamental difference between normal and malignant cells is
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regulation The difference must he in the proteins that start, stop or maintain the 
invasion programme at times and places that are inappropriate for non-malignant cells 
A major goal is to understand what signals and signal transduction pathways are 
perpetually activated or deregulated in malignant invasion (Kohn and Liotta, 1997)
Multidrug resistant (MDR) cells can survive chemotherapy and migrate to distant sites 
in the body, highly metastatic cells can evade the chemotherapeutic effect altogether 
Cillo et a l , (1987) demonstrated that some invasive/metastatic cells develop drug 
resistance more readily than their non-invasive counterparts In 1994, Lucke-Huhle 
also found that some chemotherapeutic drug resistant cell lines were more invasive 
relative to non-resistant cells Previously, studies of drug resistance and invasion 
proceeded along separate research pathways, however a better understanding of the 
relationship between chemotherapeutic drug resistance and invasion in cancer could 
led to a more effective treatment for the disease (Liang et a l , 2002)
Array technology can help answer increasingly complex questions and allow for more 
intricate experiments to be performed It can be used, to infer probable functions of 
new genes based on similarities in expression patterns with those of known genes, to 
aid understanding of how genes coordinate and mter-relate, and to speed the 
identification of genes involved in the development of various diseases Expression 
arrays can also aid the examination of the integration of gene expression and function 
at the cellular level, revealing how multiple gene products work together to produce 
physical and chemical responses to both static and changing cellular needs
In a study by Ramaswamy et a l , (2003) microarrays were utilised to identify a gene 
signature that would differentiate between various primary and metastatic 
adenocarcinomas This group reported a metastasis-associated gene signature that 
contained eight up regulated and nine down-regulated genes None of these acted as 
individual metastasis markers in their own right, rather the signature as a whole was of 
value in predicting metastatic spread in patients with primary tumours The predictive 
value of this signature suggests that the clinical behaviour of solid tumours is, at the 
very least, partly determined by the intrinsic biological behaviour of the tumour cells 
and not simply by sensitivity to cancer therapies Many different tumour types shared 
the metastatic signature identified in the study, which suggests the possibility that 
therapeutic targets could be developed that may be useful in different cancer types
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A study to identify genes involved in chemo-resistance in gastric cancers was 
conducted by Suganuma et al (2003) This group compared gene expression and drug 
resistance patterns in gastric cancer surgical specimen and, although they identified 
several resistance related candidate genes, they concluded that the mechanisms of 
resistance to chemotherapeutic agent are very complex In 2005, Rickardson et al 
compared the gene expression patterns of ten human tumour cell lines, including 
parental cells and resistant subtypes using cDNA microarray technology The resistant 
cells were selected for resistance to the cytotoxic effects of doxorubicin, teniposide, 
melphalan and vincristine The drug activity of 66 cancer agents was determined in the 
cell lines and facilitated the calculation and ranking of correlations between drug 
activity and gene expression The group found that a number of apoptosis related genes 
including mitogen-activated protein kinase I (MAPK1) and focal adhesion kinase 
(FAK) were associated with drug resistance, while signal transducer of activator of 
transcription 5 A (STAT 5 A) was associated with general drug sensitivity
Orian-Rousseau et a l , (2005) used suppression subtractive hybridisation to identify 
genes differentially expressed between the metastatic human colon cancer cell line 
HT29p and its non-metastatic counterpart HT29-MTX This led to the identification of 
fifty-eight genes with increased expression in the invasive cell line compared with the 
non-invasive line The majority of those genes had not been previously linked to the 
metastatic process While the study of clinical tumour samples using array 
methodology is useful to elucidate the mechanisms involved in tumour development, 
they can also generate data that is difficult to interpret This may be due to the complex 
nature of and the environmental impact on the samples for example, the age of the 
patient, smoker or non-smoker, effect of poor diet and so on The advantage of 
studying cancer progression using cell line models is that the samples can be cultured 
and processed using the same conditions, thereby eliminating any additional 
environmental impact on their gene expression, with the result that the transcriptional 
profile should reflect cancer development only
Therapeutic treatment of metastatic disease will need the development of biology- 
based approaches that will utilise the novel information on the molecular biology 
underlying metastasis to identify molecular targets that can interfere with expression
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and thereby function (Brodt et al, 2000) Comparing the gene expression profiles of 
five lung cancer cell lines with different in vitro invasive abilities using DNA array 
methodology was the strategy employed to achieve this goal Two invasive parental 
DLKP cell lines (DLKP-1 and DLKP-2), an invasive Taxotere (TXT) resistant DLKP 
variant (TXT-2), a poorly invasive TXT selected DLKP cell line that had lost it’s 
resistance to TXT (TXT-1) and a mildly invasive vincristine selected DLKP cell line 
(VCR) were used as a lung cancer cell model in this study The aim of this expression 
array analysis was to identify genes involved in the development of an invasive 
phenotype in lung cancer cell lines These cell lines with different invasive capacities 
(but from the same origin) offered a unique opportunity to study the less-well 
characterised mechanisms of invasion An important point to remember when 
considering this analysis is that there are potentially two ways to approach this data in 
that one could look at drug resistance and invasion In this study, the main focus was to 
analyse differences between the invasive and poorly invasive cell lines Theoretically 
however, any differentially expressed genes identified by the microarray analysis could 
relate to drug resistance and invasion
274
4.1.1 Genomatix analysis
The Genomatix analysis used in this study generated (Section 3 13) two promoter 
models each containing 5 elements involving three genes, VEGF, FSTL1 and FN1 
(Figures 3 1 9 and 3 1 10) Genomatix would suggest that genes with the same 
promoter models are potentially co-regulated To determine if these genes were in fact 
co-regulated, RT-PCR analysis was used to investigate VEGF, FSTL1 and FN1 
mRNA expression in our DLKP cell model (Appendices) The RT-PCR results did not 
demonstrate differential expression of these genes with invasion thus were not subject 
to further investigation
Although the promoter models in Figures 3 1 9 and 3 110 generated from Genomatix 
analysis did not identify co-regulated genes as suggested by RT-PCR results, a second 
vincristine-related analysis demonstrated the potential power of the software as a tool 
for data analysis This work is not presented in the Results section as it is not focused 
on invasion but it does demonstrate the potential of this analytical approach In this 
case the array data was mined to generate a vincristine related genelist by comparing 
the expression of DLKP-1, DLKP-2, TXT-1 and TXT-2 with VCR in the GeneSpnng 
software This generated a list of genes that theoretically related to vincristine 
resistance/treatment only
The vincristine-related gene list divided was into the various Gene Ontology (GO) 
categories and weightings were assigned by the BiblioSphere software according to the 
over-, under-representation of genes in a given category (z-score) compared to what 
would be expected randomly This gave some indication of the pathways, processes, 
cellular functions, etc being affected in VCR resistant cells One category, Structural 
Molecule Activity received a high z-score and this group of genes was chosen for more 
detailed analysis
The promoter sequences upstream of the genes were extracted from the El Dorado 
database hosted by Genomatix and analysed for the presence of common transcription 
factor (TF) binding sites Potential promoter modules (two or more TF binding sites 
with defined spatial relationships) common to several of the input promoter sequences
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were generated Two of these modules were found to contain three common TF 
binding sites As a measure of the specificity of the models and to identify other genes 
potentially regulated by these promoter modules, the entire human genome was 
searched for all occurrences of the models One model was detected in the promoter 
sequences of several hundred other genes These genes were grouped according to GO 
as before and the category with the highest z-score (>10) turned out to be genes 
associated with Sensory Perception of Taste or Smell Though this did not initially 
appear to be of any significance, further investigation revealed that loss of sense of 
taste and smell is a well-documented physiological side effect experienced by patients 
undergoing a vincristine treatment regimen As a further piece of corroborating 
evidence, the structural proteins identified in this analysis and in the microarray 
analysis are normally expressed in a tissue-specific manner - this usually indicates a 
co-regulatory mechanism In particular, it was interesting to note that a subgroup is 
expressed in the olfactory bulb of the brain, a region involved in smell/taste perception 
These findings provide multiple independent lines of evidence to support the 
probability of having identified a biologically relevant promoter module in this system
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4.2 Confirmation of array results by RT-PCR
Microarray data is quite accurate in terms of quantifying changes in mRNA 
abundance, however we felt it was important to confirm the trends observed, in a small 
panel of target genes, by an alternative quantification method To this end a panel of 
genes were selected for RT-PCR analysis to validate the differential expression 
identified by array analysis by RT-PCR This gave greater confidence in the 
significance of gene lists generated from array data mining and also functioned as a 
validation step before particular target genes were chosen for further investigation
Twenty-eight genes were selected, based on information in the literature and on 
intuitive functions for a given gene, for RT-PCR analysis across the five DLKP cell 
lines Tables 3 2 1 and 3 2 2, list the genes subject to RT-PCR analysis in the five cell 
lines comprising our cell model and give a summary of the PCR results The actual 
gels representing each PCR are available for examination in the Appendices
The ideal situation would be for the PCR results to reflect the array data for each gene 
both exactly and consistently However, this was not always the case For many genes, 
eg  AKAP11 and NRG1 there were no significant expression differences across the 
panel of cell lines It was less clear-cut for other genes e g TFPI-2 (Section 3 8 2) In 
this case the RT-PCR results, using various RNA samples as templates, did not always 
tally The limitation of semi-quantitative RT-PCR must be considered here Thirty and 
in some cases 35 cycles were used m the RT-PCR analysis so it is possible that the 
linear phase of target amplification was passed by the end of the last cycle In this 
'plateau’ phase subtle differences become compressed - reflected in the intensities of 
the bands when analysed by gel electrophoresis and ethidium bromide staining
The confirmatory RT-PCR analysis for IGF-1R (Section 3 4 2) correlated more closely 
with the array data, which demonstrated that IGF-1R expression was increased in the 
more invasive cell lines compared with the mildly invasive cell lines
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Subtle changes at mRNA level are more accurately detected by quantitative real time 
PCR (qPCR) This advantage of this technology was apparent when one compared the 
results of the siRNA timecourse experiments by RT-PCR and qPCR In this case RT- 
PCR gels displayed bands with little variation in target intensity, however knockdown 
was measured more sensitively and was more apparent in the qPCR results Thus gene 
expression should be measured using qPCR where possible Where more than one RT- 
PCR result for the various RNA samples matched the array data trend it was 
considered for future analysis as a target
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4.3 Validation of invasion status of the DLKP cell lines used in 
this study
In order to establish defined conditions for the study of invasion using the DLKP cell 
model, fresh cell line stocks were thawed and analysed by in vitro invasion assays with 
increasing passage number to determine if cell characteristics were changing over time 
(Section 3 3 1) Commercial invasion assay kits were used throughout this study In 
order to verify that that batch-to-batch variation was negligible between the 
commercial kits, cells with the same passage number and from the same cell 
suspension were applied to two different kits with different batch and lot numbers 
(Figure 3 3 12) The degrees of invasion for each of the DLKP variants were 
consistent between invasion assay kit batches
The relative invasiveness of the sub-lines compared to each other remained constant 
over ten passages and this was the time frame used for all invasion analysis This 
confirmed that the panel of DLKP cell lines described in this thesis represent robust, 
valuable models for the study of mechanisms of in vitro invasion
Also, the invasion assay itself was optimised and performed using defined culture 
conditions The inserts were placed in medium containing 5% serum Cell suspensions 
were prepared in medium containing 1% serum and lOOpil of a lx l06 cells/ml 
suspension was added to each insert This provided serum gradient in the assay The 
cells were incubated at 37°C for 24 hours After this time, the underside of the insert 
stained with crystal violet and allowed to air dry The definition of these assay 
protocols and culture boundaries gave confidence in the phenotypic changes observed 
following the deliberate manipulations of target molecules The overall trend for the 
DLKP cell lines is as follows, starting from the most to least invasive, TXT-2 > 
DLKP-1 > DLKP-2 > TXT-1 > VCR
The invasion assay validation studies also demonstrate that DLKP remains invasive 
over ten passages, which was the window in which subsequent studies involving 
selected array targets were performed
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To confirm that the differential invasive capacities of DLKP were matched with 
differential gene expression correlating with invasion, twelve genes that were 
differentially expressed in the invasive and less invasive cell lines were picked for 
analysis by RT-PCR These included genes with a known role in invasion such as 
ICAM1, IGF-1R, EFNB2, VEGF-C, FN1, MMP3 and TFPI2 Genes whose expression 
pattern correlated with invasion status but that had unreported roles in invasion, 
including KCNJ8 and FSTL1, were also analysed The SFN gene that has been both 
positively and negatively correlated with an invasive phenotype previously (Umbncht 
et a l , 2001, Ide et a l , 2004) was also investigated along with the transcription factors 
TCF4 and TLX1 The genes tabulated in 3 3 1 are those whose mRNA expression 
across the five DLKP cell lines correlated with invasion assay results with increasing 
passage number EFNB2 was the only exception and was not selected for further study 
in any case These results indicated reproducible correlation with the invasion assay 
results from the cell line validation study and highlight repeatable results over ten 
passages for the cell lines They also confirmed the suitability of the cell lines, in 
conjunction with the optimised invasion assay, as a model system suitable for use in 
subsequent investigations into the molecular mechanisms of invasion
}
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4.4 Selection of Target genes for functional analysis
The results and discussion to this point demonstrate that the microarray comparison of 
the DLKP cell line variants is a suitable approach for the identification of genes 
involved in invasion However, the challenge was that there are thousands of genes 
differentially expressed between the cell lines It was only feasible to work with a 
small number of genes at a given time The stringent filtering criteria used to narrow 
down genelists to a manageable number inevitably meant discarding of potentially 
interesting genes
Based on the compiled genelists, and taking into account the results from the RT-PCR 
validation study, in addition to an extensive literature search, five genes were selected 
for further functional investigation in the context of our invasion model These were, 
IGF-1R, KCNJ8, S100A13, SFN and TFPI2 Little is known about KCNJ8 and 
S100A13, particularly in relation to cancer and the development of an invasive 
phenotype It was decided to investigate IGF-1R, KCNJ8, S100A13, SFN and TFPI2 
as initial, high priority targets - which were considered a manageable number of 
experiments in the laboratory
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4 4 1 Experimental design for functional analysis of array targets
To study the individual role of IGF-1R, KCNJ8, S100A13, SFN and TFPI-2 in 
invasion in our cell model the following experimental plan was designed and is 
summarised in the table below
Table 4 11 Summary of experimental design to determine functional effect of 
array target genes in invasion in our cell model
Gene IGF-1R KCNJ8 TFPI2 S100A13 SFN
Cell lines used 
for siRNA 
transfection
DLKP-l 
DLKP-2 
TXT-1 
TXT-2 
VCR
DLKP-l
DLKP-2
TXT-2
TXT-1
VCR
DLKP-l
DLKP-2
TXT-2
DLKP-l
DLKP-2
TXT-2
Cell lines used 
for cDNA 
transfection
Sequence
unavailable
TXT-1
VCR
DLKP-l
DLKP-2
TXT-2
TXT-1
VCR
TXT-1
VCR
PCR
confirmation
of
increased/decr
eased
expression
Y, by qRT- 
PCR
Y, RT-PCR & 
qRT-PCR for 
siRNA analysis
Y, RT-PCR & 
qRT-PCR
Y, RT-PCR & 
qRT-PCR for 
siRNA analysis
Y, RT-PCR & 
qRT-PCR for 
siRNA analysis
Confirmation 
by western
Yes Western for over- 
expression study
Western for
over-expression
study
Western for
over-expression
study
Western for
over-expression
study
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The functional effect of the above manipulations of target genes on invasion are 
summarised in the table below (4 1 2)
Table 4 12 Summary of functional effect of manipulation of array target genes 
on invasion, as determined by in vitro invasion assay, in our cell model
Gene IGF-1R KCNJ8 TFPI2 S100A13 SFN
Effect of 
siRNA
transfection on 
Invasion (72hr)
Invasion was 
decreased in 
IGF-1R 
siRNA 
transfected 
cell lines 
(P<0 001)
Contrary to
expectation,
KCNJ8
knockdown
increased
invasion
compared to
controls*
(P<0 001)
No effect of 
TFPI2
knockdown on 
non-mvasive cell 
lines
S100A13 
knockdown 
decreased 
mvasion in all 
cell lmes 
(P<0 001)
SFN knockdown 
mcreased 
invasion 
compared to 
controls*
(P<0 001)
Effect of cDNA 
transfection on 
Invasion (72hr)
No effect on 
invasion was 
observed
Invasion was 
decreased 
compared to 
controls 
(POOOl)
No effect on 
mvasion was 
observed
No effect on 
mvasion was 
observed
• * siRNA controls Non-treated cells anc scrambled siRIs A transfected ce Is
• *cDNA controls Non-treated cells and pSport6 empty vector transfected cells
• ^Invasion assay controls RPMI-Mel and RPMT parent
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4.5 Insulin-like growth factor-1 receptor (IGF-1R)
The IGF-1R is a receptor tyrosine kinase (RTK) that plays a critical role in signalling 
cell survival, regulation of the cell cycle, transformation, proliferation, motility and 
invasion This heterotetrameric receptor is comprised of two 130-135kDa a- and two 
90-95kDa (3-chains, linked with many homo- and hetro-disulfide bridges IGF-1R 
ligands include IGF-1, IGF-2 and insulin, but the receptor binds to IGF-1 with the 
highest affinity (Brodt et a l , 2000) Regulation of IGF-1R gene expression is closely 
associated with the function of a variety of tumour suppressor genes and oncogenes
IGF-1R was identified as a gene potentially involved in invasion in this microarray 
study The data indicated that IGF-1R expression was increased in the more invasive 
cell lines compared with the mildly invasive cell lines The aims of the experiments, 
the results of which are detailed in section 3 4, were as follows
1 To confirm by PCR that IGF-1R is differentially expressed between the 
DLKP cell lines
2 To quantify endogenous IGF-1R levels in the cell model by qRT-PCR and 
western blot
3 To knockdown IGF-1R expression by transfecting a validated gene specific 
siRNA using optimised transfection conditions
4 To measure transfection efficiency of the siRNA using 
immunofluorescence
5 To demonstrate IGF-lR-specific siRNA knockdown at mRNA and protein 
level
6 To evaluate the effect of decreased IGF-1R knockdown on proliferation
7 To evaluate the effect of decreased IGF-1R knockdown on invasion
8 To compare the effect of treatment using an IGF-1R blocking antibody 
aIR3 on invasion, with the effect of IGF-1R siRNA knockdown on 
invasion
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The array profile indicated that IGF-1R expression was increased in the more invasive 
cell lines than the lesser invasive cell lines This agrees with a study by Jiang et a l , 
(2004) who reported that strong IGF-IR expression in primary tumours correlated with 
an increased incidence of metastasis The array data was confirmed using RT-PCR, 
qRT-PCR and western blot to investigate endogenous IGF-IR levels in the five DLKP 
variant cell lines (Sections 3 4 2 and 3 4 3) The RT-PCR validation of the array data 
did serve to demonstrate the predicted differential IGF-1R mRNA expression between 
the DLKP variants (Figures 3 4 2 1 and 3 4 2 2) However, there were incidences 
where the PCR trend differed slightly from the array prediction (Figure 3 4 2 3) and is 
most likely due to the semi-quantitative nature of the RT-PCR analysis, but in any case 
the least invasive cell line VCR consistently displayed lowest mRNA levels qPCR 
provided a more accurate measure of IGF-1R mRNA expression
Endogenous IGF-1R mRNA expression across the DLKP cell model was determined 
by qRT-PCR using a commercial TaqMan IGF-IR probe and normalised using P-actin 
(Figure 3 4 3 1) Expression levels were compared relative to DLKP-1, which was set 
to 1 for the analysis This result, for the most part, correlates with the array results and 
demonstrated differential IGF-IR expression, with higher expression associated with 
the invasive cell lines, DLKP-2 and TXT-2 and lower expression in the mildly 
invasive cell line VCR DLKP-1 and TXT-1, unexpectedly, have similar IGF-IR 
mRNA levels despite DLKP-1 being more invasive than TXT-1 There was no 
detectable IGF-IR mRNA in the VCR cell line
Endogenous IGF-IR protein expression was determined by western blot (figure 
3 4 3 2) a-tubulin and GAPDH antibodies were used to demonstrate even loading 
between the samples This result correlated with the qPCR results, and demonstrated 
differential IGF-IR expression, with higher expression in the invasive cell lines, 
DLKP-2 and TXT-2 and lower expression in the poorly invasive cell line VCR 
DLKP-1 and TXT-1, unexpectedly, have similar IGF-IR protein levels despite DLKP- 
1 being more invasive than TXT-1 To address this, one could speculate that although 
the IGF-IR may be present in both cell lines, that differences in the signalling
4.5.1 Endogenous IGF-1R expression m the DLKP variants
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pathways activated may be responsible for either the presence or absence of invasive 
ability. This has previously been shown by Zhang et al (2004) where MMP-2 (crucial 
in invasion) synthesis was regulated via PI 3-kinase/Akt/mTOR while the Raf/ERK 
pathway resulted in negative regulatory signals. Indeed the sub-cellular location and 
phosphorylation status of the IGF-1R can also impact on receptor function (Dupont 
and Le Roith, 2001), and the measurement of IGF-1R expression levels in these cell 
lines may not give the complete picture. A further point for discussion is the absence 
of detectable IGF-1R mRNA or protein in the VCR cell line, despite the parental cell 
line expressing the protein endogenously. This suggests that treatment of DLKP with 
Vincristine decreases endogenous IGF-1R expression or that cells that do not express 
IGF-1R are being selected by the treatment. This may have potential effects on cell 
motility, for example. It would be interesting to re-pulse a parental DLKP cell line 
with Vincristine and try to identify the point/points at which the drug affects IGF-1R 
levels and by which mechanism this occurs.
4.5.2 siRNA Transfection Optimisation for the DLKP variants
There were a number of different parameters that had to be determined to establish an 
optimised protocol for the siRNA transfection of DLKP and its variants. Initially, only 
the transfection protocol itself was considered. 2\i\ of NeoFx transfection reagent per 
well of a 6-well plate was used to transfect 30nM of target siRNA into the cells. The 
siRNA used for IGF-1R targeting was a commercial validated sequence from Ambion, 
which they guarantee to decrease IGF-1R expression. This was important since Bohula 
et al., (2003) demonstrated that the efficiency of siRNA’s to IGF-1R is influenced by 
secondary structure in the IGF-1R transcript, where poor IGF-1R knockdown was 
associated with poor accessibility of the siRNA to the IGF-1R transcript.
A protocol was also optimised for the analysis of a target siRNA specific effect on 
invasion. The invasion assays were initially performed 48h post-siRNA transfection 
(Figure 3.4.4.1). Non treated and scrambled siRNA transfected cell lines were the 
controls for these experiments. While a specific decrease in invasion can be attributed 
to the IGF-1R siRNA for DLKP-1, there was no related decrease in invasion in the
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other four samples Also, there was a considerable non-specific effect on invasion in 
the scrambled siRNA treated cells compared with the non-treated cells One assumed 
that this was due to the transfection process and not the scrambled siRNA, since the 
scrambled siRNA was one of only three sequences that Ambion sells as a transfection 
control as they do not target any RNA sequence
It was decided that allowing the cells to recover from the transfection for as long as 
possible before invasion analysis, could minimise the non-specific transfection effect 
on invasion To this end invasion assays were performed 48 and 72 hours post- 
transfection on the invasive cell line TXT-2 and the mildly invasive TXT-1 (figure 
3 4 4 2) Non treated and scrambled siRNA transfected cell lines were again included 
as the controls for this experiment These results suggested that performing the 
invasion assay 72 hours post siRNA transfection allows more recovery time for the 
cells and decreases the non-specific transfection effect on invasion It was not 
surprising that that exposure to NeoFx or a similar transfection reagent affects a 
mechanism such as invasion, given the impact on membrane integrity The longer 
recovery time possibly facilitates the repair of renewal of damage caused by the 
transfection reagent 72h post transfection was the time point at which further invasion 
analysis of siRNA transfected samples were performed This data also suggests that 
the invasive capacity both the cell lines are decreased at 72h compared with the 48h 
analysis The cells were more confluent at 72h with decreased nutrients in the medium, 
which may have decreased the capacity to invade
siRNA transfection efficiency was evaluated using immunofluorescence and confocal 
microscopy (Figure 3 4 4 3 and 3 4 4 4) These immunofluorescence results 
demonstrate siRNA transfection efficiencies of 90% The kinesin experiment (Figure 
3 4 4 4) also provides a visual measure of excellent transfection efficiency
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4 5 3 Evaluation of IGF-1R siRNA targeting on mRNA and protein levels
RNA and protein were harvested 48 and 72h post-siRNA transfection respectively and 
used to determine an IGF-1R siRNA mediated decrease in mRNA and protein levels 
(Figures 3 4 4 5 and 3 4 4 6) Figure 3 44  5 illustrates an IGF-1R siRNA specific 
decrease in mRNA for samples at 48h, albeit a slight decrease There is a noticeable 
increase in IGF-1R mRNA expression in the scrambled siRNA transfected DLKP-1, 
DLKP-2 and TXT-1 samples This is surprising, as the scrambled siRNA sequences 
are not reported to affect target expression However an explanation for this anomaly 
may be attributed to noise in the data i e that increases of one or two relative quantities 
when mRNA levels are low, impact on this data, whereas increases of one or two 
relative quantities would not impact on the data to such a great extent if the mRNA 
relative quantities were higher
Figure 3 4 4 6 demonstrates that IGF-1R protein expression was almost completely 
silenced in siRNA transfected cells compared with scrambled and non-treated samples 
This would indicate that the siRNA may be acting like a microRNA (miRNA) by not 
destroying mRNA but preventing its translation
In the case of IGF-1R, endogenous protein levels were measurable by western blotting 
thus the decrease in protein expression in response to siRNA transfection was clear by 
western blotting However, endogenous KCNJ8, S100A13, SFN and TFPI2 protein 
levels were below the detection limits of western blot Consequently, the effect of 
siRNA transfection on protein levels could not be demonstrated It may helpful 
immunoprecipitate the protein under investigation before western blot analysis to help 
visualise conclusively any potential decrease in protein expression in response to 
siRNA transfection
4 5.4 Evaluation of IGF-1R siRNA targeting on proliferation
Many studies have reported that decreasing endogenous IGF-1R decreases cell/tumour 
growth Galvan et a l , (2003) state that IGF-1R binds to it’s ligand (IGF-1) and 
activates phosphoinositide 3-kinase (PI3K) This promotes cell proliferation by 
activating the MAPK cascade and simultaneously prevents apoptosis by inducing the
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phosphorylation and inhibition of proapoptotic proteins such as BAD Remmuth et a l ,
(2002) put forward a similar scenario Here, KM12L4 human colon cancer cells were 
transfected with a truncated dominant negative form of IGF-1R The transfected ceils 
showed decreased growth and increased apoptosis and had decreased expression of 
VEGF at both the mRNA and protein levels Grzmil et a l , (2004) report that using an 
antisense IGF-1R sequence in human PC-3 prostate cancer cells also decreased 
proliferation and increased spontaneous apoptosis by up to 17-fold Sekharam et a l ,
(2003) transfected the human colon cancer cell line HCT116 with an expression 
plasmid containing the full length IGF-1R protein sequence Growth curve analysis in 
this study revealed a two-fold increase in proliferation in the IGF-1R transfected cells 
compared with the parental cells Resistance to serum deprivation induced apoptosis 
was also observed in the IGF-1R transfected cells
To study the effect of IGF-1R siRNA targeting on the DLKP variants, cells were 
seeded at both low (2 5 x 103 cells/well) and high (5 x 103 cells/well) densities in a 96- 
well plate format (Figures 3 4 4 7 and 3 4 4 8) Proliferation was measured using the 
acid phosphatase assay and an IGF-1R siRNA specific effect on cell proliferation was 
assessed by comparing with scrambled siRNA and non-treated cells An siRNA 
sequence to Kinesin was transfected as a positive control and acted by preventing cell 
doubling thus kinesin siRNA transfected cells did not increase in number compared 
with the non-treated, scrambled siRNA- and IGF-1R siRNA- transfected cells This is 
also visually demonstrated in Figure 3 4 4 4 Surprisingly, IGF-1R siRNA treatment 
did not appear to affect proliferation compared with the scrambled siRNA and non- 
treated cells
The IGF-1R siRNA treated DLKP variants, exhibited no decrease in proliferation 
Indeed, this is a major difference between this and other studies on IGF-1R It is 
possible that the decreased IGF-1R expression was compensated for (as regards 
proliferation) by the presence of epidermal growth factor receptor (EGFR) Personal 
communications within our laboratories have confirmed EGFR expression in all of the 
DLKP cell lines In a review by Adams et a l , (2004) an overview is given of the 
interrelationship between IGF-1R and EGFR This is in agreement with the idea that 
cross talk between the IGF-1R and EGFR can significantly effect intracellular 
signalling in that EGFR expression can maintain DLKP cell growth despite decreasing
i
I
289
IGF-1R expression These experiments were carried out in the presence of serum, 
which contains a variety of growth factors, which may have compensated for IGF-1R 
silencing and maintained proliferation
When IGF-1R is silenced the proliferation is unaffected possibly due to the presence of 
other growth factors in the medium An indication of the pathway involved could be 
determined by serum starving the DLKP variants and re-feeding with either serum 
containing medium and serum free medium supplemented with IGF-1 only Following 
stimulation, levels of the relevant signalling molecules 1 e phospho-PI3K, phospho- 
AKT, phosphor-ERK could be measured and differences in the signalling identified 
This would also be a useful study in cells with the IFG-1R silenced by siRNA, and 
would provide a mechanistic explanation for the data presented Similarly, the result 
where proliferation in serum is maintained despite IGF-1R signalling should be 
investigate by silencing the IGF-1R and then growing the cells in SFM only 
supplemented with IGF-1 If only IGF-1 is present in the medium then proliferation 
should be reduced when IGF-1R is silenced, as there would be no other growth factor 
to signal cell growth
4.5 5 Evaluation of IGF-1R knockdown on invasion
Many studies have demonstrated that IGF-1R expression modulates metastatic 
potency In 1998 Long et a l , found that lung carcinoma cells transfected with cDNA 
overexpressing IGF-1R had enhanced ability to invade and colonise the liver In 
addition to blocking tumour growth, IGF-1R antisense treatment has also been shown 
to inhibit metastasis (Chemicky et a l , 2000, Scotlandi et a l , 2002) Tanno et a l ,
(2001) demonstrated that constitutively actived Akt or Src-activated Akt increased 
IGF-1R gene expression, and rendered pancreatic cancer cells more invasive 
Sekharam et a l , (2003) found that injecting colon cancer cells overexpressing IGF-1R 
into mice resulted in the formation of bigger tumours which metastasised to distant 
organs, compared to mice injected with parental colon cancer cells Grzmil et a l ,
(2004) report that using an antisense IGF-1R sequence in human PC-3 prostate cancer 
cells also decreased PC-3 invasive capacity and MMP-2 expression Furthermore, 
Jiang et a l , (2004) examined IGF-1R expression in human gastric cancer and found
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strong correlation with increased tumour angiogenesis and lymph node metastasis 
IGF-1R was expressed more strongly at the metastatic site
Two independent methods were employed in this study to decrease IGF-1R expression 
and investigate this effect on invasion These included an siRNA to IGF-1R and an 
IGF-1R blocking antibody, aIR3 Sections 3 4 6 and 3 4 7 demonstrate the effect of 
IGF-1R siRNA transfection on DLKP variant invasion The invasion assays were 
performed 72 hours post-transfection Untransfected- and scrambled siRNA 
transfected- cell lines were the controls for this experiment RPMI-Mel and RPMI- 
2650 are included as positive and negative invasion assay controls respectively Counts 
per insert were averaged and plotted as percentage invasion normalised to the 
scrambled siRNA for each cell line The invasive capacities of non-treated samples 
were not included graphically and were photographed to demonstrate the non-specific 
effect on the cells due to the transfection process It was more statistically relevant to 
compare control (scrambled) siRNA transfected cells with target siRNA transfected 
cells
Invasion was decreased in IGF-1R siRNA transfected cells compared with the 
scrambled siRNA and non-treated cells (Figure 3 4 4 9) In transfection I (Figure 
3 4 4 10) invasion was decreased in IGF-1R siRNA transfected DLKP-2 (P<0 001), 
TXT-1 and TXT-2 (P<0 005) compared with the scrambled siRNA control VCR does 
not express endogenous IGF-1R and is also non-invasive, so one would not expect an 
IGF-1R siRNA related effect on invasion in this cell line and the data concurs with 
this However, only a slight IGF-1R siRNA related decrease in invasion was observed 
for DLKP-1 This may be accounted for by reduced transfection efficiency in this cell 
line, since results for transfection II (Figures 3 44  11 and 3 44  12) saw a 60% 
reduction in DLKP-1 (P<0 001) IGF-1R invasion compared with scrambled siRNA 
transfected cells Invasion was decreased by -50% in IGF-1R siRNA treated DLKP-2, 
TXT-1 and TXT-2 in this transfection (P<0 001) These results correlate with the 
studies outlined above and demonstrate that decreasing IGF-1R expression in DLKP 
variants using an IGF-1R siRNA decreases their capacity to invade
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An IGF-1R blocking antibody, aIR3 (Calbiochem, UK) was also used to achieve 
decreased IGF-1R expression by neutralising the -130 kDa a and the -90 kDa P 
subunits of IGF-I receptor The effect of this aIR3 treatment on m vitro invasion was 
examined (Figure 3 4 4 13) The cell lines were seeded for invasion analysis with or 
without the addition of lOOOng/ml aIR3 monoclonal antibody over 24 hours Only the 
invasive cell lines DLKP-1, DLKP-2 and TXT-2 were included in this experiment, 
since TXT-1 is only mildly invasive and VCR does not detectably express IGF-1R 
protein The results demonstrate that a reduction in invasion of 50% or greater was 
achieved in aIR3 treated cells (P<0 001) It would have been interesting to evaluate 
the amount of IGF-1R being blocked by the antibody This could have been achieved 
by taking a sample of aIR3 treated and non-treated cells and using protein G sepharose 
to pull down the IGF-1R and compare the treated versus non-treated IGF-1R amounts 
The decrease in IGF-1R amounts could then be correlated with the effect on invasion 
Furthermore, it would be beneficial to include a control antibody in this experiment, to 
demonstrate the aIR3-specific effect on the IGF-1R activity and effect on invasion 
Overall, it appears that employing either an IGF-1R specific siRNA sequence or an 
antibody to block IGF-1R expression yield comparable decreases in DLKP variant 
invasion
The results above indicate the suitability of IGF-1R as a target for cancer therapy in 
that cancer spread can be decreased and/or maintained at a certain level IGF-1R is also 
a suitable target for therapy, since inhibition causes a clinical response in a high 
proportion of IGF-1R bearing tumours, decreasing the requirement for other defined 
biomarkers to monitor response to therapy A further aspect of this study would be to 
examine the effect of decreasing IGF-1R expression on DLKP variant sensitivity to 
chemotherapeutic drugs One would hope that combining IGF-1R siRNA with 
chemotherapeutic drug treatment would result in an additive or synergistic effect 
Sakuntala Warshamana-Greene et a l , (2005) found that inhibition of IGF-1R 
signalling using a kinase inhibitor, NVP-ADW742 enhanced the sensitivity of small 
cell lung cancer cell lines to etoposide and carboplatin, which correlated with 
inhibition of PI3K-Akt activation Another group, Camirand et a l , (2005) found that 
combining the EGFR targeting drug, gefitmib with the IGF-1R specific inhibitor,
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AG1024 had an additive to synergistic effect on cell growth inhibition on a panel of 
breast cancer cell lines
Mitsiades et a l , (2004) studied the transcriptional and proteomic profile of NVP- 
ADW742 treated cancer cells and identified the antiproliferative and proapoptotic 
sequence that is triggered in response to this treatment They also found that NVP- 
ADW742 monotherapy or its combination with cytotoxic chemotherapy had 
significant antitumour activity in a mouse xenograft multiple myeloma model, proving 
the success in vivo of the use of selective IGF-1R inhibitors in cancer therapy Goetsch 
et a l , (2005) treated nude mice bearing MCF-7 cells or A549 cells with a humanised 
anti-IGF-lR antibody, h7C10 An almost complete inhibition of A459 tumour growth 
was observed in mice treated with h7C10 combined with the chemotherapeutic agent, 
vinorelbine or the anti-EGFR antibody, 225 This study also highlights the potential of 
IGF-1R targeting in cancer therapy either with a chemotherapeutic agent or inhibitors 
of other growth factor receptors such as EGFR Obviously carefully designed clinical 
trials will be required to monitor the effect of IGF-1R inhibition on host glucose 
metabolism to avoid the induction of type I and type II diabetes through inhibition of 
the related insulin receptor (Yee, 2006) To this end, Macaulay (2004) used an array 
based screen to identify accessible IGF-1R mRNA regions to subsequently design an 
siRNA that silence IGF-1R without affecting the insulin receptor The Ambion 
validated siRNA against IGF-1R is known to be specific The clinical efficacy of IGF- 
1R targeting will be determined by the role of the receptor in established tumours, the 
extent to which IGF-1R expression can be decreased in vivo and the extent to which 
other signalling pathways compensate for IGF-1R silencing Naturally this therapy will 
have the usual difficulties associated with gene therapy, namely targeting and efficient 
delivery of a therapeutic dose to the site of action
293
4.6 Inwardly rectifying potassium channel J8 (KCNJ8)
KCNJ8 is of particular interest as it’s role in cancer and invasion has not been 
previously reported in the literature K+ channels are a diverse class of ion channels in 
the cytoplasmic membrane Ion channels are pores in the cell membrane that allow the 
passage of specific ions They are opened and closed by changes in membrane 
potential, ligand binding, intracellular calcium concentration and membrane tension 
(Lamado et a l , 2001) There is accumulating evidence that various K+ channels in 
tumour cells play important roles in regulating tumour cell proliferation and apoptosis 
There is also increasing interest in the potential implications of K+ channels as 
pharmacological targets for cancer therapy and for use as biomarkers to aid diagnosis 
(Wang, 2004) The potassium channels termed “inward rectifiers” of which KCNJ8 is 
included, pass currents over a hyperpolarized voltage range They have an important 
role in the maintenance of resting membrane potential in many cell types The gating 
of some inward rectifiers (including KCNJ8) is tightly regulated by intracellular ATP 
levels, thereby providing a link between cellular metabolism and membrane potential
4 6 1 KCNJ8 expression in DLKP variants
Inagaki et a l , (1995) identified a K atp channel, uKAtp-1 (KCNJ8/Kir6 1), which 
represented a new subfamily of the inwardly rectifying K+ channel family KCNJ8 was 
identified as a gene potentially involved in invasion in this microarray study KCNJ8 
expression was increased in the more invasive cell lines compared to less invasive cell 
lines A study of KCNJ8 mRNA expression by RT-PCR (Section 3 5 2) confirmed 
increased expression in the invasive cell lines DLKP-1, DLKP-2 and TXT-2 compared 
with the less invasive cell lines TXT-1 and VCR Inagaki et a l , (1995) suggested that 
KCNJ8 might be involved in regulating cell membrane potential Our novel results 
indicate that KCNJ8 contributes to the invasive phenotypes of the variants in the 
DLKP cell model It is possible that this is achieved by regulation of cell membrane 
potential by KCNJ8 Lamado et a l , (2001) also examined whether the activity of K+ 
channels were different between cells with different invasive capacities, by testing 
strongly metastatic PC-3 and weakly metastatic LNCaP human prostate cancer cell
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lines The group reported larger voltage-gated K+ current density in LNCaP than PC-3 
cells They also discovered that the K+ currents in a PC-3 sub-population were 
sensitive to calcium ion levels These results were reflective of the different metastatic 
capabilities of the two cell lines, with PC-3 cells appearing potentially “more 
excitable”
Aguilar-Bryan et a l , (1998) and Erginel-Unaltuna et a l , (1998) dismissed the notion 
that KCNJ8 was a K+ channel in its own right but rather that it encoded a subunit that 
forms a K Atp channel when coexpressed with sulfonylurea receptors (SURs) SURs are 
part of the ABC transporter superfamily, and have greatest similarity with multidrug 
resistance proteins (MDRs) and multidrug resistance-associated protein (MRP) This 
association of KCNJ8 with the MDR- and MRP-like SUR proteins indicate that 
KCNJ8 may be involved, not only in invasion but also in drug resistance in our cell 
model Jtrsch et a l , (1993) compared K + channels in NCI-H69 cells with NCI-H69 
derived MRP-1 overexpressing H69AR cells K+ channels were undetected in NCI- 
H69 cells, but were present in the MRP-1 overexpressing cells In a contrasting study, 
Sakai et a l , (2002) showed that a SCLC cell line, which did not express MRP-1 or 
MDR-1 had large inwardly rectifying K+ currents present The association of KCNJ8 
with drug resistance in our cell model has yet to be investigated
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4 6.2 Evaluation of functional effects of KCNJ8 in DLKP variants
To define the role of KCNJ8 in metastatic lung cancer, two independent commercial 
KCNJ8 specific siRNA sequences were transfected into the invasive cell lines DLKP- 
1, DLKP-2 and TXT-2 and the effect of this decrease in KCNJ8 expression on both 
proliferation and invasion was examined Conversely, KCNJ8 cDNA was transiently 
transfected into the non-invasive cell lines TXT-1 and VCR It was hoped that 
decreasing KCNJ8 expression would decrease the invasive potential of the invasive 
cell lines and that a corresponding increase in invasion would be observed in response 
to an increase in KCNJ8 expression in the non-invasive cell lines
4 6.2.1 KCNJ8 siRNA transfection
A decrease in KCNJ8 expression in response to KCNJ8 siRNA transfection was 
confirmed by PCR analysis (Section 3 5 3 2) The increased sensitivity of qPCR over 
semi-quantitative PCR is apparent in that small changes in expression can be precisely 
monitored For the initial siRNA transfection (Figures 3 5 3 1-3 5 3 4) qPCR at 24h 
post transfection and a semi quantitative RT-PCR study over 96 hours was used to 
analyse the siRNA effect on KCNJ8 mRNA expression For the second KCNJ8 siRNA 
transfection qPCR was used to analyse the effect of siRNA transfection over 72 hours 
(Figures 3 5 3 5-3 5 3 7) A marginal decrease in KCNJ8 mRNA was achieved in 
response to transfection of the KCNJ8 siRNA sequences
The timecourse analyses by RT-PCR yielded interesting results (Figures 3 5 3 2 to 
3 5 3 4) Taking DLKP-1 as an example (Figure 3 5 3 2), it appears there is an increase 
in KCNJ8 mRNA expression in the KCNJ8 siRNA 1-treated samples, at 48hours A 
decrease is again observed at 72 hours, with expression increasing at 96 hours This 
fluctuation in KCNJ8 mRNA levels in response to KCNJ8 siRNA transfection over 
time is most apparent in the DLKP-1 cell line, but also occurs in DLKP-2 and TXT-2 
However, this data is less informative than the more sensitive qPCR timecourse 
analyses
In the qPCR timecourse analysis in Figures 3 5 3 5  to 3 5 3 7  KCNJ8 mRNA 
knockdown is not achieved at 48h particularly for the KCNJ8 siRNA 1 transfected cell
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lines This may be due to decreased transfection efficiency for this siRNA sequence 
What is also interesting is the fluctuation in KCNJ8 mRNA expression levels in non­
treated samples over the 72h timecourse In figure 3 5 3 2 and 3 5 3 4 KCNJ8 mRNA 
expression is increased at 72h compared to expression at 24 and 48h This may 
indicate that KCNJ8 expression is increased when the cells become confluent possibly 
due to nutrient depletion There is a dramatic increase in KCNJ8 expression in the 
scrambled transfected siRNA DLKP-1 and DLKP-2 cells at 72h This is difficult to 
explain, as there are not supposed to be target effects attributed to scrambled siRNA 
transfection, although this is a controversial topic The exact role of KCNJ8 in 
maintenance of cell physiology in not defined in our model system as yet, but it is 
obviously of importance Miki et al (2002) demonstrate the importance of KCNJ8 
physiologically, since KCNJ8 null mice die prematurely due to myocardial ischameia
Binggeli and Weinstein (1986) proposed that altered signalling of plasma membrane 
electric potential of cancer cells can contribute to tumour growth Bianchi et a l , (1998) 
showed that plasma membrane electric potential in tumour cells is often modulated by 
the activity of K + channels Zhou et a l , (2003) found that a high concentration of a 
potent K atp inhibitor, Glibenclamide inhibited hepatocarcinoma cell adhesion and 
proliferation The effect of siRNA targeting KCNJ8 on proliferation is demonstrated in 
Figure 3 5 4 1 Unlike the study by Zhou et al (2003) decreasing KCNJ8 expression 
had no effect on proliferation However, by using Glibenclamide Zhou may also have 
inhibited Kir6 2 as well as KCNJ8 (Kir6 1) To qualify the role of KCNJ8 in cell 
growth or apoptosis in these cell lines one could use the H-Thymidine incorporation 
and TUNEL assays respectively
Stringer et a l , (2001) used Representational Difference Analysis (RDA) to identify 
genes whose expressions are aberrantly increased in invasive breast carcinoma 
compared with adjacent normal breast tissue from the same person The group 
identified GIRK1, an inwardly rectifying K+ channel, whose expression correlated 
with lymph node metastasis, where the increase in GIRK1 expression was greatest in 
tumours with more than one positive lymph node The group postulate the use of this 
channel as a biomarker for breast cancer if correlated with the expression of other 
biomarkers Our array data and RT-PCR validation of KCNJ8 mRNA levels across the 
cell line panel indicated that KCNJ8 expression was associated with the invasive
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compared with the lesser invasive cell lines included in this study One would expect 
then, that decreasing KCNJ8 expression using siRNA would decrease the invasive 
capacity of the invasive cell lines DLKP-1, DLKP-2 and TXT-2 Figures 3 5 5 1 to 
3 5 5 3 demonstrate the effect of decreasing KCNJ8 expression on in vitro invasion As 
observed in our IGF-1R work, a slight decrease in mRNA expression was reflected in 
a substantial phenotypic effect suggesting that the siRNA sequences might be acting 
like miRNAs by inhibiting translation Surprisingly, a decrease in KCNJ8 mRNA 
expression generated a substantial increase in invasion Invasion was increased by 
between 45% to over 100% in KCNJ8 siRNA treated cell lines compared with 
scrambled siRNA transfected cell lines (P<0 001) It is possible that the decrease in 
KCNJ8 expression generated a “compensation” response, whereby the expression of 
other proteins was increased to cause an additional increase in the invasive phenotype 
of these cell lines This is merely hypothesis though and would require further 
investigation
Ion channels can mediate cell migration as well as invasion Liu et a l , (2004) treated 
murine melanoma B-16 cells with endothelin-1 (ET-1) to decrease potassium channel 
current amplitude, thereby decreasing B-16 cell migration Another study by Schwab 
et a l , (1999) demonstrated that migration of transformed renal epithelial cells is a K+ 
channel-dependent process The group looked at migration of NIH3T3 fibroblasts and 
human melanoma cells using time-lapse photography in the presence and absence on a 
specific K+ channel blocker Charybdotoxin (CTX) The treatment affected migration 
of both cell types in a dose dependent manner The group also investigated whether 
blocking potassium channel activity could modulate melanoma cell invasion In 
contrast to our novel finding above that decreasing KCNJ8 increased invasion, 
decreasing potassium channel activity in the Schwab study did not modulate the 
invasive capacity of melanoma cells
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4 6 2 2 KCNJ8 cDNA transfection
In 2004 Lastraioli et a l , reported that the K+ channels from the HERG family are 
involved in the establishment of an invasive phenotype in colorectal cells in vitro and 
in vivo With this in mind, we decided to investigate whether KCNJ8 overexpression 
could induce an invasive phenotype in the mildly invasive cell lines TXT-1 and VCR 
by transiently transfecting the expression vector pSport6 containing the KCNJ8 cDNA 
sequence An increase in invasion was observed in the KCNJ8 cDNA transfected 
TXT-1 cell line (P<0 001) No effect on invasion was observed in KCNJ8 cDNA 
transfected VCR cells compared with the empty vector control cells (Figures 3 5 6 7 
and 3 5 6 8) This may potentially be attributed to poor transfection efficiency in this 
cell line This result is inconclusive, as an increase in KCNJ8 protein expression was 
not confirmed by western blot, as the protocol is not yet fully optimised (Figures
3 5 6 4 and 3 5 6 5) To overcome this difficulty one could use a HA tag to optimise 
the western blot for this protein A further optimisation strategy could include the 
development of an in-house antibody to KCNJ8 to aid more sensitive KCNJ8 protein 
detection, although Yoshida et a l , (2004) demonstrated the difficulties in developing a 
specific and sensitive antibody to this protein One could also speculate that an 
increase in KCNJ8 expression alone is insufficient to induce invasion in the non- 
mvasive cell lines, however this theory remains inconclusive without confirmation of 
protein increases in response to the exogenous transfection by western or 
immunofluorescence These results suggest that it is the deregulated expression of 
KCNJ8 that modulates cell line invasive capacity
4 6 3 Assigning a function for KCNJ8
This work suggests a previously unreported role for KCNI8 in lung cancer cell 
invasion In fact, no cancer related function has ever been attributed to KCNJ8 These 
experiments do not suggest a function for KCNJ8 in the regulation of proliferation or 
apoptosis A further aspect of this study would be to examine the effect of decreasing 
KCNJ8 expression on DLKP variant sensitivity to chemotherapeutic drugs, as there are 
lines of evidence to suggest that KCNJ8 may also be involved in drug resistance The 
mechanisms by which KCNJ8 specifically regulates the invasive phenotype remain 
unclear at present and warrant further investigation
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4.7 S100A13
SI00 proteins are small EF hand Ca2+ binding proteins of variable length and 
sequence There are a number of functions associated with SI00 proteins, many 
associated with tumour development In 1996, Wicki et al identified a new SI00 
member termed S100A13 by screening expresses sequence tags (EST) databases The 
C-terminus of S100A13 protein ends with the motif RKK, which is also seen in the 
metastasis-associated protein S100A4 (Kim and Helfman, 2003) and S100A10 The 
results described in Section 3 6 describe a novel function for S100A13 in the 
modulation of an invasive phenotype
4 7 1 S100A13 expression in the DLKP variants
S100A13 has been demonstrated to be overexpressed in brain tumours m concert with 
FGF-1 (Landriscina et a l , 2002) and has been proven to be essential in the regulation 
and release of pro-angiogenic molecules FGF-1 and IL-la in a copper dependent 
manner (Madinova et a l , 2003, and Landrsicina et a l , 2001) The array data indicated 
that S100A13 expression was increased in the more invasive cell lines in our model 
system Analysis of SI00A l3 mRNA by RT-PCR (Section 3 6 2) confirmed increased 
expression in the invasive cell lines DLKP-1, DLKP-2 and TXT-2 compared with the 
poorly invasive cell lines TXT-1 and VCR This data concurs with a study by Smirnov 
et a l , (2005) who identified S100A13 as a novel predictor of metastasis following its 
detection in circulating tumour cells in blood Section 3 6 2 demonstrates differences 
in S100A13 mRNA levels between the invasive cell lines DLKP-1 and TXT-2 and this 
was again evident in the qPCR analysis of the cell lines in Section 3 6 3 2 This data 
would suggest that although high S100A13 mRNA expression correlates with a more 
aggressive and invasive phenotype, that S100A13 mRNA expression cannot induce an 
invasive phenotype by itself, since S100A13 mRNA levels are low in the invasive cell 
line DLKP-1
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4 7 2 Evaluation of functional effects of S100A13 in DLKP variants
To help define the potential role of S100A13 in invasive lung cancer, we decided to 
transfect three independent Ambion S100A13 specific siRNA sequences in the 
invasive cell lines DLKP-1, DLKP-2 and TXT-2 and to examine the effect of this 
decrease in S100A13 expression on both proliferation and invasion Additionally, 
S100A13 cDNA was transiently transfected into the non-mvasive cell lines TXT-1 and 
VCR It was theorised that decreasing S100A13 expression would decrease the 
invasive potential of the invasive cell lines and that a corresponding increase in 
invasion would be observed in response to an increase in S100A13 expression in the 
non-invasive cell lines
An S100A13 siRNA-specific decrease in mRNA levels was confirmed by PCR 
analysis in Section 3 6 3 2 The siRNA’s used in the IGF-1R and KCNJ8 work 
potentially acted like microRNA’s by preventing mRNA translation into protein (Kim, 
2003, Ke et a l , 2003) In this experiment the clear reduction in mRNA is indicative of 
mRNA cleavage through RISC action (Hutvagner and Zamore, 2002) Endogenous 
S100A13 protein levels were below western blotting detection limits A strategy to 
demonstrate S100A13 siRNA-specific knockdown would include the immuno­
précipitation of S100A13 from the cell lines followed by western blot analysis 
Alternatively one could pulse siRNA transfected cells with a radiolabelled ammo acid 
for a defined length of time, using immuno-precipitation to pull down the protein of 
interest The radiolabelled protein could then be counted and compared with a non­
specific antibody to indicate new protein synthesis following siRNA knockdown
In Figure 3 6 3 5 S100A13 expression in DLKP-1 is increased at 72h compared to the 
earlier timepoints in both non-treated, scrambled siRNA transfected and S100A13 
siRNA transfected cells This trend is again evident for DLKP-2 (Figure 3 6 3 6) but is 
not as obvious in TXT-2 (Figure 3 6 3 7) The changes involved are only 2-3 fold (see 
scale bar) and may be linked to increased confluency at 72h Elevated S100A13 levels 
in the scrambled siRNA were evident in these qPCR analyses The impact of these 
spikes is unclear, they were evident in the IGF-1R qPCR analysis also but western 
blotting demonstrated that IGF-1R protein levels remained unaffected in the scrambled 
siRNA samples
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SI00 proteins can regulate progression through the cell cycle. For example, Breen and 
Tang (2003) used an antisense sequence to S100A6 and inhibited fibroblast 
proliferation. Figure 3.6.4.1 demonstrates that decreasing S100A13 expression had no 
obvious effect on DLKP variant proliferation thereby indicating no obvious role for 
S100A13 in cell growth or apoptosis in these cell lines, although more specific 
analysis such as H-thymididine incorporation assays and TUNEL assays would clarify 
this suggestion. Landriscina et al., (2000) limited S100A13 availability through 
treatment with the anti-allergic drug Amlexanox. This resulted in non-apoptotic 
inhibition of cell migration and proliferation, by inducing tyrosine phosphorylation of 
cortactin, a Src substrate that regulates actin bundling. However, the decrease in 
proliferation in the study by Landriscina et al., (2000) may also be attributed to the 
inhibition of FGF-1 release by Amlexanox and not simply the limited availability of 
S100A13.
The identification and characterisation of molecular markers that can identify patients 
at high risk for metastatic spread and improve clinical management, therapeutic 
outcome and patient survival is of paramount importance. SI00 family members have 
been identified as molecular markers for metastatic potential. S100A2 is of prognostic 
significance in lung cancer in that it allows for the discrimination of high- and low- 
risk patients in the lymph node negative sub group. Clinically this translates as 
aggressive initial treatment of S100A2-negative patients thereby avoiding 
undertreatment. It also allows for the selection of S100A2-positive patients who would 
benefit from less aggressive treatment (Diederichs et a l 2004). Komatsu eta l., (2002) 
associated S100A6 expression with human colorectal adenocarcinoma tumourigenesis 
and metastasis.
S100A13 has been recently implicated as a marker of angiogenesis in endometriosis 
(Hayrabedyan et al., 2005) and was identified as a novel predictor of metastasis 
following global gene expression profiling of circulating tumour cells by Smirnov et 
al., (2005). The novel results in Section 3.6.5 show that decreasing S100A13 
expression in invasive cell lines can reduce their invasive capacity by as much as 84% 
in siRNA treated cells compared with their scrambled siRNA transfected counterparts 
(P<0.001). This is the first study to give causal evidence for the role of S100A13 in
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invasion, since in vitro invasion can be inhibited by reduced S100A13 expression 
However, the results from the S100A13 overexpression experiment (Figures 3 664)  
show that transient S100A13 expression (confirmed by western blotting) decreased 
invasion in S100A13 cDNA transfected cells compared with the empty vector, 
although this decrease was significant for the TXT-1 S100A13 cDNA transfected cells 
(P<0 01) and not VCR S100A13 cDNA transfected cells Stable transfection of 
S100A13 would help to elucidate further the role sustained increased S100A13 
expression on invasion
Given the impact of S100A13 knockdown on invasive capacity and the correlation of 
S100A13 mRNA expression with a more invasive phenotype, it is possible that 
S100A13 acts as a potential enhancer of metastasis given an already invasive 
background To this end S100A13 may act in a similar manner to S100A4, whose 
expression is also increased in metastatic tumours but transgenic mice overexpressing 
S100A4 do not develop tumours S100A4, like S100A13 can be secreted and once 
extracellular can affect angiogenesis (Kim and Helfman, 2003, Hayrabedyan et a l , 
2005) Additionally, extracellular S100A4 can also affect cell differentiation and 
migration (Kim and Helfman, 2003) although a role for S100A13 has not been 
demonstrated in these processes at this point S100A13 is involved in the secretion of 
the pro-angiogenic molecules FGF-1 and IL -la (Madinova et a l , 2003, and 
Landrsicina et a l , 2001), S100A4 can also interact with other proteins both mtra- and 
extra-cellular level For example, S100A4 binds to myosin heavy chain IIA (MHC- 
IIA) and may modulate metastatic phenotype by regulating cellular motility and MHC- 
IIA function (Kim and Helfman, 2003, Garrett et a l , 2005)
The results detailed here clearly show S100A13 is a novel regulator of invasion as 
measured by in vitro invasion assay However, the way in which S100A13 regulates 
cellular functions remain to be determined, although preliminary indications are that it 
is not involved in the regulation of cell growth (Figure 3 6 4 1) The identification and 
characterisation of the molecular mechanisms by which S100A13 effects invasion will 
aid the understanding of the contribution of S100A13 to the metastatic process A 
further aspect of this study would be to examine the effect of decreasing S100A13 
expression on DLKP variant sensitivity to chemotherapeutic drugs One would hope
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that combining S100A13 siRNA with chemotherapeutic drug treatment would result in 
an additive or synergistic effect
The results here combined with the fact that S100A13 expression can help predict 
metastatic spread and is detectable from circulating tumour cells in blood indicate the 
suitability of S100A13 as a novel target for cancer therapy, in that cancer spread can 
be decreased and/or maintained at a certain level S100A13 may also be of clinical 
value in the selection of patients for more aggressive chemotherapeutic regimens, or 
indeed drugs or siRNAs targeting S100A13 may act synergistically with other 
therapeutic drugs
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4.8 Stratifin (SFN/14-3-3-ct)
SFN (or 14-3-3 protein sigma) belongs to the highly conserved 14-3-3 protein family, 
whose members play a role in the regulation of signal transduction pathways 
implicated in the control of cell proliferation, differentiation and survival It has been 
described as a p53-induced inhibitor of G2/M progression (Taylor and Stark, 2001) 
although this mechanism has not yet fully described In 2003, Yang et a l , studied the 
link between SFN activities and p53 regulation The group found that increased SFN 
expression stabilised p53 expression by antagonising the biological functions of Mdm2 
and by blocking Mdm2-mediated p53 ubiquitination and nuclear export SFN also 
enhanced the oligomerisation and transcriptional activity of p53 and appeared to have 
a positive feedback effect on p53 activity
4 8 1 SFN expression m the DLKP variants
SFN repeatedly came through the various bioinformatic analyses of array data as a 
potential target for functional investigation It was increased, in the invasive cell lines 
included in this study, as confirmed by PCR (Section 3 7 2) SFN has been found to be 
among the most differentially expressed genes in some gene expression profiling 
studies of human cancers (Iacobuzio-Donahue et a l , 2003, Santin et a l , 2004) The 
expression pattern for SFN identified by this study does not tally with the majority of 
published expression patterns for SFN SFN is frequently inactivated in human 
cancers Suzuki et a l , (2000) reported that this is due to methylation of the 5’ region 
Umbricht et a l , (2001) also found that SFN is frequently silenced in breast carcinomas 
due to hypermethyaltion and suggest that his occurs at an early stage in the progression 
to invasive breast cancer This is in complete contrast to the preliminary finding that 
SFN expression is higher in the invasive cell lines compared with their mildly invasive 
counterparts
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In 2002, Osada et a l , examined the DNA methylation status and expression level of 
SFN gene in 37 lung cancer cell lines and 30 primary lung tumour specimens The 
group found that SCLC cell lines were frequently hypermethylated, which silenced 
stratifin expression (9 of 13 lines) Hypermethylation and silencing of SFN was also 
observed in 4 of 7 large cell lung cancer cell lines However, in other NSCLC cell lines 
hypermethylation only occurred in 1 of 17 lines In the primary specimens, all eight 
SCLC tumours had decreased SFN expression, while loss of expression was rare in 
primary NSCLC specimens This demonstrates a possible role for SFN in lung 
tumongenesis in a histological type-specific manner In addition, Liu et a l , (2004) 
examined the protein profiles of four different human NSCLC cell lines compared with 
normal bronchial epithelial cells by 2D-PAGE and MALDI-TOF mass spectrometry 
They found a decrease in SFN expression and postulate that altered expression of SFN 
might be involved in lung carcinogenesis Guweidhi et a l , (2004) found that SFN 
mRNA levels were 54-fold higher in pancreatic adenocarcinoma in comparison with 
normal pancreatic samples and was localised in pancreatic cancer cells as determined 
by laser capture microdissection High SFN expression was not indicative of 
maintenance of G(2)/M cell cycle checkpoint or apoptosis induction in the pancreatic 
cell lines The group propose an important role of aberrant SFN downstream signalling 
in pancreatic cancer Ide et a l , (2004) found that hypermethylation of SFN was a rare 
event in colorectal cancers They found by immunohistochemistry, that SFN was 
localised to the invasion-front of the tumour (i e the deep peripheral area of the 
tumour) They also demonstrated that SFN positive cases exhibited higher proliferative 
activity compared to cases with silenced SFN The results detailed in Section 3 7 also 
indicate a role for deregulated SFN expression in lung cancer and do not suggest that 
SFN acts as a tumour suppressor gene
Hermeking et a l , (1997) reported that SFN expression is induced following exposure 
to DNA damaging agents and that this increase in SFN expression leads to G2 cell 
cycle arrest through p53 signalling, a finding supported by Chan et a l , (1999), who 
propose that this occurs to prevent mitotic catastrophe following DNA damage
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4 8 2 Evaluation of functional effects of SFN in DLKP variants
A SFN siRNA-specific decrease in mRNA levels was confirmed by qPCR analysis at 
24h in Figure 3 7 3 1 However the timecourse analysis of this knockdown by RT-PCR 
is of limited value and is quite subjective since the differences between SFN band 
intensities are so small (Figures 3 7 3 2  to 373  5) qPCR seems to give a more 
accurate representation of SFN knockdown
Corresponding with a (measurable knockdown in SFN expression at 24h, invasion was 
increased in SFN siRNA transfected DLKP-2 and TXT-2 cells compared with the 
scrambled siRNA control (P<0 001) (Figure 3 7 4 1 and 3 7 4 2) Invasion was not 
significantly affected in SFN siRNA transfected DLKP-1 cells, this may be due to 
reduced transfection efficiency in this cell line These data were unexpected in relation 
to the array data, however correlate with the view that SFN expression is decreased 
during the progression of a cancer phenotype (Umbncht et a l , 2001, Osada et a l , 
2002, and Liu et a l , 2004)
Zhang et a l , (2004) reported SFN as a positive mediator of IGF-1R induced cell 
proliferation where treatment of MCF-7 cells with IGF-1 resulted in a four-fold 
increase in SFN mRNA and protein levels Increased IGF-1R expression has already 
been demonstrated in the invasive cell lines included in this study and it is possible 
that the increased SFN levels observed in these cell lines are as a result of IGF-1 
signalling through IGF-1R in a manner independent of p53 When SFN expression was 
reduced in MCF-7 cell lines it resulted in a reduction in cell proliferation and a delay 
in cell cycle progression (Zhang et a l , 2004) It would be interesting to investigate the 
effect of SFN siRNA transfection on proliferation
An investigation into SFN expression in thyroid neoplasms by Ito et a l , (2003) 
revealed that normal follicules, follicular carcinomas and follicular adenomas did not 
express the protein All of the papillary carcinomas studied expressed SFN with 
increased expression in advanced stage and poorly differentiated types 21 of 23 
anaplastic carcinomas expressed SFN at higher levels than those detected in papillary 
carcinomas Huang et a l , (2004) demonstrated by immunohistochemical analysis the 
nuclear localisation of SFN in higher Gleason grade prostate cancers relative to benign
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glands Exogenous expression of SFN the poorly invasive cell lines TXT-1 and VCR 
did not result in any change in invasion (Figures 3 7 6 1 and 3 7 6 2) despite 
confirmation of increased SFN expression by western blot (Figures 3 7 51 and 3 7 5 2) 
This suggests that increasing SFN expression over a 72h period cannot induce 
invasion
There are many lines of evidence to suggest that SFN acts as a tumour suppressor gene 
(Mhawech, 2005) This is not supported in this study Indeed it seems that higher SFN 
expression in the invasive DLKP variants may be a result of IGF-1 induction mediated 
by IGF-1R signalling Modulating SFN expression in the DLKP variants does not alter 
their in vitro invasion capacities
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4.9Tissue Factor Pathway Inhibitor 2 (TFPI2)
Human TFPI2 is a 32kDa serine protease inhibitor that is associated with the ECM It 
has high homology to TFPI1, a regulator of the extrinsic blood coagulation pathway 
(Sprecher et a l , 1994) TFPI2 inhibits the tissue factor Vila complex and many serine 
proteases including trypsin and plasmin However, it does not inhibit uPA and tPA 
(Petersen et a l , 1996)
4.9.1 TFPI2 expression in the DLKP variants
Many studies have demonstrated the down regulation of TFPI2 in the development of 
an invasive phenotype in cancer For example, Wojtukiewicz et a l , (2003) used 
immunohistochemical procedures to examine TFPI2 expression in neoplastic cells of 
laryngeal, breast, gastnc, colon, pancreatic, renal and endometrial cancer and in glial 
neoplasms A higher staining intensity was observed in more differentiated tumours 
This group also observed that TFPI2 expression decreased with increased malignancy 
In a gene expression profile study of invasive cervical carcinomas versus normal 
cervical keratinocytes, TFPI2 expression was lower in the invasive carcinomas (Santin 
et a l , 2005) The results in Section 3 8 2 agrees with these findings and demonstrates 
lower TFPI2 mRNA expression in the invasive cell lines, particularly in TXT-2, 
compared with the poorly invasive cell lines TXT-1 and VCR
4 9 2 Evaluation of functional effects of TFPI2 in DLKP variants
To define the role of TFPI2 in a panel of lung cancer cell lines with different 
phenotypic levels of invasion, it was decided to transfect a TFPI2 specific siRNA 
sequence in the lesser-invasive cell lines TXT-1 and VCR and to examine the effect of 
this decrease in TFPI2 expression on invasion Additionally, TFPI2 cDNA was 
transiently transfected into the invasive cell lines DLKP-1, DLKP-2 and TXT-2 and 
the effect on proliferation and m vitro invasion examined It was theorised that 
increasing TFPI2 expression would decrease the invasive potential of the invasive cell
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lines and that a corresponding increase in invasion would be observed in response to a 
silencing of TFPI2 expression in the mildly invasive cell lines.
A TFPI2 siRNA-specific decrease in mRNA levels was confirmed by PCR analysis in 
Figure 3.8.3.1 for VCR but not TXT-1. There was a dramatic knockdown of TFPI2 in 
VCR; this might indicate decreased transfection efficiency for the TXT-1 sample. This 
siRNA caused a substantial decrease in TFPI2 mRNA expression in VCR whereas the 
IGF-1R siRNA used in these studies did not exert their effects at mRNA level and 
potentially acted like microRNA’s by preventing mRNA translation into protein.
A decrease in TFPI2 expression in response to siRNA transfection did not significantly 
increase invasion in the poorly invasive cell line TXT-1. It should be noted that in 
Figure 3.8.3.2 a decrease in TFPI2 mRNA expression was achieved in TXT-1 at 24h, 
however the invasion assays were not performed until 72h, hence the effect on TFPI2 
knockdown on invasion may have been missed. Invasion assay analysis was performed 
at 72h to allow the cells to recover following the transfection process and this 
minimised the non-specific effect of the transfection reagent on the cells. However, 
invasion was increased in TFPI2 siRNA transfected VCR cells compared with the 
scrambled siRNA control Invasion was increased in TFPI2 siRNA transfected VCR 
cells compared with the scrambled siRNA control (P<0.005). (Figures 3.8.4.1 and 
3.8.4 2). It is possible that there was a decreased efficiency of the TFPI2 siRNA 
transfection in the TXT-1 cell line. However, the decrease in TFPI2 mRNA expression 
in response to siRNA transfection in the VCR cell line and corresponding increase in 
invasion (P<0.005) indicates that a decrease in TFPI2 expression can induce invasion. 
This result concurs with a study by Lakka et al., (2000) who increased the invasiveness 
of A549, a lung cancer cell line expressing high TFPI2 levels, using an antisense 
cDNA to TFPI2. Decreasing TFPI2 expression in all of the cell lines could help to 
elucidate whether decreasing TFPI2 can further induce invasion given an already 
invasive background or determine if decreasing TFPI2 is itself insufficient to induce an 
invasive phenotype in poorly invasive cell lines.
TFPI2 is an ECM-associated serine protease inhibitor with a role in ECM degradation 
during tumour cell invasion and metastasis, wound healing and angiogenesis (Konduri 
et al., 2000). An early study by Rao et al., (1998) reported that recombinant TFPI2
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inhibits plasmin that is bound to HT-1080 cells, preventing matrix degradation and 
invasion Eitzman et a l , (1996), suggested that interfering with the plasminogen- 
activation system by inhibiting plasmin, rather than at the level of uPA and tPA may 
provide a more effective strategy for the inhibition of tumour cell invasion and 
metastasis As such increasing TFPI2 expression, thereby inhibiting plasmin, may be 
of therapeutic benefit in cancer therapy
In the present study, overexpression of TFPI2 following transient transfection in 
DLKP-1, DLKP-2 and TXT-2 was confirmed by western blot (Figures 3 8 5 2 to 
3 8 5 3) This resulted in a reduction of invasive capacity for TFPI2 cDNA transfected 
cells ranging from 50% to 88% (P<0 001) (Figures 3 8 5 5 to 3 8 5 7) as compared 
with the invasivness of parental and empty vector transfected cells These results 
suggest that overexpression of TFPI2 inhibits in vitro invasion in the DLKP lung 
cancer cell lines In a similar study, Kondun et al, (2000) stably transfected a vector 
expressing TFPI2 in the melanoma cell line C-32 and also observed a decrease in 
invasion in TFPI2 transfected clones Sense and antisense vectors to TFPI2 were used 
in by Konduri et a l , (2001) to examine the role of TFPI2 in human glioma 
invasiveness Sense clones were much less invasive compared to antisense clones in 
vitro and formed smaller tumours in vivo A study by Zhong et a l , (2003) revealed that 
TFPI2 expression inhibited the invasive, but not the migratory, capability of ovarian 
tumour cells in vitro In 2004, Chand et a l , put forward the theory that secretion of 
TFPI-2 by a highly metastatic tumour decreases its growth and metastasis in vivo by 
regulating ECM remodelling and angiogenesis The data presented in Section 3 8 4 
support the former hypothesis
TFPI2 mRNA could not be detected in a high proportion of pancreatic cancer cell lines 
and in primary pancreatic ductal neoplasms (Sato et a l , 2005) Loss of TFPI2 
expression was attributed to hypermethylation of CpG islands in the promoter Phorbal 
12-myristate 13-acetate (PMA) induced TFPI2 expression in cell lines with 
unmethylated or partially methylated TFPI2, but no induction was achieved in cell 
lines with fully methylated TFPI2 Restored TFPI2 expression in pancreatic cells 
resulted in decreased proliferation, migration and invasive potential in vitro (Sato et 
a l , 2005) Unlike the study by Sato et a l , (2005) restored TFPI2 expression had no 
obvious effect on invasive DLKP variant proliferation thereby indicating no obvious
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role for TFPI2 in cell growth or apoptosis in these cell lines (Figure 3 8 5 4) and more 
specific assays can be employed to confirm this Induction of TFPI2 was also achieved 
in epithelial cell lines (including HEK293, A549 and MCF7) using PMA The PMA 
induction of TFPI2 was blocked with the MEK inhibitor, U0126 which indicated that 
the ERK/MAPK pathway regulates TFPI2 promoter activity (Kast et a l , 2003) This 
may suggest that a signalling pathway other than the ERK/MAPK pathway mediates 
the increase in TFPI2 expression in cDNA transfected DLKP variants, since no effect 
on proliferation was observed
Konduri et a l , (2002) used TFPI2 promoter deletion constructs linked to a luciferase 
reporter gene to identify critical promoter regions that regulate TFPI2 expression in 
gliomas The group demonstrated a region -312 to -81 upstream of the transcriptional 
start site as essential for the transcription of TFPI2 in glioma cells This promoter 
region contained potential SP1 and API binding motifs and did not have TATA and 
CAAT boxes immediately upstream of the transcriptional initiation site A repressor 
region was found in -927 to -1181 and an enhancer region at -115 to -1181 upstream 
of the transcriptional initiation site (Konduri et a l , 2002)
Hube et a l , (2003) identified a complete CpG island spanning exon 1 and three 
transcription start sites in the TFPI2 promoter They also demonstrated that treatment 
with 5’-aza-2’-deoxycytidine (5ac) restores TFPI2 transcription in JAR 
choriocarcinoma cells that have low TFPI2 expression levels Thus transcriptional 
silencing of TFPI2 can be attributed (at least in part) to methylation of CpG islands 
(Hube et a l , 2003) 5ac and Trichostatin A (TSA) (inhibitors of DNA 
methyltransferase and hi stone deacetylase respectively (HD AC)) were used to induce 
TFPI2 mRNA in SNB19 glioblastoma cells that have no detectable TFPI2 expression 
An increase in mRNA and protein was observed with TSA being a more potent 
inducer than 5ac, although a 5ac and TSA combination proved highly synergistic 
(Konduri et a l , 2003) It would be interesting to identify the mechanisms by which 
TFPI2 expression is silenced in the invasive DLKP variants Comparison of TFPI2 
expression levels following treatments with 5ac and TSA should indicate if the 
promoter is methylated and thus silenced or if histone deacetylation is involved
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A further interesting study by Yanamandra et a l , (2005) in which a 0 8kb TFPI2 
fragment was cloned into an adeno-associated viral vector (rAAV-TFPI2) and then 
transfected into SNB19 glioblastoma cells, resulted in decreased migration and 
invasion in a dose dependent manner Angiogenesis, both in vitro and in vivo was also 
markedly decreased by the increase in TFPI2 expression This study suggests that 
rAAV-TFPI2 mediated gene therapy could be used as a treatment for brain tumours
The primary cause of therapeutic failure in the treatment of cancer is invasion 
Proteolytic degradation of the ECM is considered an essential step in the invasion and 
metastasis of a malignant cell to distant sites Protease inhibitors that could effectively 
protect the ECM from degradation by circulating tumour cells could be of use as 
therapeutic agents The results discussed here clearly show that the serine protease 
inhibitor TFPI2, is a regulator of invasion as measured by in vitro invasion assay and 
has undoubted potential as a new therapy for cancer treatment Increasing TFPI2 
expression using rAAV or HD AC inhibitors in conjunction with chemotherapeutic 
drug treatment may potentially provide a more aggressive treatment for patients with 
metastatic cancer
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Section 5.0: Conclusions & Future work
5.1 Conclusions
Metastatic cancer is frequently unresponsive to chemotherapy, surgery and 
radiotherapy. Future treatment of metastatic disease will require the development of 
biology-based approaches that will utilise the novel information on the molecular 
mechanisms underlying metastasis in order to identify therapeutic targets whose 
expression, and thereby function, can be modified (Brodt et al, 2000).
In this study, the gene expression profiles of a panel of five, increasingly invasive, 
lung cancer cell lines were compared in order to identify molecules involved in this 
aspect of the metastatic process.
The results presented in this thesis identify molecules associated with a more 
aggressive invasive phenotype in lung cancer cell lines and demonstrate that altering 
the expression of these molecules can modulate the invasive capacity of these lung 
cancer cells.
5.1.1 Characterisation of a panel of lung cell lines with defined behaviour in an in 
vitro invasion assay
• The panel of DLKP cell lines described in this thesis represent robust, valuable 
models for the study of mechanisms of in vitro invasion. The relative 
invasiveness of the sub-lines compared to each other remained constant over 
ten passages and this was the time-frame used for all invasion analysis.
• The invasion assay itself was optimised and performed using defined culture 
conditions. The definition of these assay protocols and culture boundaries lends 
confidence to the phenotypic changes observed following the deliberate 
manipulations of target molecules.
5.1.2 Microarray profiling of a panel of invasive lung cancer cell lines
• This work generated many genelists, some of which may potentially serve as 
molecular ‘signatures’ for invasiveness in lung cancer cell lines. These types of 
signatures may help provide earlier diagnosis and influence and individualise 
the therapies prescribed to cancer patients and thereby improve patient 
prognosis.
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• Five genes were associated with changes in the invasive phenotype in the 
DLKP lung cancer cell lines This was the first study within the NICB to apply 
this experimental approach with the workflow comprising microarray analysis, 
bioinformatic analysis, identification of targets and knock-up/down functional 
investigation This was highly successful, given the challenges of using new 
technology and of becoming familiar with bioinformatic software for the 
microrray analysis Indeed, the success of this study is reflected in the high “hit 
rate” whereby the experimental manipulation of all five targets studied caused a 
phenotypic functional effect in the cell line model This project has yielded 
many interesting results that should be further investigated
5 1.3 IGF-1R
Increased IGF-1R expression has been previously linked with tumour invasion (Grzmil 
et a l , 2004, Jiang et a l , 2004) The findings in this thesis concur with previous results 
m that decreasing IGF-1R expression decreases the in vitro mvasiveness of the DLKP 
variants Since decreasing IGF-1R expression did not affect growth one could 
postulate the suitability of IGF-1R as an adjuvant therapeutic target to inhibit/decrease 
cancer metastasis while killing the still actively growing primary tumour cells with 
conventional chemotherapeutic agents
5 1 4  KCNJ8
This work identifies a previously unreported role for KCNJ8 in lung cancer cell 
invasion In fact, no cancer related function has ever been attributed to KCNJ8 These 
experiments do not suggest a function for KCNJ8 in the regulation of proliferation or 
apoptosis The association of KCNJ8 with the MDR- and MRP-like SUR proteins 
indicate that KCNJ8 may be involved, not only in invasion but also in drug resistance 
in our cell model This has yet to be investigated The mechanisms by which KCNJ8 
specifically regulates the invasive phenotype remain unclear at present and warrant 
further investigation Increasing KCNJ8 expression did not increase invasion in the 
poorly invasive cell lines TXT-1 and VCR Decreasing KCNJ8 expression increased 
invasion in the invasive DLKP variants DLKP-1, DLKP-2 and TXT-2 (P<0 001), 
suggesting that deregulated KCNJ8 expression can modulate the amplitude of invasion 
in invasive lung cancer cell lines
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51.5 S100A13
Possibly the most exciting results in this thesis, that decreasing S100A13 expression 
decreases the in vitro invasive capacity of invasive cell lines by up to 84% (P<0 001), 
suggests S100A13 as a novel regulator of an invasive phenotype Exogenously 
increasing S100A13 expression did not induce an invasive phenotype in poorly 
invasive cell lines, demonstrating that S100A13 on its own cannot induce an invasive 
phenotype in mildly or non-invasive cells Preliminary indications are that S100A13 is 
not involved in cell survival or apoptosis, since decreasing S100A13 expression did 
not affect cell number S100A13 may also be of value clinically in the selection of 
cancer patients for more aggressive therapy in a manner similar to the study of SI00A2 
expression in lung cancer patients (Diederichs et a l , 2004) S100A13 may also have 
potential as a therapeutic target in its own right and may be suitable as a treatment to 
inhibit cancer spread in cancer patients who are undergoing chemotherapy This may 
be especially beneficial since multidrug resistant cells can survive chemotherapy and 
migrate to ^ distant sites in the body and highly metastatic cells can evade the 
chemotherapeutic effect altogether Thus targeting S100A13 expression in conjunction 
with conventional chemotherapy may provide a more effective cancer treatment
5 1 6  TFPI2
TFPI2 was differentially expressed across the cell line panel with lower expression of 
the gene correlating with increasing invasiveness Decreased TFPI2 expression has 
been previously linked with the development of an invasive phenotype Lakka et a l , 
2000, Yanamandra et a l , 2005) and the results of this study concur with these 
findings Overexpression of TFPI2 in invasive DLKP variants caused a decrease in the 
ability of these cells to traverse the matrigel inserts in our assay (P<0 001)
We suggest that increasing TFPI2 expression may have real therapeutic potential in 
cancer to decrease metastatic spread Indeed, this potential is already under serious 
consideration by other groups interested in targeting brain cancer Our results 
demonstrate that it is also a powerful inhibitor of invasion in lung cancer-derived cells 
In contrast, decreasing TFPI2 expression did not increase the invasive capacities of the 
poorly invasive cell lines TXT-1 and VCR suggesting that a decrease in TFPI2 
expression cannot independently induce or activate an invasive phenotype
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5 1 7  SFN
Stratifin was identified as being highly expressed in the invasive compared with the 
poorly invasive DLKP variants Increased SFN expression is frequently correlated 
with good prognosis and many studies support the notion that it acts as a tumour 
suppressor gene through interaction with p53 in response to DNA damage An siRNA- 
dependent decrease in SFN expression in this study was not definitively demonstrated 
Western blots or immunohistochemistry would help to confirm the extent to which 
SFN expression was decreased by siRNA transfection thereby allowing much firmer 
conclusions to be made
318
5.2 Future work
5.2 1 Microarray Analysis
• The panel of DLKP cell lines in this thesis represent valuable models for the 
study of mechanisms of in vitro invasion and also in the study of mechanisms 
of drug resistance The microarray analysis in this thesis focused on the 
identification of molecules involved in invasion, however, similar analysis 
could be performed to identify targets that are involved in the development of 
resistance to taxotere and vincristine The microarray data could be re­
examined using the various bioinformatic tools available in the NICB and 
candidate genes for development of taxotere and/or vincristine resistance could 
be identified
• The microarray analyses carried out in this thesis generated vast amounts of 
data Only a fraction of the potential information contained within this dataset 
was mined An alternative method of analysis, other than that used in this thesis 
might include examining the large gene lists generated by dChip in Pathway 
Analysis packages Pathway analysis can help identify additional targets (that 
may not have been represented on the array or failed to pass the filters applied) 
based on their association with other genes in a common pathway Biological 
association rather than correlation of expression levels drives this type of 
analysis
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52 2 IGF-1R
• We have established that decreasing IGF-1R expression can decrease in vitro 
invasion To further this investigation it is planned to identify the pathway 
through which IGF-1R exerts its effect on proliferation To date IGF-1R was 
silenced in serum-containing medium, which contains IGF, EGF, insulin and 
PDGF therefore proliferation was unaffected because of these other growth 
factors in the medium By silencing IGF-1R in serum starved cells in serum 
free medium supplemented with IGF-1 one would expect to see a reduction in 
proliferation
• It would also be interesting to examine the effect of IGF-1R silencing in DLKP 
variants on their sensitivity to chemotherapeutic drugs One would hope to 
achieve an additive or synergistic effect to further prove the suitability of 
targeting IGF-1R as a cancer therapy, either alone or in combination with 
chemotherapeutic drug treatment
• The VCR cell line did not express endogenous IGF-1R, despite endogenous 
expression in the parental DLKP cell lines This is interesting in itself and 
suggests that development of resistance to vincristine may require loss of IGF- 
1R expression It is hoped to re-pulse an invasive parental DLKP cell line with 
vincristine and attempt to identify the points at which the drug impacts IGF-1R 
levels and the cells lose their capacity to invade
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5 2.3 KCNJ8
• Given the novelty of the findings regarding KCNJ8’s role in invasion, further 
effort will be applied to the optimisation of western blot and/or 
immunohistochemistry to accurately determine an increase or decrease in 
KCNJ8 expression in response to cDNA or siRNA transfection respectively
• The possibility that KCNJ8 may regulate both invasion and drug resistance will 
be examined This will be achieved by investigating the effect of KCNJ8 over- 
or under- expression on drug sensitivity in the DLKP variants and possibly in 
other cell models
• KCNJ8 will be stably transfected into less/non-invasive DLKP variants in order 
to investigate the impact of sustained overexpression on the invasive 
characteristics of these cell lines It may be that we did not witness any 
functional impact due to the transient approach reported in this work
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5 2 4 S100A13
• S100A13 was identified as a functional regulator of in vitro invasion in the 
DLKP variants and further elucidation of the mechanism involved would be 
interesting This might be achieved by examining the expression of FGF-1 and 
IL-la levels in S100A13 siRNA transfected cells These molecules have been 
shown to be regulated by S100A13 in the process of angiogenesis and are co­
expressed in brain tumours
• Stably transfecting S100A13 into non-invasive cell lines may help to identify 
whether S100A13 can contribute to the development of an invasive phenotype 
over time An invasive phenotype can be induced in cell lines by treatment with 
a chenotherapeutic drug over time (eg the TXT-2 cell line) It would be 
interesting to see whether SI0013 overexpressing cells were more or less 
susceptible to this induction
• S100A13 has already been associated with angiogenesis and this work has now 
demonstrated a clear role in invasion Invasion (in embryogenesis for example) 
is a normal part of new blood vessel formation, and rapidly growing tumours 
also require a blood supply It would be interesting to investigate the effect of 
decreasing S100A13 expression on this panel of cell lines in an in vitro model 
of angiogenesis
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5.2 5 TFPI2
• Decreased TFPI2 expression has already been associated with a more 
aggressive/invasive cancer phenotype It would be interesting to compare the 
mechanisms by which TFPI2 is silenced in lung cancer with that of brain 
cancer where promoter silencing by methylation/deacetylation has been 
demonstrated There are many different lung cancer and brain cancer cell lines 
available in the NICB to facilitate this study The application of 5ac or HDAC 
could help to identify whether the gene is silence by methylation or hi stone 
deacetylation in the cell lines
• The application of rAAV for the transduction of TFPI2 as a potential therapy 
for brain cancer has also been demonstrated This methodology will shortly be 
available in the NICB and could be employed to examine the effect of rAAV- 
TFPI2 transfection on the invasive capacity of lung cell lines grown as 
spheroids in a 3D matrix, which would better represent the biology of tumours 
in the body
• In addition the effect of increasing TFPI2 expression on drug sensitivity should 
also be investigated with a view to the development of improved anti- 
metastatic therapy for cancer treatment (assuming there is any impact)
5 2 6 Other work
• Three other targets, ICAM-1, TLX-1 and TCF4 were identified in this study as 
potentially being involved in invasion Functional studies similar to those 
detailed in this thesis should give an indication of the potential role in invasion 
and suggest whether or not they merit further investigation
• It would also be of interest to investigate the expression of these targets in 
clinical samples
• DLKP-1 is an interesting cell line, in that it is invasive but was an outlier in 
terms of the expression of the targets investigated in this thesis Examination of 
the subcellular localisation of the targets and post-translational modification 
status could help to explain this anomaly
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\Section 7.0: Appendices
7.1 Appendix 1 -  RT-PCR investgation of genes with increased 
expression in the invasive DLKP variants from microarray analysis
Semi qualitative RT-PCR was used to confirm that expression changes in the array 
data were reflected in the cell lines studied
To ensure that results from the array study matched to independent analysis of the cell 
lines, RNA samples from the preliminary Affymetrix array study by Dr Rasha 
Linehan in 2003, RNA from the duplicate array samples 2004, RNA from a fresh set 
of cultures harvested separately to those for array analysis including RNA from three 
samples analysed on the Agilent array platform and RNA from cells with increasing 
passage number were included in this analysis The Agilent data was not analysed 
further in this work
In all of the PCRs in this section P-actin was used as an endogenous control to 
normalise for RNA quantities added to each reaction The reactions were analysed by 
gel electrophoresis (GE) on a 2% agarose gel cDNA negative control (cDNA neg) 
consisted of PCR master mix with cDNA but without addition of Taq enzyme PCR 
negative controls consisted of consisted of PCR master mix to which no cDNA 
template was added Densitometnc values were normalised by dividing target 
intensity values by P-actin intensity values and were graphed for each sample The 
gels included in this section are representative of at least two independent repeats
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Figure 7.1.1.1RT-PCR of AKAP11 expression from RNA used in array samples 
2003.
The band size for AKAP11 was 233bp.
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Figure 7.1.2.1RT-PCR of BCHE expression from RNA used in array samples 
2003.
The band size for BCHE was 180bp.
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Figure 7.1.2.2RT-PCR of BCHE mRNA expression from RNA used in duplicate 
array samples 2004.
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Figure 7.1.2.3RT-PCR of BCHE mRNA in a separate sample set and Agilent 
samples.
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Figure 7.1.3.1 RT-PCR of CYB5R2 mRNA expression from RNA used in
duplicate array samples 2004.
The band size size for CYB5R2 is 172bp.
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Figure 7.1.3.2RT-PCR of CYB5R2 mRNA in a separate sample set and Agilent 
samples.
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Figure 7.1.4.1 RT-PCR of EFNB2 mRNA expression from RNA used in duplicate
array samples 2004.
The band size size for EFNB2 is 220bp.
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Figure 7.1.4.3 RT-PCR of EFNB2 mRNA in samples with increasing passage 
number.
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Figure 7.1.5.1 RT-PCR of GLP1R expression from RNA used in array samples 
2003.
The band size for GLP1R was 228bp.
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Figure 7.1.6.1 RT-PCR of ICAM1 expression from RNA used in array samples 
2003.
The band size for ICAM1 was 245bp.
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Figure 7.1.6.2 RT-PCR of ICAM1 mRNA expression from RNA used in 
duplicate array samples 2004.
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Figure 7.1.6.3RT-PCR of ICAM1 mRNA in samples in a separate sample set and 
Agilent samples.
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Figure 7.1.6.4RT-PCR of ICAM1 mRNA in samples with increasing passage 
number.
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Figure 7.1.7.1 RT-PCR of IGF-1R expression from RNA used in array samples 
2003.
The band size for IGF-1R was 241bp.
375
B-actin
IGF1R
IGFIrPCR Affy Samples
Figure 7.1.7.2RT-PCR of IGF-1R mRNA expression from RNA used in 
duplicate array samples 2004.
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Figure 7.1.7.3RT-PCR of IGF-1R mRNA in samples in a separate sample set 
and Agilent samples.
378
TXT -1  p.47 
TXT -1 p.48 
TXT-1 p. 49
VCR p.32 
VCR p.33 
VCR p.34
cDNA Neg 
PCR Neg
lkb Marker 
DLKP -1 p.43 
DLKP -1 p.44
DLKP -2 p.27 
DLKP -2 p.28 
DLKP -2 p.29
TXT -2  p.27 
TXT -2  p.28
7.1.8 KCNJ8
o
g
PCuOh a
a
Q
PCu>
<L>
t
8
KCNJ8
B-actin
DLKP-2 DLKP-1 TXT-2 TXT-1
Samples
VCR
Figure 7.1.8.1 RT-PCR of KCNJ8 expression from RNA used in array samples 
2003.
The band size for KCNJ8 was 210bp.
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Figure 7.1.8.2RT-PCR of KCNJ8 mRNA expression from RNA used in duplicate 
array samples 2004.
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Figure 7.1.8.3RT-PCR of KCNJ8 mRNA in samples in a separate sample set and 
Agilent samples.
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Figure 7.1.8.4RT-PCR of KCNJ8 mRNA in samples with increasing passage 
number.
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Figure 7.1.9.1 RT-PCR of LOC5119 expression from RNA used in array samples 
2003.
The band size for LOC5199 was 249bp.
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Figure 7.1.10.1 RT-PCR of MFAP2 mRNA expression from RNA used in
duplicate array samples 2004.
The band size for MFAP2 was 422bp.
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Figure 7.1.10.2 RT-PCR of MFAP2 mRNA in samples in a separate sample 
set and Agilent samples.
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Figure 7.1.11.1 RT-PCR of MGC3900 mRNA expression from RNA used
in duplicate array samples 2004.
The band size for MFAP2 was 219bp.
B-actin
MGC3900
386
DLKP-1 DLKP-2 TXT-1 TXT-2 VCR DLKP-1 DLKP-2 TXT-2 Ag
Ag Ag
Sample
Figure 7.1.11.2 RT-PCR of MGC3900 mRNA in samples in a separate 
sample set and Agilent samples.
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Figure 7.1.12.1 RT-PCR of MMP3 mRNA expression from RNA used in 
duplicate array samples 2004.
The band size for MMP3 was 241 bp.
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Figure 7.1.12.3b RT-PCR of MMP3 mRNA in samples with increasing 
passage number.
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Figure 7.1.13.1 RT-PCR of S100A13 mRNA expression from RNA used in
duplicate array samples 2004.
The band size for S100A13 was 219bp.
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Figure 7.1.13.2 RT-PCR of S100A13 mRNA in samples in a separate 
sample set and Agilent samples.
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Figure 7.1.14.1 RT-PCR of SFN expression from RNA used in array 
samples 2003.
The band size for SFN was 195bp.
I
DLKP-2 DLKP-1 TXT-2 TXT-1 VCR
Samples
394
•tf " 3 CO X)H <N CN «5 X)
^  £j £? H HJ  J  J  J  x xS Q Q Q Q H H
<N CN
DLKP- DLKP- DLKP- DLKP- TXT-1a TXT-1b TXT-2a TXT-2b VCRa VCRb 
1a 1b 2a 2b
Sample
Figure 7.1.14.2 RT-PCR of SFN mRNA expression from RNA used in 
duplicate array samples 2004.
395
ÖD ÖD
DLKP-1 DLKP-2 TXT-1 7XT-2 VCR DLKP-1 DLKP-2 TXT-2 Ag
Ag Ag
Sample
Figure 7.1.14.3 RT-PCR of SFN mRNA in samples in a separate sample set 
and Agilent samples.
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Figure 7.1.14.4a RT-PCR of SFN mRNA in samples with increasing passage 
number.
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Figure 7.1.14.4b 
number.
RT-PCR of SFN mRNA in samples with increasing passage
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Figure 7.1.15.1 RT-PCR of TCF4 mRNA expression from RNA used in
duplicate array samples 2004.
The band size for TCF4 is 204bp.
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Figure 7.1.15.2 RT-PCR of TCF4 mRNA in samples in a separate sample 
set and Agilent samples.
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Figure 7.1.16.1 RT-PCR of TEM7 expression from RNA used in array 
samples 2003.
The band size for TEM7 was 239bp.
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Figure 7.1.16.2 RT-PCR of TEM7 mRNA expression from RNA used in 
duplicate array samples 2004.
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Figure 7.1.16.3 RT-PCR of TEM7 mRNA in samples in a separate sample 
set and Agilent samples.
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The band size for TLX1 was 201 bp
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Figure 7.1.18.2 RT-PCR of TLX1 mRNA expression from RNA used in 
duplicate array samples 2004.
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Figure 7.1.18.3 RT-PCR of TLX1 mRNA in samples in a separate sample 
set and Agilent samples.
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Figure 7.1.18.4b RT-PCR of TLX1 mRNA in samples with increasing 
passage number.
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Figure 7.1.19.1 RT-PCR of VEGF-A mRNA expression from RNA used in
duplicate array samples 2004.
The band size for VEGF-A was 186bp.
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Figure 7.1.19.2 RT-PCR of VEGF-A mRNA in samples in a separate 
sample set and Agilent samples.
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Figure 7.1.20.1 RT-PCR of VEGF-C mRNA expression from RNA used in
duplicate array samples 2004.
The band size for VEGF-A was 249bp.
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Figure 7.1.20.2 RT-PCR of VEGF-C mRNA in samples in a separate 
sample set and Agilent samples.
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Figure 7.1.20.3 RT-PCR of VEGF-C mRNA in samples with increasing 
passage number.
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7.2 Appendix 2 -  RT-PCR investgation of genes with decreased 
expression in the invasive DLKP variants from microarray analysis
Semi quantative RT-PCR was used to confirm that expression changes in the array 
data were reflected in the cell lines studied
To ensure that results from the array study matched to independent analysis of the cell 
lines, RNA samples from the preliminary Affymetrix array study by Dr Rasha 
Linehan in 2003, RNA from the duplicate array samples 2004, RNA from a fresh set 
of cultures harvested separately to those for array analysis including RNA from three 
samples analysed on the Agilent array platform and RNA from cells with increasing 
passage numb;er were included in this analysis The Agilent data was not analysed 
further in this work
In all of the PCRs in this section P-actin was used as an endogenous control to 
normalise for RNA quantities added to each reaction The reactions were analysed by 
gel electrophoresis (GE) on a 2% agarose gel cDNA negative control (cDNA neg) 
consisted of PCR master mix with cDNA but without addition of Taq enzyme PCR 
negative controls consisted of consisted of PCR master mix to which no cDNA 
template was added Densitometnc values were normalised by dividing target 
intensity values by (3-actin intensity values and were graphed for each sample The 
gels included in this section are representative of at least two independent repeats
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Figure 7.2.1.1RT-PCR of FN1 mRNA expression from RNA used in duplicate
array samples 2004.
The band size for FN1 was 230bp.
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Figure 7.2.1.2RT-PCR of FN1 mRNA in a separate sample set and Agilent 
samples.
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Figure 7.2.1.3b RT-PCR of FN1 mRNA in samples with increasing passage 
number.
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Figure 7.2.2.1RT-PCR of FSTL1 mRNA expression from RNA used in duplicate
array samples 2004.
The band size for FSTL1 was 242bp.
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Figure 7.2.3.1RT-PCR of MAP3K12 mRNA expression from RNA used in
duplicate array samples 2004.
The band size for MAP3K12 was 240bp.
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Figure 7.2.3.2RT-PCR of MAP3K12 mRNA in a separate sample set and Agilent
samples.
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Figure 7.1.4.1 RT-PCR of NRG1 expression from RNA used in array samples
2003.
The band size for NRG 1 was 190bp.
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Figure 7.2.4.2 RT-PCR of NRG1 mRNA expression from RNA used in duplicate 
array samples 2004.
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Figure 7.2.4.2 RT-PCR of NRG1 mRNA in a separate sample set and Agilent
samples.
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Figure 7.2.5.1RT-PCR of RNABP2 expression from RNA used in array samples
2003.
The band size for RNABP2 was 218bp.
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Figure 7.2.6.1RT-PCR of SCHIP1 mRNA expression from RNA used in
duplicate array samples 2004.
The band size for SCHIP1 was 355bp.
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Figure 7.2.6.2 RT-PCR of SCHIP1 mRNA in a separate sample set and Agilent
samples.
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Figure 7.2.7.1RT-PCR of SPP1 mRNA expression from RNA used in duplicate
array samples 2004.
The band size for SPP1 was 244bp.
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Figure 7.2.7.2 RT-PCR of SPP1 mRNA in a separate sample set and Agilent 
samples.
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Figure 7.2.8.1RT-PCR of TEM6 expression from RNA used in array samples
2003.
The band size for TEM6 was 199bp.
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Figure 7.2.9.1RT-PCR of TFPI2 expression from RNA used in array samples 
2003.
The band size for TFPI2 was 183bp.
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Figure 7.2.9.2 RT-PCR of TFPI2 mRNA expression from RNA used in duplicate
array samples 2004.
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Figure 7.2.9.3 RT-PCR of TFPI2 mRNA in a separate sample set and Agilent 
samples.
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7.3 Appendix 3 -  Table of PCR pnmers used in this study
Name Supplier Band
size
(bp)
Primer Sequences
AX API 1 Sigma 233 AAG GGC ACA AAC ATG GAA AG (s) 
AGC TGG AGT ACA GCC TCC AA (as)
BCHE Sigma 180 AAG CTG GCC TGT CTT CAA AA (s) 
TGG AAT CCT GCT TTC CAC TC (as)
CYB5R2 Sigma 172 CCCAGGACATGATTTTCACC (s) 
CACCCAAAAGAGGAGAACCA (as)
EFNB2 Sigma 220 TCCATGGGTAATCCGTTCAT (s) 
T C AGC A A A AC C A A AGT GCT G (as)
GLP1R Sigma 228 GTTCCCCTGCTGTTTGTTGT (s) 
CTTGGCAAGTCTGCATTTGA (as)
KCNJ8 Sigma 210 AGTTGGTGAAACCCAGATCG (s) 
CG AC AGAC AAAGCG AAT GAA (as)
LOC5119 Sigma 249 CAATGGTTCTGGGGATATGG (s) 
CCCTTTGGATTCTGAAGCAC (as)
MFAP2 Sigma 422 GCAGTGAACGGAGTCACAAA (s) 
GTCTGGGTTGTCGATCTGGT (as)
MGC3900 Sigma 219 CTCAGTCAAACCACGAAGCA (s) 
AAGTGGAGCTCTGGAGGTGA (as)
MMP3 MWG
Biotech
214 GCAGTTTGCTCAGCCTATCC (s) 
GAGTGTCGGAGTCCAGCTTC (as)
S100A13 Sigma 219 TAATGGCAGCAGAACCACTG (s) 
TTGAGCTCCGAGTCCTGATT (as)
SFN Sigma 195 GGATCCCACTCTTCTTGCAG (s) 
CTGTCCAGTTCTCAGCCACA (as)
TCF4 MWG
Biotech
204 GCAGAGTCTCCTTGGAGGTG (s) 
GTGCTTGCTGATGGAGCATA (as)
TEM7 Sigma 239 GTCCTCCAGAGATGCTCCAG (s)
437
TLX1 Sigma 201 GGTCAGGGGTGACACAGACT (s) 
TGGGCTGCATTTATGTGAAA (as)
VEGF-A MWG
Biotech
186 CCCACTGAGGAGTCCAACAT (s) 
TTTCTTGCGCTTTCGTTTTT (as)
VEGF-C Sigma 249 GGAAAGAAGTTCCACCACCA (s) 
TTTGTTAGCATGGACCCACA (as)
FN1 MWG
Biotech
230 ACC AACCT ACGGATGACTCG (s) 
GCTCATCATCTGGCCATTTT (as)
FSTL1 MWG
Biotech
242 GCACAGGCAACTGTGAGAAA (s) 
CATAGTGTCCAAGGGCTGGT (as)
MAP3K12 Sigma 240 AGAAGGTGCGAGACCTCAAA (s) 
TCTTGTGCAGGTGCAGGTAG (as)
SCHIP1 Sigma 355 ATGCT GTT GCT AAAGGT GGC (s) 
AC AT ATT ACGG AGAGCT AC A (as)
SPP1 Sigma 244 CCC AC AGACCCTTCCAAGT A (s) 
GGGGACAACTGGAGTGAAAA (as)
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